WO2022186802A1 - Liposomal ozone nanosolutions - Google Patents
Liposomal ozone nanosolutions Download PDFInfo
- Publication number
- WO2022186802A1 WO2022186802A1 PCT/TR2022/050177 TR2022050177W WO2022186802A1 WO 2022186802 A1 WO2022186802 A1 WO 2022186802A1 TR 2022050177 W TR2022050177 W TR 2022050177W WO 2022186802 A1 WO2022186802 A1 WO 2022186802A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- ozone
- nanosolution
- oil
- ppm
- acid
- Prior art date
Links
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 title claims abstract description 296
- 230000000844 anti-bacterial effect Effects 0.000 claims abstract description 46
- 235000013305 food Nutrition 0.000 claims abstract description 15
- 230000000840 anti-viral effect Effects 0.000 claims abstract description 11
- 230000000843 anti-fungal effect Effects 0.000 claims abstract description 9
- 229940121375 antifungal agent Drugs 0.000 claims abstract description 8
- 239000003995 emulsifying agent Substances 0.000 claims description 125
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 86
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 74
- 239000003921 oil Substances 0.000 claims description 73
- 235000019198 oils Nutrition 0.000 claims description 73
- 239000000203 mixture Substances 0.000 claims description 61
- 229910001868 water Inorganic materials 0.000 claims description 59
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 55
- 239000003814 drug Substances 0.000 claims description 50
- 235000011187 glycerol Nutrition 0.000 claims description 43
- 229920001223 polyethylene glycol Polymers 0.000 claims description 43
- 239000002202 Polyethylene glycol Substances 0.000 claims description 41
- 229960005150 glycerol Drugs 0.000 claims description 41
- 238000000034 method Methods 0.000 claims description 39
- 241000196324 Embryophyta Species 0.000 claims description 37
- 238000009472 formulation Methods 0.000 claims description 34
- MGSRCZKZVOBKFT-UHFFFAOYSA-N thymol Chemical compound CC(C)C1=CC=C(C)C=C1O MGSRCZKZVOBKFT-UHFFFAOYSA-N 0.000 claims description 32
- 239000002105 nanoparticle Substances 0.000 claims description 30
- 239000002199 base oil Substances 0.000 claims description 28
- 238000000576 coating method Methods 0.000 claims description 27
- 230000001580 bacterial effect Effects 0.000 claims description 26
- 239000011248 coating agent Substances 0.000 claims description 25
- 229920000136 polysorbate Polymers 0.000 claims description 22
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 21
- 235000011054 acetic acid Nutrition 0.000 claims description 18
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 18
- 241000244206 Nematoda Species 0.000 claims description 17
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 17
- 239000005844 Thymol Substances 0.000 claims description 16
- 229960000790 thymol Drugs 0.000 claims description 16
- -1 lysophospholipid Substances 0.000 claims description 15
- 235000002639 sodium chloride Nutrition 0.000 claims description 15
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 14
- 206010028980 Neoplasm Diseases 0.000 claims description 14
- 229920002674 hyaluronan Polymers 0.000 claims description 14
- 229960003160 hyaluronic acid Drugs 0.000 claims description 14
- 239000007927 intramuscular injection Substances 0.000 claims description 14
- 238000010255 intramuscular injection Methods 0.000 claims description 14
- 150000007524 organic acids Chemical class 0.000 claims description 14
- 239000007929 subcutaneous injection Substances 0.000 claims description 14
- 238000010254 subcutaneous injection Methods 0.000 claims description 14
- 229940088594 vitamin Drugs 0.000 claims description 14
- 229930003231 vitamin Natural products 0.000 claims description 14
- 235000013343 vitamin Nutrition 0.000 claims description 14
- 239000011782 vitamin Substances 0.000 claims description 14
- 201000011510 cancer Diseases 0.000 claims description 13
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims description 13
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 13
- 229940068968 polysorbate 80 Drugs 0.000 claims description 13
- 229920000053 polysorbate 80 Polymers 0.000 claims description 13
- 239000002253 acid Substances 0.000 claims description 12
- 239000012153 distilled water Substances 0.000 claims description 12
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 12
- 235000010755 mineral Nutrition 0.000 claims description 12
- 239000011707 mineral Substances 0.000 claims description 12
- 102000004169 proteins and genes Human genes 0.000 claims description 11
- 108090000623 proteins and genes Proteins 0.000 claims description 11
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 claims description 10
- 241001126829 Nosema Species 0.000 claims description 10
- 229960004308 acetylcysteine Drugs 0.000 claims description 10
- 235000019441 ethanol Nutrition 0.000 claims description 10
- 229920000642 polymer Polymers 0.000 claims description 10
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 claims description 9
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 claims description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 9
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 claims description 9
- 239000013543 active substance Substances 0.000 claims description 9
- 235000012000 cholesterol Nutrition 0.000 claims description 9
- 229940041616 menthol Drugs 0.000 claims description 9
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 9
- 150000003505 terpenes Chemical class 0.000 claims description 9
- 235000019486 Sunflower oil Nutrition 0.000 claims description 8
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims description 8
- 238000002156 mixing Methods 0.000 claims description 8
- 239000002600 sunflower oil Substances 0.000 claims description 8
- 229920002307 Dextran Polymers 0.000 claims description 7
- 235000001014 amino acid Nutrition 0.000 claims description 7
- 229940024606 amino acid Drugs 0.000 claims description 7
- 230000015572 biosynthetic process Effects 0.000 claims description 7
- 229960004194 lidocaine Drugs 0.000 claims description 7
- 150000002632 lipids Chemical class 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 239000004006 olive oil Substances 0.000 claims description 7
- 235000008390 olive oil Nutrition 0.000 claims description 7
- 229940068965 polysorbates Drugs 0.000 claims description 7
- 235000000346 sugar Nutrition 0.000 claims description 7
- 235000015112 vegetable and seed oil Nutrition 0.000 claims description 7
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 6
- 229930195725 Mannitol Natural products 0.000 claims description 6
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims description 6
- 102000004142 Trypsin Human genes 0.000 claims description 6
- 108090000631 Trypsin Proteins 0.000 claims description 6
- 241000607479 Yersinia pestis Species 0.000 claims description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 6
- 235000010355 mannitol Nutrition 0.000 claims description 6
- 239000000594 mannitol Substances 0.000 claims description 6
- 235000018102 proteins Nutrition 0.000 claims description 6
- 239000003549 soybean oil Substances 0.000 claims description 6
- 235000012424 soybean oil Nutrition 0.000 claims description 6
- 239000012588 trypsin Substances 0.000 claims description 6
- 238000005303 weighing Methods 0.000 claims description 6
- 241000260546 Carpoglyphus lactis Species 0.000 claims description 5
- 229920001213 Polysorbate 20 Polymers 0.000 claims description 5
- 241001454293 Tetranychus urticae Species 0.000 claims description 5
- 150000001413 amino acids Chemical class 0.000 claims description 5
- 235000003599 food sweetener Nutrition 0.000 claims description 5
- 238000006385 ozonation reaction Methods 0.000 claims description 5
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims description 5
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims description 5
- 229940068977 polysorbate 20 Drugs 0.000 claims description 5
- 239000003765 sweetening agent Substances 0.000 claims description 5
- 235000007586 terpenes Nutrition 0.000 claims description 5
- 239000008158 vegetable oil Substances 0.000 claims description 5
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 claims description 4
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 claims description 4
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 claims description 4
- 108010024636 Glutathione Proteins 0.000 claims description 4
- 229930186217 Glycolipid Natural products 0.000 claims description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 4
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 4
- 229920002651 Polysorbate 85 Polymers 0.000 claims description 4
- 102000016202 Proteolipids Human genes 0.000 claims description 4
- 108010010974 Proteolipids Proteins 0.000 claims description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 4
- UYXTWWCETRIEDR-UHFFFAOYSA-N Tributyrin Chemical compound CCCC(=O)OCC(OC(=O)CCC)COC(=O)CCC UYXTWWCETRIEDR-UHFFFAOYSA-N 0.000 claims description 4
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 4
- 229940106189 ceramide Drugs 0.000 claims description 4
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 claims description 4
- 239000003240 coconut oil Substances 0.000 claims description 4
- 235000019864 coconut oil Nutrition 0.000 claims description 4
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims description 4
- 229960003180 glutathione Drugs 0.000 claims description 4
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 claims description 4
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 claims description 4
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 claims description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims description 4
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 claims description 4
- 229940056211 paraffin Drugs 0.000 claims description 4
- 239000012188 paraffin wax Substances 0.000 claims description 4
- 239000002504 physiological saline solution Substances 0.000 claims description 4
- 229940113171 polysorbate 85 Drugs 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims description 4
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 claims description 4
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 3
- 102000004190 Enzymes Human genes 0.000 claims description 3
- 108090000790 Enzymes Proteins 0.000 claims description 3
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 claims description 3
- 239000004367 Lipase Substances 0.000 claims description 3
- 102000004882 Lipase Human genes 0.000 claims description 3
- 108090001060 Lipase Proteins 0.000 claims description 3
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 claims description 3
- 102000016387 Pancreatic elastase Human genes 0.000 claims description 3
- 108010067372 Pancreatic elastase Proteins 0.000 claims description 3
- 229920001214 Polysorbate 60 Polymers 0.000 claims description 3
- 150000007513 acids Chemical class 0.000 claims description 3
- 150000001298 alcohols Chemical class 0.000 claims description 3
- 229940088598 enzyme Drugs 0.000 claims description 3
- 235000019197 fats Nutrition 0.000 claims description 3
- 239000003193 general anesthetic agent Substances 0.000 claims description 3
- 150000002327 glycerophospholipids Chemical class 0.000 claims description 3
- 208000015181 infectious disease Diseases 0.000 claims description 3
- 239000000787 lecithin Substances 0.000 claims description 3
- 235000010445 lecithin Nutrition 0.000 claims description 3
- 229940067606 lecithin Drugs 0.000 claims description 3
- 235000019421 lipase Nutrition 0.000 claims description 3
- 150000008104 phosphatidylethanolamines Chemical class 0.000 claims description 3
- 150000003904 phospholipids Chemical class 0.000 claims description 3
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 claims description 3
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 claims description 3
- 229940113124 polysorbate 60 Drugs 0.000 claims description 3
- 230000009467 reduction Effects 0.000 claims description 3
- 239000008159 sesame oil Substances 0.000 claims description 3
- 235000011803 sesame oil Nutrition 0.000 claims description 3
- 150000003408 sphingolipids Chemical class 0.000 claims description 3
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims description 2
- MGRVRXRGTBOSHW-UHFFFAOYSA-N (aminomethyl)phosphonic acid Chemical compound NCP(O)(O)=O MGRVRXRGTBOSHW-UHFFFAOYSA-N 0.000 claims description 2
- PZNPLUBHRSSFHT-RRHRGVEJSA-N 1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCCCC PZNPLUBHRSSFHT-RRHRGVEJSA-N 0.000 claims description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 claims description 2
- 239000005711 Benzoic acid Substances 0.000 claims description 2
- 241000501711 Centaurium Species 0.000 claims description 2
- 102000029816 Collagenase Human genes 0.000 claims description 2
- 108060005980 Collagenase Proteins 0.000 claims description 2
- 235000015655 Crocus sativus Nutrition 0.000 claims description 2
- 244000124209 Crocus sativus Species 0.000 claims description 2
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 claims description 2
- 235000019482 Palm oil Nutrition 0.000 claims description 2
- 235000008753 Papaver somniferum Nutrition 0.000 claims description 2
- 240000001090 Papaver somniferum Species 0.000 claims description 2
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 claims description 2
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 claims description 2
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 claims description 2
- 150000001335 aliphatic alkanes Chemical class 0.000 claims description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 2
- 229940035674 anesthetics Drugs 0.000 claims description 2
- 238000009341 apiculture Methods 0.000 claims description 2
- 235000010233 benzoic acid Nutrition 0.000 claims description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 claims description 2
- 239000004359 castor oil Substances 0.000 claims description 2
- 235000019438 castor oil Nutrition 0.000 claims description 2
- 229960000541 cetyl alcohol Drugs 0.000 claims description 2
- 235000015165 citric acid Nutrition 0.000 claims description 2
- 229960002424 collagenase Drugs 0.000 claims description 2
- 239000008367 deionised water Substances 0.000 claims description 2
- 229910021641 deionized water Inorganic materials 0.000 claims description 2
- QYDYPVFESGNLHU-UHFFFAOYSA-N elaidic acid methyl ester Natural products CCCCCCCCC=CCCCCCCCC(=O)OC QYDYPVFESGNLHU-UHFFFAOYSA-N 0.000 claims description 2
- 229960004756 ethanol Drugs 0.000 claims description 2
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 claims description 2
- 229940093471 ethyl oleate Drugs 0.000 claims description 2
- 235000021323 fish oil Nutrition 0.000 claims description 2
- 235000019253 formic acid Nutrition 0.000 claims description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 2
- 239000012676 herbal extract Substances 0.000 claims description 2
- 235000011167 hydrochloric acid Nutrition 0.000 claims description 2
- 239000004310 lactic acid Substances 0.000 claims description 2
- 235000014655 lactic acid Nutrition 0.000 claims description 2
- 239000001630 malic acid Substances 0.000 claims description 2
- 235000011090 malic acid Nutrition 0.000 claims description 2
- QYDYPVFESGNLHU-KHPPLWFESA-N methyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC QYDYPVFESGNLHU-KHPPLWFESA-N 0.000 claims description 2
- 229940073769 methyl oleate Drugs 0.000 claims description 2
- 235000006408 oxalic acid Nutrition 0.000 claims description 2
- 239000002540 palm oil Substances 0.000 claims description 2
- 229960003742 phenol Drugs 0.000 claims description 2
- 235000011007 phosphoric acid Nutrition 0.000 claims description 2
- 229920001983 poloxamer Polymers 0.000 claims description 2
- 235000019260 propionic acid Nutrition 0.000 claims description 2
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 claims description 2
- 239000004248 saffron Substances 0.000 claims description 2
- 235000013974 saffron Nutrition 0.000 claims description 2
- 229910052710 silicon Inorganic materials 0.000 claims description 2
- 239000010703 silicon Substances 0.000 claims description 2
- 239000000377 silicon dioxide Substances 0.000 claims description 2
- 235000012239 silicon dioxide Nutrition 0.000 claims description 2
- 239000008347 soybean phospholipid Substances 0.000 claims description 2
- 229960003080 taurine Drugs 0.000 claims description 2
- 150000003626 triacylglycerols Chemical class 0.000 claims description 2
- MAYCICSNZYXLHB-UHFFFAOYSA-N tricaproin Chemical compound CCCCCC(=O)OCC(OC(=O)CCCCC)COC(=O)CCCCC MAYCICSNZYXLHB-UHFFFAOYSA-N 0.000 claims description 2
- 229940093609 tricaprylin Drugs 0.000 claims description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims description 2
- VLPFTAMPNXLGLX-UHFFFAOYSA-N trioctanoin Chemical compound CCCCCCCC(=O)OCC(OC(=O)CCCCCCC)COC(=O)CCCCCCC VLPFTAMPNXLGLX-UHFFFAOYSA-N 0.000 claims description 2
- 229940116269 uric acid Drugs 0.000 claims description 2
- 229940005605 valeric acid Drugs 0.000 claims description 2
- 239000003643 water by type Substances 0.000 claims description 2
- 229940072358 xylocaine Drugs 0.000 claims description 2
- 230000008591 skin barrier function Effects 0.000 claims 1
- 239000000243 solution Substances 0.000 abstract description 92
- 238000007920 subcutaneous administration Methods 0.000 abstract description 26
- 239000007921 spray Substances 0.000 abstract description 22
- 241000894006 Bacteria Species 0.000 abstract description 16
- 241000588724 Escherichia coli Species 0.000 abstract description 14
- 241000191967 Staphylococcus aureus Species 0.000 abstract description 13
- 239000000645 desinfectant Substances 0.000 abstract description 13
- 238000007918 intramuscular administration Methods 0.000 abstract description 10
- 241000700605 Viruses Species 0.000 abstract description 7
- 239000003889 eye drop Substances 0.000 abstract description 6
- 229940012356 eye drops Drugs 0.000 abstract description 6
- 239000002537 cosmetic Substances 0.000 abstract description 5
- 230000035876 healing Effects 0.000 abstract description 5
- 229940097496 nasal spray Drugs 0.000 abstract description 5
- 239000007922 nasal spray Substances 0.000 abstract description 5
- 230000029663 wound healing Effects 0.000 abstract description 5
- 241000711573 Coronaviridae Species 0.000 abstract description 4
- 239000003221 ear drop Substances 0.000 abstract description 3
- 229940047652 ear drops Drugs 0.000 abstract description 3
- 206010022000 influenza Diseases 0.000 abstract 1
- 238000010253 intravenous injection Methods 0.000 abstract 1
- 241000712461 unidentified influenza virus Species 0.000 abstract 1
- 238000012360 testing method Methods 0.000 description 147
- 239000000463 material Substances 0.000 description 59
- 230000000694 effects Effects 0.000 description 58
- 210000004027 cell Anatomy 0.000 description 49
- 229940079593 drug Drugs 0.000 description 45
- 239000000047 product Substances 0.000 description 41
- 241001465754 Metazoa Species 0.000 description 34
- 238000002347 injection Methods 0.000 description 30
- 239000007924 injection Substances 0.000 description 30
- 239000007789 gas Substances 0.000 description 29
- 239000002502 liposome Substances 0.000 description 29
- 210000001519 tissue Anatomy 0.000 description 29
- 230000007794 irritation Effects 0.000 description 28
- 231100000331 toxic Toxicity 0.000 description 28
- 230000002588 toxic effect Effects 0.000 description 28
- 238000002474 experimental method Methods 0.000 description 27
- 238000002513 implantation Methods 0.000 description 25
- 230000032683 aging Effects 0.000 description 23
- 210000003491 skin Anatomy 0.000 description 23
- 238000011282 treatment Methods 0.000 description 22
- 239000007788 liquid Substances 0.000 description 20
- 239000000126 substance Substances 0.000 description 20
- 240000003768 Solanum lycopersicum Species 0.000 description 19
- 239000013641 positive control Substances 0.000 description 19
- 239000000523 sample Substances 0.000 description 19
- 239000013642 negative control Substances 0.000 description 18
- 235000007688 Lycopersicon esculentum Nutrition 0.000 description 16
- 238000011156 evaluation Methods 0.000 description 16
- 210000003205 muscle Anatomy 0.000 description 16
- 210000001508 eye Anatomy 0.000 description 15
- 210000000056 organ Anatomy 0.000 description 15
- 229950008882 polysorbate Drugs 0.000 description 15
- 230000036541 health Effects 0.000 description 14
- 238000004458 analytical method Methods 0.000 description 13
- 238000009826 distribution Methods 0.000 description 13
- 240000004201 Lactuca sativa var. crispa Species 0.000 description 12
- 241000488583 Panonychus ulmi Species 0.000 description 12
- 241000700159 Rattus Species 0.000 description 12
- 235000013399 edible fruits Nutrition 0.000 description 12
- 235000013601 eggs Nutrition 0.000 description 12
- 238000002360 preparation method Methods 0.000 description 12
- 238000010998 test method Methods 0.000 description 12
- 241000256844 Apis mellifera Species 0.000 description 11
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 11
- 235000015802 Lactuca sativa var crispa Nutrition 0.000 description 11
- 239000012091 fetal bovine serum Substances 0.000 description 11
- 239000001963 growth medium Substances 0.000 description 11
- 239000002245 particle Substances 0.000 description 11
- 239000011780 sodium chloride Substances 0.000 description 11
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 10
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 10
- 230000001965 increasing effect Effects 0.000 description 10
- 238000005259 measurement Methods 0.000 description 10
- 241000283973 Oryctolagus cuniculus Species 0.000 description 9
- 239000000284 extract Substances 0.000 description 9
- 238000000338 in vitro Methods 0.000 description 9
- 239000002609 medium Substances 0.000 description 9
- 241001143352 Meloidogyne Species 0.000 description 8
- 235000019502 Orange oil Nutrition 0.000 description 8
- 244000061458 Solanum melongena Species 0.000 description 8
- 238000010171 animal model Methods 0.000 description 8
- 230000037396 body weight Effects 0.000 description 8
- 238000004113 cell culture Methods 0.000 description 8
- 231100000263 cytotoxicity test Toxicity 0.000 description 8
- 210000002569 neuron Anatomy 0.000 description 8
- 239000010502 orange oil Substances 0.000 description 8
- 239000005871 repellent Substances 0.000 description 8
- 230000002940 repellent Effects 0.000 description 8
- 230000035899 viability Effects 0.000 description 8
- 235000002597 Solanum melongena Nutrition 0.000 description 7
- 206010052428 Wound Diseases 0.000 description 7
- 208000027418 Wounds and injury Diseases 0.000 description 7
- 230000006399 behavior Effects 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 231100000433 cytotoxic Toxicity 0.000 description 7
- 230000001472 cytotoxic effect Effects 0.000 description 7
- 238000010790 dilution Methods 0.000 description 7
- 239000012895 dilution Substances 0.000 description 7
- 239000002917 insecticide Substances 0.000 description 7
- 230000000622 irritating effect Effects 0.000 description 7
- 210000004185 liver Anatomy 0.000 description 7
- 238000000694 mesotherapy Methods 0.000 description 7
- 238000005507 spraying Methods 0.000 description 7
- 238000004659 sterilization and disinfection Methods 0.000 description 7
- 241000238876 Acari Species 0.000 description 6
- 238000010953 Ames test Methods 0.000 description 6
- 231100000039 Ames test Toxicity 0.000 description 6
- 241000221785 Erysiphales Species 0.000 description 6
- 240000008415 Lactuca sativa Species 0.000 description 6
- 230000015556 catabolic process Effects 0.000 description 6
- 235000008504 concentrate Nutrition 0.000 description 6
- 239000012141 concentrate Substances 0.000 description 6
- 210000004209 hair Anatomy 0.000 description 6
- 208000000509 infertility Diseases 0.000 description 6
- 230000036512 infertility Effects 0.000 description 6
- 238000001990 intravenous administration Methods 0.000 description 6
- 239000000171 lavandula angustifolia l. flower oil Substances 0.000 description 6
- 239000002101 nanobubble Substances 0.000 description 6
- 239000002539 nanocarrier Substances 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 238000007390 skin biopsy Methods 0.000 description 6
- 206010002091 Anaesthesia Diseases 0.000 description 5
- 206010015150 Erythema Diseases 0.000 description 5
- 241000257303 Hymenoptera Species 0.000 description 5
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 5
- 235000003228 Lactuca sativa Nutrition 0.000 description 5
- 235000009827 Prunus armeniaca Nutrition 0.000 description 5
- 244000018633 Prunus armeniaca Species 0.000 description 5
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 5
- 239000004141 Sodium laurylsulphate Substances 0.000 description 5
- 210000001015 abdomen Anatomy 0.000 description 5
- 230000005856 abnormality Effects 0.000 description 5
- 230000004913 activation Effects 0.000 description 5
- 238000001994 activation Methods 0.000 description 5
- 230000037005 anaesthesia Effects 0.000 description 5
- 230000002141 anti-parasite Effects 0.000 description 5
- 239000003096 antiparasitic agent Substances 0.000 description 5
- 239000010634 clove oil Substances 0.000 description 5
- 230000034994 death Effects 0.000 description 5
- 231100000517 death Toxicity 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 230000018109 developmental process Effects 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- 238000003306 harvesting Methods 0.000 description 5
- 230000008595 infiltration Effects 0.000 description 5
- 238000001764 infiltration Methods 0.000 description 5
- 229960003299 ketamine Drugs 0.000 description 5
- 239000002353 niosome Substances 0.000 description 5
- 239000000575 pesticide Substances 0.000 description 5
- 238000001556 precipitation Methods 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 5
- 239000004094 surface-active agent Substances 0.000 description 5
- 239000010678 thyme oil Substances 0.000 description 5
- 235000013311 vegetables Nutrition 0.000 description 5
- 230000003612 virological effect Effects 0.000 description 5
- BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 5
- 229960001600 xylazine Drugs 0.000 description 5
- 229910052725 zinc Inorganic materials 0.000 description 5
- 239000011701 zinc Substances 0.000 description 5
- 235000016804 zinc Nutrition 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- 241000239290 Araneae Species 0.000 description 4
- 235000003097 Artemisia absinthium Nutrition 0.000 description 4
- 240000002877 Artemisia absinthium Species 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- 235000019501 Lemon oil Nutrition 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 231100000107 OECD 471 Bacterial Reverse Mutation Test Toxicity 0.000 description 4
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 4
- 208000025865 Ulcer Diseases 0.000 description 4
- 244000274883 Urtica dioica Species 0.000 description 4
- 235000009108 Urtica dioica Nutrition 0.000 description 4
- 239000001138 artemisia absinthium Substances 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 229930002875 chlorophyll Natural products 0.000 description 4
- 235000019804 chlorophyll Nutrition 0.000 description 4
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 238000006731 degradation reaction Methods 0.000 description 4
- 238000007865 diluting Methods 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 210000000981 epithelium Anatomy 0.000 description 4
- 231100000321 erythema Toxicity 0.000 description 4
- 239000004744 fabric Substances 0.000 description 4
- 231100000025 genetic toxicology Toxicity 0.000 description 4
- 239000011521 glass Substances 0.000 description 4
- 239000007943 implant Substances 0.000 description 4
- 230000002757 inflammatory effect Effects 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 229940102223 injectable solution Drugs 0.000 description 4
- 239000010501 lemon oil Substances 0.000 description 4
- 230000001665 lethal effect Effects 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 210000000214 mouth Anatomy 0.000 description 4
- 210000004877 mucosa Anatomy 0.000 description 4
- 231100000243 mutagenic effect Toxicity 0.000 description 4
- 230000002688 persistence Effects 0.000 description 4
- 229940098467 rectal solution Drugs 0.000 description 4
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 238000013207 serial dilution Methods 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 235000020374 simple syrup Nutrition 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- 230000036269 ulceration Effects 0.000 description 4
- 150000003722 vitamin derivatives Chemical class 0.000 description 4
- ZXQYGBMAQZUVMI-RDDWSQKMSA-N (1S)-cis-(alphaR)-cyhalothrin Chemical compound CC1(C)[C@H](\C=C(/Cl)C(F)(F)F)[C@@H]1C(=O)O[C@@H](C#N)C1=CC=CC(OC=2C=CC=CC=2)=C1 ZXQYGBMAQZUVMI-RDDWSQKMSA-N 0.000 description 3
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 3
- 241001260012 Bursa Species 0.000 description 3
- 241000700198 Cavia Species 0.000 description 3
- 235000010469 Glycine max Nutrition 0.000 description 3
- 102000004895 Lipoproteins Human genes 0.000 description 3
- 108090001030 Lipoproteins Proteins 0.000 description 3
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 3
- 206010070834 Sensitisation Diseases 0.000 description 3
- 206010040914 Skin reaction Diseases 0.000 description 3
- 241001454295 Tetranychidae Species 0.000 description 3
- 208000024780 Urticaria Diseases 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 231100000899 acute systemic toxicity Toxicity 0.000 description 3
- 230000002421 anti-septic effect Effects 0.000 description 3
- 230000004888 barrier function Effects 0.000 description 3
- 238000012925 biological evaluation Methods 0.000 description 3
- 210000001217 buttock Anatomy 0.000 description 3
- 238000011109 contamination Methods 0.000 description 3
- 230000003013 cytotoxicity Effects 0.000 description 3
- 231100000135 cytotoxicity Toxicity 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 210000002249 digestive system Anatomy 0.000 description 3
- 235000011869 dried fruits Nutrition 0.000 description 3
- 230000003628 erosive effect Effects 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000001738 genotoxic effect Effects 0.000 description 3
- 235000003969 glutathione Nutrition 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 238000007912 intraperitoneal administration Methods 0.000 description 3
- 238000011835 investigation Methods 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 238000009533 lab test Methods 0.000 description 3
- 239000005910 lambda-Cyhalothrin Substances 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 230000001926 lymphatic effect Effects 0.000 description 3
- 210000003470 mitochondria Anatomy 0.000 description 3
- 231100000017 mucous membrane irritation Toxicity 0.000 description 3
- 230000003505 mutagenic effect Effects 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 3
- 210000003928 nasal cavity Anatomy 0.000 description 3
- 210000001331 nose Anatomy 0.000 description 3
- 208000013441 ocular lesion Diseases 0.000 description 3
- 230000035515 penetration Effects 0.000 description 3
- 229920001296 polysiloxane Polymers 0.000 description 3
- 230000002335 preservative effect Effects 0.000 description 3
- 230000003716 rejuvenation Effects 0.000 description 3
- 230000008439 repair process Effects 0.000 description 3
- 210000002345 respiratory system Anatomy 0.000 description 3
- WTGQALLALWYDJH-AKTDCHNFSA-N scopolamine hydrobromide Chemical compound Br.C1([C@@H](CO)C(=O)OC2C[C@@H]3N([C@@H](C2)[C@H]2[C@@H]3O2)C)=CC=CC=C1 WTGQALLALWYDJH-AKTDCHNFSA-N 0.000 description 3
- 230000008313 sensitization Effects 0.000 description 3
- 230000035483 skin reaction Effects 0.000 description 3
- 231100000430 skin reaction Toxicity 0.000 description 3
- 230000011273 social behavior Effects 0.000 description 3
- 239000002689 soil Substances 0.000 description 3
- 208000003265 stomatitis Diseases 0.000 description 3
- 230000035882 stress Effects 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 230000002195 synergetic effect Effects 0.000 description 3
- 239000004753 textile Substances 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 229960000401 tranexamic acid Drugs 0.000 description 3
- GYDJEQRTZSCIOI-LJGSYFOKSA-N tranexamic acid Chemical compound NC[C@H]1CC[C@H](C(O)=O)CC1 GYDJEQRTZSCIOI-LJGSYFOKSA-N 0.000 description 3
- 229940055835 triptone Drugs 0.000 description 3
- 230000009723 vascular congestion Effects 0.000 description 3
- 239000000341 volatile oil Substances 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- 241000256837 Apidae Species 0.000 description 2
- 235000003261 Artemisia vulgaris Nutrition 0.000 description 2
- 241000193830 Bacillus <bacterium> Species 0.000 description 2
- 208000035143 Bacterial infection Diseases 0.000 description 2
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 2
- 229920001661 Chitosan Polymers 0.000 description 2
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 2
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 206010051814 Eschar Diseases 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 241000699673 Mesocricetus auratus Species 0.000 description 2
- 206010061297 Mucosal erosion Diseases 0.000 description 2
- 206010028400 Mutagenic effect Diseases 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- 241001492486 Nosema apis Species 0.000 description 2
- 241000819999 Nymphes Species 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 238000011481 absorbance measurement Methods 0.000 description 2
- 239000002250 absorbent Substances 0.000 description 2
- 230000002745 absorbent Effects 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 231100000403 acute toxicity Toxicity 0.000 description 2
- 230000007059 acute toxicity Effects 0.000 description 2
- 230000016571 aggressive behavior Effects 0.000 description 2
- 239000003708 ampul Substances 0.000 description 2
- 239000003674 animal food additive Substances 0.000 description 2
- 230000002155 anti-virotic effect Effects 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 239000000560 biocompatible material Substances 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 239000012620 biological material Substances 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 239000007844 bleaching agent Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 239000003560 cancer drug Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000005779 cell damage Effects 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 239000010639 cypress oil Substances 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 239000003599 detergent Substances 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 238000007598 dipping method Methods 0.000 description 2
- NJDNXYGOVLYJHP-UHFFFAOYSA-L disodium;2-(3-oxido-6-oxoxanthen-9-yl)benzoate Chemical compound [Na+].[Na+].[O-]C(=O)C1=CC=CC=C1C1=C2C=CC(=O)C=C2OC2=CC([O-])=CC=C21 NJDNXYGOVLYJHP-UHFFFAOYSA-L 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- 239000006196 drop Substances 0.000 description 2
- 210000000613 ear canal Anatomy 0.000 description 2
- 235000006694 eating habits Nutrition 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 231100000333 eschar Toxicity 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 210000000744 eyelid Anatomy 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- YYJNOYZRYGDPNH-MFKUBSTISA-N fenpyroximate Chemical compound C=1C=C(C(=O)OC(C)(C)C)C=CC=1CO/N=C/C=1C(C)=NN(C)C=1OC1=CC=CC=C1 YYJNOYZRYGDPNH-MFKUBSTISA-N 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000005452 food preservative Substances 0.000 description 2
- 235000019249 food preservative Nutrition 0.000 description 2
- 235000012055 fruits and vegetables Nutrition 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- 230000003779 hair growth Effects 0.000 description 2
- 235000012907 honey Nutrition 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 238000001361 intraarterial administration Methods 0.000 description 2
- 229940102212 intraperitoneal solution Drugs 0.000 description 2
- 231100000021 irritant Toxicity 0.000 description 2
- 239000002085 irritant Substances 0.000 description 2
- 208000021788 large intestine disease Diseases 0.000 description 2
- 231100000518 lethal Toxicity 0.000 description 2
- 231100000225 lethality Toxicity 0.000 description 2
- 244000144972 livestock Species 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 235000013372 meat Nutrition 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 238000007431 microscopic evaluation Methods 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- 239000003471 mutagenic agent Substances 0.000 description 2
- 231100000707 mutagenic chemical Toxicity 0.000 description 2
- 210000004165 myocardium Anatomy 0.000 description 2
- 210000002850 nasal mucosa Anatomy 0.000 description 2
- 229960003966 nicotinamide Drugs 0.000 description 2
- 235000005152 nicotinamide Nutrition 0.000 description 2
- 239000011570 nicotinamide Substances 0.000 description 2
- 239000000346 nonvolatile oil Substances 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 230000036407 pain Effects 0.000 description 2
- 235000019161 pantothenic acid Nutrition 0.000 description 2
- 239000011713 pantothenic acid Substances 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 239000003209 petroleum derivative Substances 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 230000007096 poisonous effect Effects 0.000 description 2
- 230000008092 positive effect Effects 0.000 description 2
- 239000013630 prepared media Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 230000000644 propagated effect Effects 0.000 description 2
- 230000001012 protector Effects 0.000 description 2
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 2
- 239000011764 pyridoxine hydrochloride Substances 0.000 description 2
- 229960004172 pyridoxine hydrochloride Drugs 0.000 description 2
- 235000019171 pyridoxine hydrochloride Nutrition 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 230000001172 regenerating effect Effects 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 229960002477 riboflavin Drugs 0.000 description 2
- 235000019192 riboflavin Nutrition 0.000 description 2
- 239000002151 riboflavin Substances 0.000 description 2
- 231100000279 safety data Toxicity 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 229910052709 silver Inorganic materials 0.000 description 2
- 239000004332 silver Substances 0.000 description 2
- 229960002668 sodium chloride Drugs 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 238000007655 standard test method Methods 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000008399 tap water Substances 0.000 description 2
- 235000020679 tap water Nutrition 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 239000011678 thiamine pyrophosphate Substances 0.000 description 2
- 229960002363 thiamine pyrophosphate Drugs 0.000 description 2
- 235000008170 thiamine pyrophosphate Nutrition 0.000 description 2
- YXVCLPJQTZXJLH-UHFFFAOYSA-N thiamine(1+) diphosphate chloride Chemical compound [Cl-].CC1=C(CCOP(O)(=O)OP(O)(O)=O)SC=[N+]1CC1=CN=C(C)N=C1N YXVCLPJQTZXJLH-UHFFFAOYSA-N 0.000 description 2
- 229940071127 thioglycolate Drugs 0.000 description 2
- CWERGRDVMFNCDR-UHFFFAOYSA-M thioglycolate(1-) Chemical compound [O-]C(=O)CS CWERGRDVMFNCDR-UHFFFAOYSA-M 0.000 description 2
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 2
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 2
- 239000002023 wood Substances 0.000 description 2
- NGGMYCMLYOUNGM-UHFFFAOYSA-N (-)-fumagillin Natural products O1C(CC=C(C)C)C1(C)C1C(OC)C(OC(=O)C=CC=CC=CC=CC(O)=O)CCC21CO2 NGGMYCMLYOUNGM-UHFFFAOYSA-N 0.000 description 1
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- NGGMYCMLYOUNGM-DEHUIYDQSA-N (2z,4e,6e,8e)-10-[[5-methoxy-4-[2-methyl-3-(3-methylbut-2-enyl)oxiran-2-yl]-1-oxaspiro[2.5]octan-6-yl]oxy]-10-oxodeca-2,4,6,8-tetraenoic acid Chemical compound O1C(CC=C(C)C)C1(C)C1C(OC)C(OC(=O)\C=C\C=C\C=C\C=C/C(O)=O)CCC21CO2 NGGMYCMLYOUNGM-DEHUIYDQSA-N 0.000 description 1
- PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 description 1
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 1
- CPKVUHPKYQGHMW-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one;molecular iodine Chemical compound II.C=CN1CCCC1=O CPKVUHPKYQGHMW-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- QDGAVODICPCDMU-UHFFFAOYSA-N 2-amino-3-[3-[bis(2-chloroethyl)amino]phenyl]propanoic acid Chemical compound OC(=O)C(N)CC1=CC=CC(N(CCCl)CCCl)=C1 QDGAVODICPCDMU-UHFFFAOYSA-N 0.000 description 1
- CFWRDBDJAOHXSH-SECBINFHSA-N 2-azaniumylethyl [(2r)-2,3-diacetyloxypropyl] phosphate Chemical compound CC(=O)OC[C@@H](OC(C)=O)COP(O)(=O)OCCN CFWRDBDJAOHXSH-SECBINFHSA-N 0.000 description 1
- AZKSAVLVSZKNRD-UHFFFAOYSA-M 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide Chemical compound [Br-].S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 AZKSAVLVSZKNRD-UHFFFAOYSA-M 0.000 description 1
- AJBZENLMTKDAEK-UHFFFAOYSA-N 3a,5a,5b,8,8,11a-hexamethyl-1-prop-1-en-2-yl-1,2,3,4,5,6,7,7a,9,10,11,11b,12,13,13a,13b-hexadecahydrocyclopenta[a]chrysene-4,9-diol Chemical compound CC12CCC(O)C(C)(C)C1CCC(C1(C)CC3O)(C)C2CCC1C1C3(C)CCC1C(=C)C AJBZENLMTKDAEK-UHFFFAOYSA-N 0.000 description 1
- IBSREHMXUMOFBB-JFUDTMANSA-N 5u8924t11h Chemical compound O1[C@@H](C)[C@H](O)[C@@H](OC)C[C@@H]1O[C@@H]1[C@@H](OC)C[C@H](O[C@@H]2C(=C/C[C@@H]3C[C@@H](C[C@@]4(O3)C=C[C@H](C)[C@@H](C(C)C)O4)OC(=O)[C@@H]3C=C(C)[C@@H](O)[C@H]4OC\C([C@@]34O)=C/C=C/[C@@H]2C)/C)O[C@H]1C.C1=C[C@H](C)[C@@H]([C@@H](C)CC)O[C@]11O[C@H](C\C=C(C)\[C@@H](O[C@@H]2O[C@@H](C)[C@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](OC)C3)[C@@H](OC)C2)[C@@H](C)\C=C\C=C/2[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\2)O)C[C@H]4C1 IBSREHMXUMOFBB-JFUDTMANSA-N 0.000 description 1
- 239000005660 Abamectin Substances 0.000 description 1
- 241000607528 Aeromonas hydrophila Species 0.000 description 1
- 206010001488 Aggression Diseases 0.000 description 1
- 235000019489 Almond oil Nutrition 0.000 description 1
- 235000009051 Ambrosia paniculata var. peruviana Nutrition 0.000 description 1
- 241000712892 Arenaviridae Species 0.000 description 1
- 235000003826 Artemisia Nutrition 0.000 description 1
- 235000017731 Artemisia dracunculus ssp. dracunculus Nutrition 0.000 description 1
- 241001292006 Arteriviridae Species 0.000 description 1
- 241000238708 Astigmata Species 0.000 description 1
- 238000011725 BALB/c mouse Methods 0.000 description 1
- 241000193738 Bacillus anthracis Species 0.000 description 1
- 241000193755 Bacillus cereus Species 0.000 description 1
- 108010077805 Bacterial Proteins Proteins 0.000 description 1
- 241000776207 Bornaviridae Species 0.000 description 1
- 108090000312 Calcium Channels Proteins 0.000 description 1
- 102000003922 Calcium Channels Human genes 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 235000003880 Calendula Nutrition 0.000 description 1
- 240000001432 Calendula officinalis Species 0.000 description 1
- 240000007436 Cananga odorata Species 0.000 description 1
- 241000260534 Carpoglyphidae Species 0.000 description 1
- 108091006146 Channels Proteins 0.000 description 1
- 241000193155 Clostridium botulinum Species 0.000 description 1
- 241000193468 Clostridium perfringens Species 0.000 description 1
- 241000193466 Clostridium septicum Species 0.000 description 1
- 241000193449 Clostridium tetani Species 0.000 description 1
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 1
- 206010010725 Conjunctival irritation Diseases 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 208000028006 Corneal injury Diseases 0.000 description 1
- 206010056476 Corneal irritation Diseases 0.000 description 1
- 206010011039 Corneal perforation Diseases 0.000 description 1
- 241000186227 Corynebacterium diphtheriae Species 0.000 description 1
- 235000007129 Cuminum cyminum Nutrition 0.000 description 1
- 244000304337 Cuminum cyminum Species 0.000 description 1
- 206010011703 Cyanosis Diseases 0.000 description 1
- 229930105110 Cyclosporin A Natural products 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 240000006491 Ehretia microphylla Species 0.000 description 1
- 206010015548 Euthanasia Diseases 0.000 description 1
- 241000711950 Filoviridae Species 0.000 description 1
- 241000710781 Flaviviridae Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 244000020551 Helianthus annuus Species 0.000 description 1
- 235000003222 Helianthus annuus Nutrition 0.000 description 1
- 241000700739 Hepadnaviridae Species 0.000 description 1
- 241000700586 Herpesviridae Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 241001500351 Influenzavirus A Species 0.000 description 1
- 241001500350 Influenzavirus B Species 0.000 description 1
- 241001500343 Influenzavirus C Species 0.000 description 1
- 241001661732 Isavirus Species 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 206010023644 Lacrimation increased Diseases 0.000 description 1
- 244000165082 Lavanda vera Species 0.000 description 1
- 235000010663 Lavandula angustifolia Nutrition 0.000 description 1
- 241000186779 Listeria monocytogenes Species 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229920000057 Mannan Polymers 0.000 description 1
- 235000010654 Melissa officinalis Nutrition 0.000 description 1
- 244000062730 Melissa officinalis Species 0.000 description 1
- 208000024556 Mendelian disease Diseases 0.000 description 1
- ZFMITUMMTDLWHR-UHFFFAOYSA-N Minoxidil Chemical compound NC1=[N+]([O-])C(N)=CC(N2CCCCC2)=N1 ZFMITUMMTDLWHR-UHFFFAOYSA-N 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 206010028347 Muscle twitching Diseases 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 240000005125 Myrtus communis Species 0.000 description 1
- 235000013418 Myrtus communis Nutrition 0.000 description 1
- 231100000493 OECD 406 (Buehler) Skin Sensitisation Toxicity 0.000 description 1
- 235000006669 Origanum minutiflorum Nutrition 0.000 description 1
- 241001518075 Origanum minutiflorum Species 0.000 description 1
- 241000712464 Orthomyxoviridae Species 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 241000193465 Paeniclostridium sordellii Species 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 241000711504 Paramyxoviridae Species 0.000 description 1
- 238000001358 Pearson's chi-squared test Methods 0.000 description 1
- 241000150350 Peribunyaviridae Species 0.000 description 1
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 1
- 235000011613 Pinus brutia Nutrition 0.000 description 1
- 241000018646 Pinus brutia Species 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 1
- 229920002873 Polyethylenimine Polymers 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 241000712907 Retroviridae Species 0.000 description 1
- 241000711931 Rhabdoviridae Species 0.000 description 1
- 206010039101 Rhinorrhoea Diseases 0.000 description 1
- 206010039424 Salivary hypersecretion Diseases 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 241000580858 Simian-Human immunodeficiency virus Species 0.000 description 1
- 206010040844 Skin exfoliation Diseases 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 241000208292 Solanaceae Species 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 208000014151 Stomatognathic disease Diseases 0.000 description 1
- 201000005010 Streptococcus pneumonia Diseases 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- 241000193996 Streptococcus pyogenes Species 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 239000004376 Sucralose Substances 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 241000779819 Syncarpia glomulifera Species 0.000 description 1
- 208000001871 Tachycardia Diseases 0.000 description 1
- 235000007303 Thymus vulgaris Nutrition 0.000 description 1
- 240000002657 Thymus vulgaris Species 0.000 description 1
- 241000710924 Togaviridae Species 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 241000186064 Trueperella pyogenes Species 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 206010064996 Ulcerative keratitis Diseases 0.000 description 1
- 241000607626 Vibrio cholerae Species 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- ATBOMIWRCZXYSZ-XZBBILGWSA-N [1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9e,12e)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC ATBOMIWRCZXYSZ-XZBBILGWSA-N 0.000 description 1
- 229950008167 abamectin Drugs 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000000895 acaricidal effect Effects 0.000 description 1
- 239000000642 acaricide Substances 0.000 description 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 208000012761 aggressive behavior Diseases 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 239000008168 almond oil Substances 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- 239000010617 anise oil Substances 0.000 description 1
- 210000002159 anterior chamber Anatomy 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000003260 anti-sepsis Effects 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 238000009360 aquaculture Methods 0.000 description 1
- 244000144974 aquaculture Species 0.000 description 1
- 244000030166 artemisia Species 0.000 description 1
- 235000009052 artemisia Nutrition 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 235000021302 avocado oil Nutrition 0.000 description 1
- 239000008163 avocado oil Substances 0.000 description 1
- 229940065181 bacillus anthracis Drugs 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 239000010619 basil oil Substances 0.000 description 1
- 229940018006 basil oil Drugs 0.000 description 1
- 229940064804 betadine Drugs 0.000 description 1
- 238000011052 biological reactivity test Methods 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 235000021324 borage oil Nutrition 0.000 description 1
- 230000036471 bradycardia Effects 0.000 description 1
- 208000006218 bradycardia Diseases 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- RECUKUPTGUEGMW-UHFFFAOYSA-N carvacrol Chemical compound CC(C)C1=CC=C(C)C(O)=C1 RECUKUPTGUEGMW-UHFFFAOYSA-N 0.000 description 1
- HHTWOMMSBMNRKP-UHFFFAOYSA-N carvacrol Natural products CC(=C)C1=CC=C(C)C(O)=C1 HHTWOMMSBMNRKP-UHFFFAOYSA-N 0.000 description 1
- 235000007746 carvacrol Nutrition 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 229930183167 cerebroside Natural products 0.000 description 1
- 150000001784 cerebrosides Chemical class 0.000 description 1
- 239000010628 chamomile oil Substances 0.000 description 1
- 235000019480 chamomile oil Nutrition 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 239000010636 coriander oil Substances 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 230000009193 crawling Effects 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 231100000050 cytotoxic potential Toxicity 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000037123 dental health Effects 0.000 description 1
- 210000004262 dental pulp cavity Anatomy 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 238000004141 dimensional analysis Methods 0.000 description 1
- 208000028659 discharge Diseases 0.000 description 1
- ZGSPNIOCEDOHGS-UHFFFAOYSA-L disodium [3-[2,3-di(octadeca-9,12-dienoyloxy)propoxy-oxidophosphoryl]oxy-2-hydroxypropyl] 2,3-di(octadeca-9,12-dienoyloxy)propyl phosphate Chemical compound [Na+].[Na+].CCCCCC=CCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COP([O-])(=O)OCC(O)COP([O-])(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COC(=O)CCCCCCCC=CCC=CCCCCC ZGSPNIOCEDOHGS-UHFFFAOYSA-L 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000010642 eucalyptus oil Substances 0.000 description 1
- 229940044949 eucalyptus oil Drugs 0.000 description 1
- 235000008524 evening primrose extract Nutrition 0.000 description 1
- 239000010475 evening primrose oil Substances 0.000 description 1
- 229940089020 evening primrose oil Drugs 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000004634 feeding behavior Effects 0.000 description 1
- 239000010643 fennel seed oil Substances 0.000 description 1
- 230000004720 fertilization Effects 0.000 description 1
- 239000003337 fertilizer Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 229960004039 finasteride Drugs 0.000 description 1
- DBEPLOCGEIEOCV-WSBQPABSSA-N finasteride Chemical compound N([C@@H]1CC2)C(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)NC(C)(C)C)[C@@]2(C)CC1 DBEPLOCGEIEOCV-WSBQPABSSA-N 0.000 description 1
- 239000000834 fixative Substances 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000021022 fresh fruits Nutrition 0.000 description 1
- 239000000446 fuel Substances 0.000 description 1
- 239000002816 fuel additive Substances 0.000 description 1
- NGGMYCMLYOUNGM-CSDLUJIJSA-N fumagillin Chemical group C([C@H]([C@H]([C@@H]1[C@]2(C)[C@H](O2)CC=C(C)C)OC)OC(=O)\C=C\C=C\C=C\C=C\C(O)=O)C[C@@]21CO2 NGGMYCMLYOUNGM-CSDLUJIJSA-N 0.000 description 1
- 229960000936 fumagillin Drugs 0.000 description 1
- 230000000855 fungicidal effect Effects 0.000 description 1
- 239000000417 fungicide Substances 0.000 description 1
- 150000002270 gangliosides Chemical class 0.000 description 1
- 239000010647 garlic oil Substances 0.000 description 1
- 238000002309 gasification Methods 0.000 description 1
- 239000003254 gasoline additive Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000010648 geranium oil Substances 0.000 description 1
- 235000019717 geranium oil Nutrition 0.000 description 1
- 230000035784 germination Effects 0.000 description 1
- 239000010649 ginger oil Substances 0.000 description 1
- 239000010651 grapefruit oil Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 210000003780 hair follicle Anatomy 0.000 description 1
- 210000002064 heart cell Anatomy 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 238000003898 horticulture Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 201000004614 iritis Diseases 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 230000002262 irrigation Effects 0.000 description 1
- 238000003973 irrigation Methods 0.000 description 1
- WYXXLXHHWYNKJF-UHFFFAOYSA-N isocarvacrol Natural products CC(C)C1=CC=C(O)C(C)=C1 WYXXLXHHWYNKJF-UHFFFAOYSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 239000010656 jasmine oil Substances 0.000 description 1
- 229940119170 jojoba wax Drugs 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 210000000629 knee joint Anatomy 0.000 description 1
- 230000004317 lacrimation Effects 0.000 description 1
- 238000002350 laparotomy Methods 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 239000001102 lavandula vera Substances 0.000 description 1
- 235000018219 lavender Nutrition 0.000 description 1
- 210000002414 leg Anatomy 0.000 description 1
- 235000021374 legumes Nutrition 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 235000011147 magnesium chloride Nutrition 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 229960003390 magnesium sulfate Drugs 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000001525 mentha piperita l. herb oil Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- AQCHWTWZEMGIFD-UHFFFAOYSA-N metolazone Chemical compound CC1NC2=CC(Cl)=C(S(N)(=O)=O)C=C2C(=O)N1C1=CC=CC=C1C AQCHWTWZEMGIFD-UHFFFAOYSA-N 0.000 description 1
- 230000003228 microsomal effect Effects 0.000 description 1
- 229960003632 minoxidil Drugs 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 210000002200 mouth mucosa Anatomy 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- 229940051866 mouthwash Drugs 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000219 mutagenic Toxicity 0.000 description 1
- 239000002086 nanomaterial Substances 0.000 description 1
- 208000010753 nasal discharge Diseases 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 231100001035 ocular change Toxicity 0.000 description 1
- 235000019645 odor Nutrition 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 210000000287 oocyte Anatomy 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000000399 orthopedic effect Effects 0.000 description 1
- 210000003101 oviduct Anatomy 0.000 description 1
- 230000017448 oviposition Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 239000003973 paint Substances 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 238000002161 passivation Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 235000019477 peppermint oil Nutrition 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 150000003905 phosphatidylinositols Chemical class 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000001920 pimenta acris kostel leaf oil terpeneless Substances 0.000 description 1
- 239000001739 pinus spp. Substances 0.000 description 1
- 239000001631 piper nigrum l. fruit oil black Substances 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 239000004476 plant protection product Substances 0.000 description 1
- 239000011505 plaster Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000001738 pogostemon cablin oil Substances 0.000 description 1
- 229920000729 poly(L-lysine) polymer Polymers 0.000 description 1
- 229920000447 polyanionic polymer Chemical class 0.000 description 1
- 229920001601 polyetherimide Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 235000013324 preserved food Nutrition 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 239000012925 reference material Substances 0.000 description 1
- 210000005084 renal tissue Anatomy 0.000 description 1
- 230000008263 repair mechanism Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 239000010666 rose oil Substances 0.000 description 1
- 235000019719 rose oil Nutrition 0.000 description 1
- 239000010668 rosemary oil Substances 0.000 description 1
- 229940058206 rosemary oil Drugs 0.000 description 1
- 239000010670 sage oil Substances 0.000 description 1
- 235000012045 salad Nutrition 0.000 description 1
- 208000026451 salivation Diseases 0.000 description 1
- 239000010671 sandalwood oil Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000001235 sensitizing effect Effects 0.000 description 1
- 229940009188 silver Drugs 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 229960002901 sodium glycerophosphate Drugs 0.000 description 1
- REULQIKBNNDNDX-UHFFFAOYSA-M sodium;2,3-dihydroxypropyl hydrogen phosphate Chemical compound [Na+].OCC(O)COP(O)([O-])=O REULQIKBNNDNDX-UHFFFAOYSA-M 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 description 1
- 235000019408 sucralose Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000006794 tachycardia Effects 0.000 description 1
- 208000008203 tachypnea Diseases 0.000 description 1
- 206010043089 tachypnoea Diseases 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 239000010677 tea tree oil Substances 0.000 description 1
- 229940111630 tea tree oil Drugs 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000007143 thioglycolate medium Substances 0.000 description 1
- 239000001585 thymus vulgaris Substances 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 229940034610 toothpaste Drugs 0.000 description 1
- 239000000606 toothpaste Substances 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- IEDVJHCEMCRBQM-UHFFFAOYSA-N trimethoprim Chemical compound COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 IEDVJHCEMCRBQM-UHFFFAOYSA-N 0.000 description 1
- 238000009966 trimming Methods 0.000 description 1
- 229940036248 turpentine Drugs 0.000 description 1
- 230000017260 vegetative to reproductive phase transition of meristem Effects 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000003253 viricidal effect Effects 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N31/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic oxygen or sulfur compounds
- A01N31/08—Oxygen or sulfur directly attached to an aromatic ring system
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N37/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids
- A01N37/02—Saturated carboxylic acids or thio analogues thereof; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N37/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids
- A01N37/16—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids containing the group; Thio analogues thereof
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
- A01N43/90—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having two or more relevant hetero rings, condensed among themselves or with a common carbocyclic ring system
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N53/00—Biocides, pest repellants or attractants, or plant growth regulators containing cyclopropane carboxylic acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N59/00—Biocides, pest repellants or attractants, or plant growth regulators containing elements or inorganic compounds
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N65/00—Biocides, pest repellants or attractants, or plant growth regulators containing material from algae, lichens, bryophyta, multi-cellular fungi or plants, or extracts thereof
- A01N65/08—Magnoliopsida [dicotyledons]
- A01N65/22—Lamiaceae or Labiatae [Mint family], e.g. thyme, rosemary, skullcap, selfheal, lavender, perilla, pennyroyal, peppermint or spearmint
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N65/00—Biocides, pest repellants or attractants, or plant growth regulators containing material from algae, lichens, bryophyta, multi-cellular fungi or plants, or extracts thereof
- A01N65/08—Magnoliopsida [dicotyledons]
- A01N65/36—Rutaceae [Rue family], e.g. lime, orange, lemon, corktree or pricklyash
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01P—BIOCIDAL, PEST REPELLANT, PEST ATTRACTANT OR PLANT GROWTH REGULATORY ACTIVITY OF CHEMICAL COMPOUNDS OR PREPARATIONS
- A01P1/00—Disinfectants; Antimicrobial compounds or mixtures thereof
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01P—BIOCIDAL, PEST REPELLANT, PEST ATTRACTANT OR PLANT GROWTH REGULATORY ACTIVITY OF CHEMICAL COMPOUNDS OR PREPARATIONS
- A01P3/00—Fungicides
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01P—BIOCIDAL, PEST REPELLANT, PEST ATTRACTANT OR PLANT GROWTH REGULATORY ACTIVITY OF CHEMICAL COMPOUNDS OR PREPARATIONS
- A01P5/00—Nematocides
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01P—BIOCIDAL, PEST REPELLANT, PEST ATTRACTANT OR PLANT GROWTH REGULATORY ACTIVITY OF CHEMICAL COMPOUNDS OR PREPARATIONS
- A01P7/00—Arthropodicides
- A01P7/02—Acaricides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/40—Peroxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
Definitions
- the present invention relates to liposomal ozone nanosolutions with antiviral, antifungal and antibacterial effects suitable for use in human, veterinary, food, agriculture and chemistry.
- nanoparticles have become widespread in the chemical industry in recent years. Efficiency in nano sizes is achieved with smaller particles, and activities on viruses and bacteria increase with the help of these technologies. Simultaneously, active drugs can be transported to organelles such as mitochondria within the cell and more effective treatments can be provided with less chemicals.
- organelles such as mitochondria within the cell and more effective treatments can be provided with less chemicals.
- nano-sized products in other sectors of the chemical industry provides advantages. For example, disinfectant products made with nanoparticles form a film in the application area and cover the environment and it is possible to provide a longer effect with a small amount of product.
- Another particle system made for this purpose is the formation of liposomes. Liposomes are made by breaking down lipids with ultrasonic fat breakdown devices or similar nanotechnological methods.
- Drugs and active substances can be transmitted in these liposomes and the transmission of active substances into cells becomes easier. Normally, it is not possible for the active substances to enter the cancer cells, however it is possible to introduce the active substance into the cancer cell in the liposome. Developments continue in the technical field regarding the use of liposomes and nanocarriers created with oils in the fields of medicine, food, agriculture, veterinary medicine, cosmetics and disinfection.
- patent EP1746976B1 provides liposome compositions containing substituted ammonium and/or polyanion and optionally a desired therapeutic or imaging entity.
- TR97/01683 national patent application relates to the development of liposomal drug delivery systems for the biodistribution of cyclosporine A or similar hydrophobic drugs in body fluids and/or tissues.
- the present invention relates to liposomal ozone nanosolutions which fulfill the abovementioned requirements, eliminate all disadvantages and bring some additional advantages.
- Another aim of the invention is to produce antiviral, antibacterial, antifungal insecticide, acaricide effective, wound healing tissue healer, plant developer, plant protector, bee treatment, liposomal ozone nanosolutions suitable for use in human, veterinary, agriculture and chemistry fields, to contribute to public health on a global scale.
- Another aim of the invention is to present liposomal ozone nanosolutions in formulations with proven stability, whose nanoparticle size distribution, effective ozone dose and ozone release profile can be determined for the field of use and type of application.
- An aim of the invention is to present liposomal ozone nanosolutions with both anti-viral and anti-bacterial activity; non-toxic effect; no negative effect on the viability of healthy cells; that have both regenerative and proliferative effects on human respiratory system (tracheo bronchial) cells.
- Another aim of the invention is to present liposomal ozone nanosolutions that offer stable antibacterial activity on bacteria such as Staphylococcus aureu or Escherichia coli and stable antiviral activity on viruses such as Sars-Cov-2.
- Another aim of the invention is to present liposomal ozone and nanocarrier polymer nanosolutions that do not have irritant or hyperreactive effects on skin, mucosal tissues or ocular, vaginal, rectal areas.
- Another aim of the invention is to present liposomal ozone nanosolutions that do not have cytotoxic effects in mucosal tissues.
- Another aim of the invention is to present products suitable for use as nasal spray, mouth spray, ear drops, eye drops, vaginal solution, rectal solution, intraperitoneal solution, bladder solution, hand and face disinfectant, and surface cleaner for personal hygiene, to be used in the prevention and healing of viral, bacterial or fungal diseases.
- Another aim of the invention is to present antiviral, antibacterial, antiparasitic, antifungal effective barrier solutions on skin and surfaces, suitable for use in human, veterinary, agriculture and chemistry fields containing liposomal ozone nanosolutions.
- Another aim of the invention is to present nasal spray, mouth spray, ear drops, eye drops, vaginal solution, rectal solution, intraperitoneal solution, intravesical solution, intravenous and intraarticular / subcutaneous / intramuscular injection solutions with antiviral, antibacterial, antifungal effect, wound healing tissue healing effect for human, veterinary use containing liposomal ozone nanosolutions.
- the invention mainly consists of nanomaterials obtained from ozonated emulsifier, and also contains nanoparticle liposomes obtained from ozonated oil providing synergetic effect.
- Figure 3 is a coating of ozonated surfactant (emulsifier polysorbates) glycerin and PEG 400. [Density (Percent) x Size (d.nm)]
- Figure 4 is coating with ozonated surfactant and non-ozone surfactant. [Density (Percent) x Size (d.nm)]
- Figure 6 shows the graph of color determination in tomato.
- Figure 8 gives TEA values in tomato.
- Figure 9 gives the yield per plant in tomato.
- Size distribution analysis was carried out only in nanosolutions obtained from ozonated oil in the studies carried out within the scope of the invention and the graph of size distribution according to density is given in Figure 1 .
- Liposomal nanosolutions made with ozonized oil containing 10% ozone gas by weight ranged between 30 nm and 6000 nm, and at most concentrated solutions of 200 and 1000 nanometers could be formed. Dimensional analysis results are shown in Chart 1 below.
- Chart 1 Size distribution analysis results according to density in nanosolution obtained from ozonated oil (Dispersant Rl 1 ,330 Sample Rl 1 , Viscosity 0,8872 cP, 25 C,)
- nanoparticles of this size can transmit ozone into the cell, for example, they will have an antiviral effect on viruses. At the same time, it will increase the energy generation potential of the cell by entering the mitochondria inside the cell and will activate the intracellular repair mechanism by inducing intracellular growth factors.
- solutions made with ozonated oil, ozonated emulsifier, and water the ozone ratio in the oil is determined and solutions are created with the same standards.
- a solution with a high oil content is used for a long-acting solution, and ozone gas is kept in the oil at a rate of 1-5% by weight.
- solutions containing 6- 15% by weight ozone gas are created.
- the effectiveness of liposomal ozone nanosolutions obtained according to the content has been proven by scientific studies in the fields of human, veterinary, food and agriculture; its use in formulations for these areas is also within the scope of the invention.
- ozone emulsifiers Since the pure structures formed by ozone emulsifiers are much smaller particles than liposomes, they reveal more active effects. These structures have active antibacterial effects and at the same time, it is important that they are be coated so as to provide slower released effects. Slower release properties are created by coating the ozone emulsifier with glycerin and PEG. Figure 3 shows the emulsifier liposome.
- niosome The smallest liposome structure formed by coating emulsifiers with emulsifiers is called niosome.
- the smallest niosome structure is formed by coating the ozone emulsifier with non-ozone emulsifiers. In this way, it is possible to obtain niosomes with active and slow- release ozone.
- ozonated polysorbate is again coated with polysorbate.
- these niosomes can be coated with polymers such as glycerin, peg, chitosan, mannitol, and dextran.
- polymers such as glycerin, peg, chitosan, mannitol, and dextran.
- these coatings can be used, especially in intravenous formulations and regional injections, so as to reduce the burning effect of ozone and to ensure that it reaches the target organ more easily.
- the invention described above is basically liposomal ozone nanosolutions containing ozonated emulsifier.
- the "emulsifier” mentioned in the invention is individuals or combinations selected from lecithin, lysophospholipid, polyethylene glycol (PEG), phosphatidylethanolamine (PEG-PE), pluronic, polysorbates (polysorbate 20, polysorbate 80, etc.), or a pharmaceutically acceptable emulsifier.
- the emulsifier mentioned is a polysorbate or PEG.
- the "ozone gas” mentioned in the invention is an allotrope of oxygen (O3), a colorless gas with molecules consisting of 3 oxygen atoms and is found in the upper layers of the atmosphere in nature. Under normal conditions, the amount of ozone in the lower parts of the atmosphere is about 0.04 ppm.
- a preferred embodiment of the invention also contains water.
- Water mentioned in the invention are individuals or combinations selected from distilled water, salt water (NaCI- H2O), sugar water, mineral water, deionized water, demineralized water, spring water, saline solution, physiological saline, and plant waters.
- a preferred embodiment of the invention also includes ozonated oil obtained by passing ozone gas through carrier oil.
- carrier oil is individuals or combinations selected from soybean oil, centaury oil, sesame oil, palm oil, poppy oil, soy lecithin, cholesterol, b-sterol, triglyceride, olive oil, fish oil, sunflower oil, castor oil, saffron oil, coconut oil, triglyceride derivatives, tributyrin, tricaproin, tricaprylin with paraffin, ethyl oleate, methyl oleate.
- a preferred application of the invention also contains at least functional oil.
- “Functional oil” mentioned in the invention is individuals or combinations selected from fixed and/or essential vegetable oils.
- the fixed oils mentioned here are vegetable fixed oils such as coconut oil, almond oil, jojoba oil, rosehip seed oil, avocado oil, sesame oil, apricot seed oil, coconut oil, olive oil, sunflower oil, soybean oil.
- the essential oils mentioned here are essential oils such as sage oil, anise oil, calendula oil, rosemary oil, pine turpentine, cypress oil, tea tree oil, evening primrose oil, bay leaf oil, basil oil, rose oil, borage oil, black pepper oil, clove oil, thyme oil, cumin oil, coriander oil, lavender oil, lemon oil, lemon balm oil, violet oil, myrtle oil, peppermint oil, eucalyptus oil, chamomile oil, orange oil, grapefruit oil, nettle oil, fennel oil, sandalwood oil, garlic oil, cypress oil, jasmine oil, ylang ylang oil, geranium oil, patchouli oil, ginger oil.
- essential oils such as sage oil, anise oil, calendula oil, rosemary oil, pine turpentine, cypress oil, tea tree oil, evening primrose oil, bay leaf oil, basil oil, rose oil, borage oil, black pepper oil, clove oil, thy
- a preferred application of the invention also contains at least one organic acid.
- Organic acid mentioned in the invention are individuals or combinations selected from among formic acid, phosphoric acid, hydrochloric acid, acetic acid, propionic acid, butyric acid, valeric acid, caproic acid, oxalic acid, lactic acid, malic acid, citric acid, benzoic acid, carbonic acid, phenol, uric acid, taurine, aminomethylphosphonic acid.
- a preferred application of the invention also contains at least an excipient.
- excipients are individuals or combinations selected from among anesthetics, pharmaceuticals pharmaceutical active substances such as water and/or fat soluble vitamins, minerals, hyaluronic acid, thymol, menthol, glycerin, ethyl alcohol, cetyl alcohol, butyl alcohol, benzyl alcohol, amino acids, acetyl cysteine, glutathione, herbal extracts, lidocaine, xylocaine.
- Preferred applications of the invention consist of nanoparticle liposomes containing ozonated emulsifier and/or ozonated carrier oil, glycerin, hyaluronic acid, menthol, distilled water, NaCI composition.
- the embodiments of the invention include 10 stock ppm- 60 000 stock ppm ozone gas.
- the embodiments of the invention contain stable active ozone gas at doses of 100 ppm, 200 ppm, 500 ppm, 1000 ppm, 1600ppm, 2000 ppm, 3000 ppm, depending on the application area.
- Preferred embodiments of the invention include liposomal ozone nanoparticles in sizes below 1000 nm, preferably below 200 nm, more preferably below 50 nm.
- the method of forming liposomal ozone nanosolutions includes the following steps:
- An example of the invention consists of ozonated emulsifier.
- the emulsifier chosen for the production of this exemplary composition is weighed. It is ozonized by passing ozone gas through the emulsifier, the amount of which is determined. Ozonation processes are carried out with ozone micro/nano-bubble generators. The ozonized emulsifier is weighed again, and the amount of ozone gas absorbed in it is measured by weight. Nanoparticle sizes containing ozone nano-bubble can be reduced to the range of 5-50 nm by nanotechnological methods. In Table 1 , the content information of an example of the invention obtained by this method is given.
- emulsifiers containing 10 - 50 000 stock ppm ozone gas are obtained.
- the preferred ozonated emulsifier herein is a polysorbate or PEG.
- These nanosolution concentrates preferably contain 10000 stock ppm of ozone gas.
- Another example of the invention is ozonated nanosolution obtained with water from ozonated emulsifiers.
- a nanosolution is obtained by mixing the ozonated emulsifier, whose ozone amount is determined as above, with the required amount of water with blade mixers with at least 12000 rpm. Nanoparticle sizes containing ozone nano-bubble can be reduced to the range of 5-50 nm by nanotechnological methods.
- first the water is ozonated and the emulsifier ozonated water is mixed.
- Table 2 the content information of an example of the invention obtained by said methods is given. Accordingly, nanosolutions containing 100 - 35 000 stock ppm ozone gas are obtained.
- the preferred ozonated emulsifier herein is a polysorbate or PEG. These examples may preferably contain at least one excipient described above. These nanosolution concentrates preferably contain 500 stock ppm of ozone gas.
- Another example of the invention is the nanosolution obtained with ozonated carrier oil and water from ozonated emulsifiers.
- the amount of emulsifier is determined, ozonized and weighed to determine the ozone content.
- the selected carrier oils are ozonated by determining their amounts and weighed to determine the ozone content.
- the obtained ozonated emulsifier, ozonated carrier oil is mixed with the required amount of water with blade mixers with at least 12000 revolutions to obtain a nanosolution.
- Ultrasonic cavitation can be used to reduce the size of liposomes containing ozone nano-bubbles to the desired range by nanotechnological methods.
- Liposomal nanoparticle sizes containing ozone nano-bubble can be reduced to the range of 5-50 nm by nanotechnological methods.
- Table 3 the content information of an example of the invention obtained by said methods is given. Accordingly, nanosolutions containing 100 - 45 000 stock ppm ozone gas are obtained.
- the preferred example of ozonated emulsifier herein is ozonated polysorbate or PEG, and ozonated carrier oil is sunflower oil or olive oil.
- thymol, orange oil, clove oil, lemon oil can be added.
- These examples may preferably contain at least one excipient described above.
- These nanosolution concentrates preferably contain 1100 stock ppm of ozone gas.
- Another example of the invention is ozonated liposomal nanosolutions obtained with ozonated carrier oil from ozonated emulsifiers, and at least one organic acid.
- the amount of emulsifier is determined, ozonized and weighed to determine the ozone content.
- the selected carrier oils are ozonated by determining their amounts and weighed to determine the ozone content.
- Nanosolution is obtained by mixing the ozonized emulsifier, ozonated carrier oil with the required amount of water and selected organic acid with blade mixers with at least 12000 rpm. Ultrasonic cavitation can be used so as to reduce particle sizes.
- Table 4 the content information of an example of the invention obtained by said methods is given.
- nanosolutions containing 10 000-60 000 stock ppm ozone gas are obtained.
- the preferred ozonated polysorbate or PEG herein is ozonated carrier oil, it is a vegetable oil preferably sunflower oil, olive oil, soybean oil, thymol, orange oil, clove oil, lavender oil, nettle oil, lemon oil, if it is organic acid; it is preferably 100% acetic acid.
- These examples may preferably contain at least one excipient described above.
- These nanosolution concentrates preferably contain 30000 stock ppm of ozone gas.
- ozonated liposomal nanosolutions obtained in situ with ozonated carrier oil, at least one organic acid and at least one functional oil from ozonated emulsifiers.
- ozonated oil, ozonated emulsifier and organic acid and functional oils are presented as a composition without mixing thereof. They stand in separate layers. Nanoparticles are formed as a result of mixing them with mixer and water by throwing them into water boilers in agriculture. The aim here is to make carrying easier. For example, 1-6 kilos of stock composition can be thrown into 1 ton of water and spraying can be done on the field.
- Table 5 the content information of an example of the invention obtained by said methods is given.
- nanosolutions containing 10 000-60 000 stock ppm ozone gas are obtained.
- the preferred ozonated polysorbate or PEG herein is ozonated carrier oil, it is a vegetable oil preferably sunflower oil, olive oil, soybean oil, functional oil preferably oil, thymol, orange oil, clove oil, lavender oil, nettle oil, if it is organic acid, it is preferably acetic acid.
- These samples preferably contain at least one excipient described above.
- These nanosolutions preferably contain 30 000 stock ppm of ozone gas.
- Another example of the invention is ozonated liposomal nanosolutions obtained from ozonated emulsifiers with ozonated carrier oil, at least one organic acid, at least one functional oil and alcohol.
- the amount of emulsifier is determined, ozonized and weighed to determine the ozone content.
- the selected carrier oils are ozonated by determining their amounts and weighed to determine the ozone content.
- Nanosolution is obtained by mixing the ozonized emulsifier, ozonated carrier oil with the required amount of water, selected organic acid, functional oil, and alcohol with blade mixers with at least 12000 rpm.
- Table 6 the content information of an example of the invention obtained by said methods is given.
- nanosolutions containing 10 000-60 000 stock ppm ozone gas are obtained.
- Preferred herein are ozonated emulsifier polysorbate or PEG, ozonated carrier oil preferably sunflower oil, olive oil and/or soybean oil; the preferred organic acid is 100% acetic acid, and the alcohol is 100% pure vegetable alcohol; the preferred functional oil is thyme oil, orange oil, clove oil, lavender oil, nettle oil and/or lemon oil.
- These examples may preferably contain at least one excipient described above.
- These nanosolution concentrates preferably contain 30000 stock ppm of ozone gas.
- the antibacterial, antivirus, antifungal, antiparasitic wound healing and tissue healing properties of the liposomal ozone nanosolutions described above have been proven by the following scientific analyzes.
- the barrier solution of the invention for barrier formation and applications for intraarticular / subcutaneous / intramuscular injection are suitable for use in the fields of human, veterinary, food, agriculture and chemistry, examples of which are as follows: as a disinfectant, preservative or food supplement in the food industry; as a disinfectant, repellent, feed additive in the livestock sector; use in the health sector, especially in dermatology, ear-nose-throat, eye diseases, oral-dental diseases, digestive system, urology, gynecology, orthopedics, circulatory system diseases, in therapeutic pharmaceutical compositions in gastroenterology, ozone therapy and mesotherapy,
- the antiviral activity mentioned within the scope of the invention may comprise the following viral classes such as Herpesviridae, Hepadnaviridae, HIV, Togaviridae, Arenaviridae, Flaviviridae, Orthomyxoviridae (Influenzavirus A, influenzavirus B, influenzavirus C, isavirus, thogotovirusj, Paramyxoviridae, Bunyaviridae, Rhabdoviridae, Filoviridae, Coronaviridae (Corona virus, in particular Sars-Cov-2), Bornaviridae, Arteriviridae and Retroviridae.
- viral classes such as Herpesviridae, Hepadnaviridae, HIV, Togaviridae, Arenaviridae, Flaviviridae, Orthomyxoviridae (Influenzavirus A, influenzavirus B, influenzavirus C, isavirus, thogotovirusj, Paramyxoviridae, Bunyaviridae
- the antibacterial activity mentioned within the scope of the invention may comprises bacterial classes such as; Aeromonas hydrophila, Arcanobacterium pyogene, Bacillus thurgiensis, Bacillus anthracis, Bacillus cereus, Clostridium botulinum, Clostridium perfringens, Clostridium septicum, Clostridium sordellii, Clostridium tetani, Corynebacterium diphtheriae, Escherichia coli, Listeria monocytogenes, Pseudomonas aeruginosa, Staphylococcus aureus, Streptococcus pneumonia, Streptococcus pyogenes intermedius or Vibrio cholera.
- Other bacterial infections considered are eye, ear, nose, throat, vaginal, rectal infections.
- Hair solutions containing combined vitamins, minerals, and active ingredients such as minoxidil and finasteride for hair growth and new hair growth 500-2000ppm Bee solutions for use in beekeeping treatments. (2000 ppm liposomal ozone nanosolution + thymol + sugar water mixture)
- Ozone emulsifier and oil mixture or ozone emulsifier water mixture containing 500-10000 ppm ozone Serum solution for use in parenteral injections.
- Injectable solution containing active ingredients such as combined fat-soluble vitamins, hyaluronic acid, amino acids and minerals, anesthetic agents such as lidocaine, for subcutaneous, intramuscular, intraarticular mesotherapy. It contains 300-2000 ppm of ozone.
- Injectable solution offered in antiseptic spray, ampoule, injection and vial forms for intracavity and root canal treatment in dental health contains 300-2000 ppm of ozone.
- Injectable solution offered in syringe, vial, ampoule forms for intramuscular, intra-articular, intravenous, subcutaneous, intravaginal, intraperitoneal injection for the treatment of infection in order to protect animal health. It contains 300-3000ppm ozone.
- - Solution for use as a repellent, insecticide and disinfectant in environments such as chicken farms, barns and pens. It contains 500-10000 ppm ozone.
- Hygiene product presented in the form of spray or solution for wound and skin care, disinfection, hygiene in order to protect animal health. It contains 2000-10000 ppm ozone.
- Hygiene product presented in the form of spray or solution for wound and skin care, disinfection, hygiene for human health. It contains 2000-10000 ppm ozone.
- - Food solution which is used by dipping or spraying method to prevent spoilage of dried foods and legumes, to provide insecticide and repellent effect. It contains 500- 3000 ppm ozone.
- - Food solution served as a food supplement, as a capsule, as a single-use beverage or in combination with other beverages and sweeteners. It contains 100-1000 ppm ozone.
- Disposable or multiple wet wipes contains 1000-10000 ppm ozone.
- It contains antibacterial, antiviral, antifungal, antiparasitic fertilizer solution for use in soilless agriculture. It contains 500-5000 ppm ozone.
- Seed solution for use in germination so as to develop seeds, to provide antibacterial effect in seed aquaculture and to remove soil pathogens. It contains 500-5000 ppm ozone
- Fuel additive solution mixed with petroleum products to increase vehicle performance in the chemical industry. It contains 1000-20000 ppm ozone.
- Ozonated emulsifier preferably polysorbate and water, thymol, carvacrol and other chemotherapeutic agents and solutions in liposome combined with ozonated oil and nanocarriers and cancer drugs such as paclitaxel combined with intravenous or local injection in cancer treatment. It contains 500-5000 ppm ozone.
- Mesotherapy products for skin repair contain ozonated emulsifier nanoparticle liposomes obtained from ozonated oil, amino acid complex, mineral complex, panthotenic acid; in particular, they contain nanoparticle ozone liposomes, l-arginine, glycine, l-histidine, I- isoleucine, l-leucine, l-lysine, l-methionine, l-phenylalanine, l-proline, l-serine, l-threonine, I- tryptophan , l-tyrosine, l-valine, sodium acetate, sodium glycerophosphate, potassium chloride, magnesium chloride, calcium chloride, panthothenic acid, sodium chloride, distilled water.
- Anti-aging mesotherapy products for skin contain ozonated emulsifier, nanoparticle liposomes from ozonated oil, vitamin complex, tranexamic acid, acetyl cysteine; in particular, they contain nanoparticle ozone liposomes, thiamine pyrophosphate, riboflavin, pyridoxine hydrochloride, niacinamide, d panthenol, ascorbic acid, glutathione, tranexamic acid, acetyl cysteine, sodium chloride, distilled water.
- Mesotherapy products for hair care contain ozonated emulsifier, nanoparticle liposomes obtained from ozonated oil, vitamin complex, biotin, acetyl cysteine, pantothenic acid; in particular, they contain nanoparticle ozone liposomes, thiamine pyrophosphate, riboflavin, pyridoxine hydrochloride, niacinamide, d panthenol, ascorbic acid, biotin, glutathione, acetyl cysteine, magnesium sulfate, sodium chloride, distilled water
- Accelerated Aging Time was calculated as 37 days corresponding to 365 days (1 year) Real Time Aging (RT) with accelerated aging (stability) tests of 1.000 ppm and 1.600 ppm applications of nanosolution according to ASTM F1980 standard. Accelerated Aging Time After 37 days, the solutions were found to be stable. After accelerated aging (stability) tests, no bacterial growth was observed in the solutions in sterility tests of 1 .000 ppm and 1 .600 ppm applications of nanosolution according to ISO 11737-2 standard.
- Staphylococcus aureus (ATCC 25923) and Escherichia coli (ATCC 25922) bacterial suspensions were adjusted to 1x105 density and applied to 1.000 ppm and 1.600 ppm solutions. At the end of 2-360 minutes, it was transferred to the culture medium and then it was evaluated whether there was any growth in the media. Test results are given in Chart 1 and 2.
- Accelerated Aging Time was calculated as 37 days corresponding to 365 days (1 year) Real Time Aging (RT) with accelerated aging (stability) tests of 1 .000 ppm and 1 .600 ppm applications of nanosolution according to ASTM F1980 standard. Accelerated Aging Time After 37 days, the solutions were found to be stable.
- the antibacterial activities of 2000 ppm and 3000 ppm applications of the nanosolution of the invention were determined according to the method adapted from the CLSI M07 A9 standard test method.
- Staphylococcus aureus (ATCC 6538) and Escherichia coli (ATCC 25922) bacterial suspensions were adjusted to 1x10 5 density and applied to 2000 ppm and
- the inventive irritation test of liposomal ozone nanosolution was carried out considering TS EN ISO 10993-10:2010 standard, the experimental animal used in the test is considered according to TS EN ISO 10993-2:2006 standard, the material preparation is made according to TS EN ISO 10993-12:2013 standard guidelines. Three healthy young New Zealand albino rabbits with a body weight of 2-3 kg were used as experimental animals.
- Sodium lauryl sulphate (SLS) was used as a positive control and distilled water was used as a negative control.
- the sponge impregnated with the nanosolution of the invention was kept in direct contact with the sample application areas. SLS impregnated sponge was applied to the positive control area.
- the samples were covered with gauze, fixed with a bandage, and topically contacted with the back skin for 4 hours.
- the primary irritation index was determined by evaluating the application areas (1 ⁇ 0.1) s, (24 ⁇ 2) s, (48 ⁇ 2) s, and (72 ⁇ 2) hours after the 4th hour application, according to the skin reaction score given in Chart 1 . As stated in the standard, the 1 st hour was not included in the calculation.
- Cytotoxicity refers to the rate of toxic effects on living cells. Cytotoxicity tests are tests that are evaluated by considering the cell proliferation rate and the toxic effect on the cell in the appropriate cell culture of the substance considered to be toxic. These test systems are carried out for morphological observation of cellular damage, determination of cellular damage by various measurement methods, determination of cellular growth, determination of any change in cellular metabolism. Cytotoxicity tests can be performed in vivo or in vitro. In in vitro tests, the substance whose cytotoxicity is investigated is administered to cells in increasing concentrations. The effects of this substance on cell morphology and cell survival rates are investigated.
- MTT method [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide]: In this method, MTT is reduced to formazan, while the color formed is measured colorimetrically. The amount of formazan produced gives the number of viable cells. MTT is a substance that is actively absorbed into cells and reduced to colored, water-insoluble formazan by a mitochondria-dependent reaction. The MTT reduction property of the cells is taken as a measure of cell viability and the dye density obtained as a result of MTT analysis correlates with the number of viable cells.
- test system used in this research is based on the following standards;
- TS EN ISO 10993-5:2009 Biological evaluation of medical devices - Part 5:Tests for in vitro cytotoxicity.
- TS EN ISO 10993-1 :2018 Biological evaluation of medical devices - Part 1 Evaluation and testing.
- TS EN ISO 10993-5:2009 Biological evaluation of medical devices - Part 12: Sample preparation and reference materials. USP 31 , 2008, Chapter 87 - Biological reactivity tests, in vitro .
- the medium on the culture was removed and 100mI of test material was added from the positive and negative control extracts. All doses were administered with at least 5 repetitions. At the end of 48 hours of waiting in an oven with 5% C02 at 37 ⁇ and 95% humidity, the culture medium was removed after the plates were examined.
- PK Positive Control
- the culture medium was removed from the wells. 50 mI of MTT solution was added to each test well. The plates were incubated for 2 hours at 37 TT Then, the MTT solution was removed from the wells and 100 mI of isopropanol was added to each well. Absorbance measurements were taken and evaluated with a microplate reader containing a 570 nm filter.
- test material If the viability of the test material is less than 70%, it is considered cytotoxic.
- Chart 1 Results of quantitative measurement of cytotoxic effects by MTT Test.
- the % vitality value was determined according to the formula below.
- OD570 TM lt is the average value of the optical density value of the test material after the blank is removed.
- OD570 NK lt is the average value of the optical density value of the negative control after removing the blank.
- test results carried out in line with the directive of the TS EN ISO 10993- 5:2009 standard it was determined that the test material, the liposomal ozone nanosolution of the invention, did not have a cytotoxic effect.
- the experiment aims to test the material or product that has the potential to cause ocular irritation.
- the ocular irritation test is only performed for materials that will come into contact with the eye or eyelid and when safety information cannot be obtained by other means.
- the test material is carried out in accordance with the directions specified in TS EN ISO 10993- 10:2010 annex A. If the material to be tested is liquid, 0.1 ml undiluted (1600 ppm dose) is dripped into the lower conjunctival sac of one eye. If the test material is in the spray pump, it is removed from the pump and tested by dropping 0.1 ml. as in liquids. We used 3 healthy young adult albino rabbits of both sexes weighing 2 kg to 3 kg from a single strain.
- the animals were kept in the environmental conditions specified in TS EN ISO 10993-2:2006. Both eyes of each rabbit are visually inspected up to 24 h prior to the start of the experiment so as to determine if an ocular abnormality is present. When the eyes are examined, 2% sodium fluorescein BP (British Pharmacopoeia) can be used to visualize any corneal damage. After the test sample was instilled into the conjunctival sac, the eyelids were held together for about 1 hour. For Observation of Animals and determination of the Irritation index, it is examined at approximately (1 ⁇ 0.1) s, (24 ⁇ 2) s, (48 ⁇ 2) s, and (72 ⁇ 2) s. Since no lesion was observed, it was not necessary to advance the observations to longer periods. Observations were graded according to the grading scale of the ocular lesions given in Chart 1.
- Oral mucosal irritation test was carried out considering the TS EN ISO 10993-10:2010 standard, the experimental animal used in the test is considered according to TS EN ISO 10993-2:2006 standard, the material preparation is made according to TS EN ISO 10993- 12:2012 standard guidelines. The test is performed for materials intended to come into contact with oral tissue and where safety data cannot be obtained by other means.
- Saline solution- impregnated absorbent gauze was used as negative control.
- HCI acid solution adjusted to pH 1 .5 was used in our laboratory based on the rule that liquids with pH 2 and below are considered irritating.
- the left inner cheek pouch of each animal was evaluated for the experimental sample, and the contralateral (Right) inner cheek was considered as the negative control. No material was placed into the right side inner cheek pouch, it was only washed with physiological saline and dissected at the end of the experiment.
- Gauze cloth impregnated with a usage dose of 1600 ppm of the nanosolution of the invention was placed in the left inner cheek pouch of Syrian hamsters under ketamine/Xylazine anesthesia, whose inner cheeks were emptied and washed with saline. After the exposure of the subject to the sample for 1 hour, the sample was removed and the inner cheek was rinsed with saline solution, taking care not to contaminate the other cheek. Experiment (left) and control (right) inner cheek pouches were evaluated macroscopically according to chart 1. The experiment was terminated after 1 hour of contact.
- Chart 1- Rating system for Oral and Penile reactions According to the standard directive, the exposure time should reflect the actual expected use time of the material, but should not be less than 5 minutes.
- the repeated observation rating (Table 1) performed at long-term chronic exposures is summed up and divided by the total repeat application 4. Since it is a device with subacute use, the application was performed 4 times with one hour intervals. Observations of the sample applied left inner cheek were compared with the right inner cheeks (negative control) washed with saline.
- Chart 2 Grading system for microscopic examination of oral, penile, rectal and vaginal tissue reaction
- Chart 4 Microscopic irritation score When the Hematoxylin-Eosin (HE) stained preparations prepared from the inner cheek samples taken for histopathological examination from the test product applied group are examined under the microscope, there was no erosion or ulceration in the mucosa, epithelium, leukocyte infiltration and vascular congestion. After Hematoxylin-Eosin (HE) stained preparations prepared from inner cheek samples taken for histopathological examination were examined under a microscope, it was evaluated whether there was any erosion or ulceration in the epithelium in the mucosa, leukocyte infiltration and vascular congestion.
- HE Hematoxylin-Eosin
- Nasal mucosal irritation test was carried out considering the TS EN ISO 10993-10:2010 standard, the experimental animal used in the test is considered according to TS EN ISO 10993-2:2006 standard, the material preparation is made according to TS EN ISO 10993- 12:2012 standard guidelines. The test is performed for materials intended to come into contact with nasal tissue and where safety data cannot be obtained by other means.
- the experimental group was formed by dripping a single dose (1 ml) of 1600 ppm nanosolution of the invention into the nasal cavity for 4 days.
- the control group was formed by dripping the same amount of saline nanosolution into the nasal cavity for 4 days.
- the noses of the subjects who were euthanized under high-dose Ketamine/Xylazine anesthesia were dissected and taken into decalcification process to soften the bones after 10% formalin fixative.
- the animals were observed clinically during the 4-day administration of the test sample. No signs of nasal redness, discharge or restlessness were observed in the experimental and control group subjects. The animals displayed normal feeding and social behavior. Microscopic evaluation in the nasal mucosal irritation test was performed by considering the parameters examined in the vaginal, rectal and penile irritation tests (Chart 2).
- Chart 2 Grading system for microscopic examination of oral, penile, rectal and vaginal tissue reaction
- Chart 3 Irritation Index Macroscopic observations and microscopic evaluations made according to TS EN ISO 10993-10:2010 standard are given in Chart 1.
- no irritation appearance (erythema or eschar) was observed in the sample-applied nasal mucosa, similar to the controls. Areas of mucosal erosion were noted in positive controls.
- the mean irritation index was calculated as zero (0) for each animal except the positive control.
- Chart 1 Microscopic irritation score After Hematoxylin-Eosin (HE) stained preparations prepared from nasal samples taken for histopathological examination were examined under a microscope, it was evaluated whether there was any erosion or ulceration in the epithelium in the mucosa, leukocyte infiltration and vascular congestion. No findings reflecting the irritating effect of the nasal mucosal structures of the application of the product samples of the nanosolution of the invention were found in the subjects in the light microscopic histopathological examination. It was determined that the nanosolution of the invention did not have an irritating effect on the nasal mucosa according to the results of the macroscopic and histopathological evaluations of the nasal mucosal irritation test applied for materials likely to come into contact with the nasal tissue (TS EN ISO 10993-10).
- HE Hematoxylin-Eosin
- Sensitization test was carried out considering the TS EN ISO 10993-10:2010 standard by the Closed Patch-Buehler Test method, the experimental animal used in the test is considered according to TS EN ISO 10993-2:2006 standard, the material preparation is made according to Annex A standard guidelines.
- Chart 1 Magnusson and Kligman rating scale
- Saline solution-impregnated absorbent gauze was used as negative control.
- As a positive control 0.8% paraformaldehyde solution is used in our laboratory.
- the gauze impregnated with the inventive nanosolution was applied in direct contact with the upper left and lower right regions of the shaved area. The samples were thus kept in contact with the shaved back skin of the animal for 6 hours.
- epithelial cell culture was first performed. Therefore, the epithelial tissue piece obtained from a biobank was taken into saline (0.09% NaCI) after thawing and separated into small pieces in sterile petri dishes. Pre-prepared medium containing 10% fetal bovine serum and 1% antibiotic was cultured. After reaching sufficient maturity and saturation in cell culture dishes, they were left to incubate for varying times with varying doses of the product.
- Tracheo-bronchial epithelial cells supplied and generally targeted by human respiratory system viruses were subjected to cell culture process by means of the bioreactor system in its infrastructure to provide an organotypic culture medium.
- DMEM pre-prepared medium
- cell culture was continued for another 48 hours by washing with ready-made media.
- cells were trypsinized with 0.25% trypsin-EDTA and passaged into other units of the bioreactor system that allow passage into the same medium.
- the culture was maintained by renewing the medium based on color and pH changes until the cells planted in these areas covered 80% of the surface area.
- the cells reach the saturation level in their environment, the cells in a single chamber are exposed to trypsin-mediated treatment, then the 3-dimensional cell culture was separated from the surface and washed.
- the active substance studies were continued with time and dose adjustments. As a result of the studies, its positive effect on cell proliferation was determined. This study was carried out using bioreactors and culture media that have the ability to imitate human nature.
- the effect of the active substance on the corona virus SARS COV-2 virus lysate was measured fluorometrically in a dose and time dependent manner in terms of both its effect on the initial volume and its effect on cDNA conversion, presented in the chart below.
- the determination of statistically significant activity at 1000 ppm in a 5-minute incubation period is also in line with previous bacterial activity studies, it has been revealed that the product subject to the study can have both viral and bacterial activity.
- the inventive liposomal ozone nanosolution was concluded that it has both viral and bacterial activity found; does not cause toxic effects; does not have a negative effect on the viability of healthy cells; has both regenerative and proliferative effects on human respiratory system (tracheo-bronchial) cells.
- Genotoxicity tests were performed on the samples of liposomal ozone nanosolutions of the invention for Intra-articular/Subcutaneous/lntramuscular Injection and has been shown to have no mutagenic potential.
- Genotoxicity (Bacterial Ames Test) (OECD 471) Information Studies for the development of various test systems to elucidate the mutagenic effect and the detection of mutagens and to reduce the risk of hereditary diseases and cancers caused by mutagenesis for humans constitute one of the most important research areas of genetic toxicology.
- the Ames test which was developed by Bruce Ames in 1972 and applied as a screening test to determine the mutagenic effects of chemical substances, is widely and reliably used as a short-time bacterial test system.
- the Ames test is considered as one of the reliable methods to examine the toxic, mutagenic-carcinogenic effects of test substances, which are intended to be used as pharmaceutical raw materials.
- test material For solid test material: According to OECD 471 guidelines, 0.5 g of test product was dissolved in 10 mL of DMSO, vortexed, and a 2-fold serial dilution was made. Final concentrations of the test were adjusted to be 5 mg/plate, 2.5 mg/plate, 1 .25 mg/plate, 0.625 mg/plate, and 0.3125 mg/plate.
- test material For liquid test material: According to OECD 471 guidelines, 50 mI_ of test product was dissolved in 1 mL of DMSO, vortexed, and a 2-fold serial dilution was made. Final concentrations of the assay were adjusted to be 5 pL/plate, 2.5 pL/plate, 1.25 pL/plate, 0.625 pL/plate, and 0.3125 pL/plate.
- Positive Control Different positive control products are used based on different bacterial strains. Description of bacterial strains and individual concentrations of mutagens are shown below:
- S9 mix For the metabolic activation system (S9 mix), Arachlor 1254- induced lyophilized rat liver S9 microsomal fraction was used. The mutagenic potential of the extracts was evaluated in the presence and absence of the S9 mixture. A 30% S9 mixture was used in the tests.
- Acute systemic toxicity test was performed on the samples of liposomal ozone nanosolutions for Intra-Articular/Subcutaneous/lntramuscular Injection of the invention and it was determined that there was no acute toxicity effect.
- Acute systemic toxicity test was carried out considering the TS EN ISO 10993-11 :2018 standard, the experimental animal used in the test is considered according to S EN ISO 10993-2:2006 standard, the material preparation is made according to TS EN ISO 10993- 12:2012 standard guidelines.
- test material was carried out in accordance with the TS EN ISO 10993-12:2012 sample preparation guide. Intra-Articular/Subcutaneous/lntramuscular Injection nanosolution was injected intramuscularly at an amount of 2ml/kg body weight (TS EN ISO 10993-11 :2018- 4, Appendix B).
- Liposomal ozone nanosolution was injected intramuscularly into the gluteal region of the subjects at an amount of 2 ml/kg body weight.
- 6 (3 $/3 ) BalbC mice were injected with saline in the amount of 2ml/kg body weight and the control group was formed.
- the control group subjects were kept in the same environment with the experimental group and fed in the same way. Subjects were kept under clinical observation for three days (Chart 1).
- Body weight The body weight of the subjects was in the range of 23-33 g, and there was no remarkable change in weights. Chart 1 : Common clinical signs, observations. Activation: No changes were observed in the motility and daily activations of the subjects. Increasing and decreasing drowsiness, fatigue, trembling, twitching behaviors were not observed.
- Body temperature 36.5°C was observed at a normal level.
- test material negative and positive groups was carried out in accordance with ISO 10993-12 standards.
- the extract was prepared by keeping 0.2 grams/ml of test material in DMEM 10% FBS for 72 ⁇ 2 hours at 37 ⁇ 1 oC in a shaking incubator at 200 rpm (The specified standard is based on irregular shaped solid devices. This case is chosen as the worst-case scenario). It was filtered through a 0.22 pm sterile filter and defined as 100% extract. Percentages of other extracts were formed by dilution of DMEM 10% FBS. No color change was observed (In-lab test method).
- L-929 mouse fibroblast cell line from ATCC for cytotoxicity test study (NCTC clone 929: CCL 1 , American Type Culture Collection [ATCC] was used.
- Cells were propagated in DMEM (dulbecco's modified eagle medium) (ATCC Cat No: 30-2006) medium supplemented with 10% FBS (fetal bovine serum) and 2% glutamine and incubated at 370 in an oven with 5% C02. A mixture of 0.25% trypsin and 0.03% EDTA was used for trypsinase of cells as recommended by ATCC.
- Cells were suspended in culture medium and 100mI was transferred to 96-well plates with 104 cells in each well.
- the medium on the culture was removed and 10OmI of test material was added from the positive and negative control extracts. All doses were administered with at least 5 repetitions. At the end of 48 hours of waiting in an oven with 5% C02 at 37 ⁇ and 95% humidity, the culture medium was removed after the plates were examined.
- Negative control Cell culture medium (DMEM + 10% FBS) was incubated under the same conditions as the extracts for 72 hours.
- PC Positive Control
- Test Material (TM) concentrations It was diluted with DMEM+ 10% FBS as 100 -30-10 -3- v/v.
- the culture medium was removed from the wells. 50 mI of MTT solution was added to one of its test wells. The plates were incubated for 2 hours at 37 O. Then, the MTT solution was re moved from the wells and 100 mI of isopropanol was added to each well. Absorbance measurements were made and evaluated with a microplate reader containing a 570 nm filter. Absorbances greater than 0.2 were accepted as the general validity criterion of the test. If the viability of the test material is less than 70%, it is considered cytotoxic.
- Chart 1 Results of quantitative measurement of cytotoxic effects by MTT Test.
- test material does not have a cytotoxic effect according to the test results carried out in line with the directive of TS EN ISO 10993-5 standard. Irritation Test result of Liposomal Ozone Nanosolutions in TS EN ISO 10993-10:2010 Standards
- Irritation test on liposomal ozone nanosolution samples of the invention for Intra- Articular/Subcutaneous/lntramuscular Injection was carried out considering TS EN ISO 10993-10:2010 standard, the experimental animal used in the test is considered according to TS EN ISO 10993-2:2006 standard, the material preparation is made according to TS EN ISO 10993-12:2013 standard guidelines.
- Test material given under the title of TS EN ISO 10993-10:2010 annex A A.2,2 Liquid test materials; Liquids should be tested without dilution or by direct precipitation or, if not applicable, by diluting with physiological saline to 1/4 dose, which is the usage dose in accordance with the directive that it should be tested by diluting with a suitable liquid.
- SLS Sodium lauryl sulphate
- the sponge impregnated with liposomal ozone nanosolution was kept in direct contact with the sample application areas no 2 as shown in figure 2.
- SLS-impregnated sponge was applied to the positive control area (area no 3).
- the samples were covered with gauze, fixed with a bandage, and topically contacted with the back skin for 4 hours.
- the primary irritation index was determined by evaluating the application areas (1 ⁇ 0.1 ) s, (24 ⁇ 2) s, (48 ⁇ 2) s, and (72 ⁇ 2) hours after the 4th hour application, according to the skin reaction score given in Chart 1 . As stated in the standard, the 1st hour was not included in the calculation.
- Subcutaneous Implantation test was performed on the inventive liposomal ozone nanosolution samples for Intra-Articular/Subcutaneous/lntramuscular Injection and it has been shown that it does not cause any inflammatory reaction.
- test method determines the history and course of the tissue response, which includes the eventual integration or resorption/degradation of the material after medical device/biomaterial implantation. Particularly, the degradation properties and texture response of the material are determined for degradable/absorbable materials.
- Implants are tested by placing them in the back subcutaneous tissue of adult mice, rats, guinea pigs or rabbits.
- Healthy Wistar rats weighing 200-300 g and 10 weeks old of both sexes were used in the test studies.
- the subjects were kept in a sheltering area with 60% humidity and a constant temperature of 22°C during the test.
- the subjects were given normal rat feed and tap water. Dust-free autoclaved wood shavings were used as substrate. At the end of the experiment, all animals were euthanized.
- Liposomal ozone nanosolution samples could not be applied directly under the skin (implantation).
- Product implantation was performed under operating room conditions by placing rats anesthetized at a dose of Ketamine 85 mg/kg, Xylazine 15 mg/kg body weight, under the dorsal skin on either side of the spine. After the hairs were removed by shaving the operation area, it was cleaned by wiping with an antiseptic solution. The implantation period was determined as 2 weeks, and at the end of the process, the subjects were euthanized using deep anesthesia, and the implantation areas were opened, and macroscopic observation was made. Tissue samples dissected from the implantation area were taken for microscopic examination.
- the treated animals did not show any abnormalities in their daily behavior and activation. No abnormality was observed in its movements and walk. Their eating habits and social behavior in the cage were normal.
- Intramuscular Implantation test of liposomal ozone nanosolution samples of the invention for Intra-Articular/Subcutaneous/lntramuscular Injection was performed and it has been shown that it does not cause any deformative or inflammatory effects in muscle tissue.
- the aim of the test method is to determine the date and course of the tissue response, which includes the eventual integration or resorption/degradation of the material after implantation of the medical device/biomaterial. Particularly, the degradation properties and texture response of the material are determined for degradable/absorbable materials.
- Implants should be inserted into the Panniculus carnosa or gluteal region muscles of adult mice, rats, guinea pigs or rabbits. Implant specimens should be implanted aseptically and without any damage prior to or during implantation. A minimum of three animals and sufficient space are used to obtain a total of 10 test and 10 control specimens for each material and implantation period. When multiple tissue samples are taken from a single implant site, the histology sections should be at least 1 cm apart.
- mice 6 (3 female/3 male) BALB/c mice weighing 17-20 g were used as subjects. The subjects were kept in a sheltering area with 60% humidity and a constant temperature of 22°C during the test. The subjects were given normal rat feed and tap water. Dust-free autoclaved wood shavings were used as substrate. At the end of the experiment, all animals were euthanized.
- Intra-Articular/Subcutaneous/lntramuscular Injection Solution 2 ml of Intra-Articular/Subcutaneous/lntramuscular Injection Solution was injected into the right and left gluteal muscles of the subjects. 14 days after the injection, the gluteal muscles of the right and left legs were dissected and examined microscopically from the subjects who were anesthetized with Ketamine 85 mg/kg and Xylazine 15 mg/kg.
- the treated animals did not show any abnormalities in their daily behavior and activation. No abnormality was observed in its movements and walk. Their eating habits and social behavior in the cage were normal.
- the intramuscular implantation test of the liposomal ozone nanosolution product was performed according to the protocol and evaluation criteria specified in the TS EN ISO 10993-6:2016 document. Intra-Articular / Subcutaneous / Intramuscular Injection product at the end of the 2-week gluteal experiment period, it was determined that the samples were completely absorbed and there was no residue left in observation and evaluations. It was determined macroscopically and microscopically that the injection was in harmony with the muscle tissue and did not cause deformation and inflammatory reaction in the muscle structure.
- Liposomal Ozone Nanosolution Biopsv+Histopatholoov/Hematoxylin Eosin Staining Test In the liposomal ozone nanosolution samples of the invention for Intra- Articular/Subcutaneous/lntramuscular Injection, in an experimental study on rats, 280 skin biopsy materials from 56 female rats of Sprague downey breed, 2 months old, were euthanized at the end of the experiment, microscopic examinations of the tissues of the lungs, liver and kidneys were made so as to observe the "Healing Effects in Regional Subcutaneous Applications”.
- the number of vascularization (in pieces) average of the first 4 days was observed as follows; while it was 7 at a dose of 10 ppm, it was 8.57 on the 30th day; while it was 6.83 at a dose of 50 ppm, it was 6.83 on the 30th day; while it was 5.33 at a dose of 100 ppm, it was 3.83 on the 30th day; while it was 6.12 at a dose of 500 ppm, it was 6.25 on the 30th day; while it was 4.84 at a dose of 1000 ppm, it was 4.57 on the 30th day; while it was 5.12 at 5000 ppm dose, it was 6.87 on the 30th day.
- Hair follicle (in number) average of the first 4 days was observed as follows; while it was
- a total of 72 skin biopsies of 72 animals from the abdomen were examined in the experimental groups in the applications on the wound lips on the skin line where the incision was made; Physiological Salt Water (FTS), 1% Lidocaine, ozone-free nanosolution, 250 ppm ozone nanosolution, 500 ppm ozone nanosolution, 500 ppm ozone nanosolution +2% Lidocaine (50% blend), 1000 ppm Ozone nanosolution + 2% Lidocaine (50% blend) and 2000 ppm ozone nanosolution + 2% Lidocaine (50% blend). Lesions were scored and group average scores were obtained.
- FTS Physiological Salt Water
- Macroscopic Findings Animals were euthanized after 10 days of repeating 100 ml serum containing 200 ppm (6mg/kg) ozone nanosolution intravenously.
- mice No pathological findings were found in the peripheral blood smears of the same animals, in the membrane structures and morphologies of erythrocytes; as well as in the lung, liver, heart muscle and kidney tissues.
- Macroscopic Findings After the defect previously performed with a 250 micrometer stopper eye scalpel to the medial condyle, disarticulation at the 6th week resulted in knee joint insertion, Serum Physiological, of Hyaluronic (HA), 500 ppm intra-articular, 1000 ppm intra- articular, 2000 ppm intra-articular, 1000 ppm +HA (1/2 ratio mixture) intra-articular, 2000 ppm +HA (1/2 ratio mixture) intra-articular, 4000 ppm +HA (1/2 mixture) namely a total of 64 tissues were examined from the joint region of 8 animals.
- HA Hyaluronic
- Carpoglyphus lactis (L.) (Astigmata: Carpoglyphidae), an important mite pest of dried fruits, causes the product to deteriorate, release unpleasant odors and eventually lose its market value when they are fed with fruit sugars of the dried apricots.
- ozone gas can be used for control purposes in dried fruits due to its poisonous property against mites.
- due to the rapid decomposition of ozone gas into 02 and 0- its short persistence limits the use of this gas in mite control.
- the biological activities of the inventive liposomal ozone nanosolutions on this harmful mite were investigated in the study carried out within the scope of the invention.
- lethal concentrations (LC), lethal time (LT)], repellent and egg laying inhibitor effects and persistence of the formulation on mites were evaluated in the study. This study showed that 0.27% concentration of the formulation killed 90% of female mites within 48 hours. According to the results of the probit analysis, lethal time (LT90) was determined as 121 , 81 .5 and 66 hours, respectively in case the liposomal ozone nanosolution of the invention is used against mites at rates of 0.1 , 0.2 and 0.4%. Persistence tests showed that there was no statistically significant change in the lethal effects of the formulation during the first 7 days. However, after 10 days, a decrease of 12-17% in its lethal effect was detected.
- LC lethal concentrations
- LT lethal time
- Bacte rial crown gall nematodes used as target pests were collected as female individuals from the galls on infected plant roots in Bursa Karacabey tomato fields. Since the period that moves freely in the soil and infects the plant is the second period, 2nd period larvae were obtained from collected female individuals and experiments were carried out on 2nd period larvae. However, the species identification of bacterial crown gall nematode Meloidogyne was not made, it was expressed over the genus (Meloidogyne sp.).
- Solution #1 (2000ppm liposomal ozone nanosolution) 50%, 25% and 12.5%
- Solutions 2 and 3 0.1%, 0.2%, 0.3% and 0.4%.
- Each solution was placed in sterile glass petri dishes with a diameter of 6 cm at the above doses, approximately 20 ml, and immediately after that, approximately 100 ( ⁇ 10) 2nd period nematode larvae were added to each petri dish. Afterwards, the petri dishes were shaken in a vortex for 1 minute and homogenization was achieved. Then, the petri dishes were covered and left for incubation at room temperature until the end of the experiment. As a control group, nematodes were kept only in sterile distilled water for the specified times. The efficiency (toxicity) of the nanosolution was determined by counting the dead nematodes at the end of each solution trial at 6, 12 and 24 hours. Each experiment was carried out in 3 replications.
- Solution 1 that is, nanosolution containing only Ozone” in its content, tends to increase in its toxic effect as the exposure time on the nematode increases. However, there is no difference in efficacy between 12 hours and 24 hours. The lowest effect was detected after 6 hours and at the lowest dose of 12.5%, 25%, it was determined after 12 and 24 hours that it was effective on almost all nematodes at 50% dose, that is, it had a toxic effect. These 3 results show that solution 1 has a promising effect in combating Meloidogyne sp.
- Solution 2 that is, nanosolution containing "Ozone + Acetic Acid" tends to increase in its toxic effect as the exposure time on the nematode increases. However, there is no difference in efficacy between 12 hours and 24 hours. While the lowest effect was detected at the rate of 35% at the lowest dose of 0.1% after 6 hours, it was determined that it had a toxic effect on almost all nematodes at 0.3% and 0.4% doses after 12 and 24 hours. This result shows that solution 2 has a promising effect in combating Meloidogyne sp.
- Solution 3 that is, nanosolution containing "Ozone + Acetic Acid + Thymol" tends to increase in its toxic effect as the exposure time on the nematode increases. However, there is no difference in efficacy between 12 hours and 24 hours. While the lowest effect was detected at the rate of 42% at the lowest dose of 0.1% after 6 hours, it was determined that it had a toxic effect on almost all nematodes at 0.3% and 0.4% doses after 12 and 24 hours. This result shows that solution 3 has a promising effect in combating Meloidogyne sp.
- Two-spotted spider mites (Tetranychus urticae Koch) (Acari: Tetranychidae) individuals used in the experiment were recruited from a sensitive population collected from Bursa 8 years ago and grown continuously without pesticides. Colonies of the pest were reproduced on the same eggplant seedlings under controlled conditions.
- Liposomal ozone nanosolutions of the invention were used in these tests. Two different (I and II) concentrations of two different formulations (N and S) were used in the first experiment. In the second experiment, combined formulations in which different concentrations of acetic acid (S+AA), orange oil (S+P), thyme oil (S+K) or lavender oil (S+L) were mixed to the I concentration of the S-coded formulation were tested.
- S+AA acetic acid
- S+P orange oil
- S+K thyme oil
- S+L lavender oil
- concentrations I and II of the N formulation showed toxic effects respectively as follows; 80% and 93% on the eggs; 100% and 47 % on larvae; 55% and 0% on nymphs and 46% and 53% on adults.
- concentrations of S formulation showed toxic effects respectively as follows; 30% and 93% on the eggs; 66% and 94 % on larvae; 0% and 0% on nymphs and 8% and 69% on adults.
- concentrations I and II of the N formulation showed toxic effects respectively as follows; 46% and 73% on the eggs; 23% and 60 % on larvae; 68% and 95% on nymphs and 14% and 71% on adults.
- concentrations of S formulation showed toxic effects respectively as follows; 5% and 0% on the eggs; 0% and 30 % on larvae; 76% and 19% on nymphs and 15% and 29% on adults.
- formulations in which a single formulation is combined with thyme oil (S+K), lavender oil (S+L), orange oil (S+P) and acetic acid (S+AA) to a concentration of 1000 mg/L showed toxic effects respectively as follows; 97, 99, 99 and 100 % on the eggs; 95, 100, 100 and 100% on larvae; 0% on nymphs and 100, 100, 100 and 100% on adults.
- the inventive liposomal ozone nanosolutions after three days, killed the eggs and larvae of the two- spotted spider mite at a rate of 30-93% and 47-100%, adults at rates of 8-69%. Results were not considered as nymphs did not occur in the first 3 days. Effects ranged from 19- 76% as nymph populations naturally increased on day 7 of the test. Accordingly, different formulations and concentrations of the invention showed varying degrees of toxic effect on all biological stages of the spider mite. According to the best results, lethality (toxic effect) was observed up to 93% of eggs, 100% of larvae, 76% of nymphs and 69% of adults.
- the red spider population in the plots is 2-3 per m 2 where the drug is used in doses of 75-100 ml A (33% ozone emulsifier, 34% ozone oil, 33% acetic acid) and drug B (30% ozone emulsifier, 30% ozone oil, 30% acetic acid, 10% functional oil thymol), in the drug A and drug B plots, which were applied at a dose of 50 ml, 7-8 live red spiders were seen per m 2 , and this was also found to be in a low population.
- Early leaf blight, powdery mildew and green worm have not been encountered since the seedling period. When we examined the green parts, no green worm eggs and larvae were found.
- the red spider population in the plots is 4-5 per m 2 where the drug is used in doses of 75-100 ml A (33% ozone emulsifier, 34% ozone oil, 33% acetic acid) and drug B (30% ozone emulsifier, 30% ozone oil, 30% acetic acid, 10% functional oil thymol), in the drug A and drug B plots, which were applied at a dose of 50 ml, 8-9 live red spiders were seen per m 2 , and this was also found to be in a low population.
- 75-100 ml A 33% ozone emulsifier, 34% ozone oil, 33% acetic acid
- drug B (30% ozone emulsifier, 30% ozone oil, 30% acetic acid, 10% functional oil thymol
- Ozone Liposomal Ozone Nanosolution
- Thymol and Artemisia absinthium extracts and their combinations were tested in 5 different concentrations and dosages. According to the efficiency rates of the three combinations found most effective in these five field trials; Ozone+Thymol (Spray): 2000 ppm 200 ml Ozone+100 ml 3% Thymol+700ml sugar syrup 89.47%, Timol+Artemisia (Oral): 250 ml 2% Thymol+200 ml 2% Artemisia absinthium+550 ml sugar syrup 85.95%, Ozone (Oral): 100 ml 1000 ppm Ozone+400 ml sugar syrup 75.08% were given respectively. This result supported the previous studies with Timol, and when the combination was enriched with nanoparticle ozone, the results were found to be more effective against Nosema. There were no deaths or side effects caused by the application.
- ozonated emulsifiers are coated with biocompatible materials. In this way, in addition to the solutions created by the transportation of ozone with oils or emulsifiers containing oil and diversified by the addition of substances such as oil, acid, vitamin and mineral, it is possible to obtain new nanocarrier structures that provide high stability.
- Coating of ozonated emulsifier is important for reducing the aggressive behavior of active ozone, providing slow release, obtaining small particle size and complying with sterilization methods.
- Ozone cannot be sterilized by heat and there is no sterilization method other than filtration. In this sense, it is necessary to realize coatings suitable for filtration and to choose suitable coating materials.
- At least one emulsifier and ozone are used.
- Polysorbates such as polysorbate 20, polysorbate 60, polysorbate 80, polysorbate 85 can be used individually or in combination as emulsifiers.
- dosage can be made by adding water (with or without mixing) to the ozonated emulsifier mentioned.
- the ozonated emulsifier is coated with at least one emulsifier and/or polymer.
- the ozonated emulsifier and the emulsifier coated on it can preferably be polysorbate 20, polysorbate 60, polysorbate 80, polysorbate 85 or a combination thereof.
- the ozonated emulsifier and the emulsifier coated on the ozonated emulsifier can be the same or different polysorbates.
- the structure obtained with polysorbate 80, and ozone can be coated with polysorbate 20. This structure may contain water. It is possible to use different polymers as a polymer, depending on the purpose and area of application.
- Polysorbate 80 contains unsaturated fatty acid in the tail. Ozonated polysorbate 80 is formed by ozonation of this fatty acid. Polysorbate 85 carries 3 unsaturated fatty acids in its tail. Therefore, more ozone can be loaded.
- polyethylene glycol (PEG) and glycerin can be used as biocompatible materials for the coating.
- Ozone emulsifiers can be coated with glycerin alone, with PEG alone, or with a combination of glycerin and PEG. Coating ozonated emulsifiers with glycerin and PEG slows down the rapid antioxidant effect. Coating the ozonated emulsifier with polymers in addition to PEG and/or glycerin contributes to increased stability. Ozonated structures in the form of nanocarriers have two-year stability and have been found to maintain their antibacterial activity.
- Coating ozonated emulsifiers with glycerin and/or PEG provides a stability-enhancing effect within the scope of the invention
- coating with mannitol and/or dextran is also possible.
- the ozone emulsifier, coated with glycerin and / or PEG reaches the target organ / tissue without the ozone gasification and, after reaching, it is possible to get rid of said coating and use it in tissue.
- cancer target protein or other cancer drugs are bind to the ozone emulsifier and this new formation is coated with glycerin and/or PEG.
- the coating dissolves rapidly and the target protein binds to the cancer cell in the target tissue. In this way, ozone is dissolved and the cancer cell is broken down. This applies to all other chemicals.
- ozonated emulsifiers are approximately 20 nanometers. Small coated nanoliposomes are formed by simply coating this molecule with PEG. Slightly larger nanoliposomes are obtained by coating with glycerin. Particle sizes increase when other chemicals are added to these nanoliposomes. It is important in drug formation that the products remain below 200 nanometers in these measurements. The amount of coating and the ratio of glycerin and/or PEG are also important in terms of intended use and size. If the coating is done only in small quantities with PEG, the particles grow minimally. If the ratio is increased or the amount of glycerin is increased, the particle size increases.
- ozonated polysorbate 80 When ozonated polysorbate 80 is first coated with glycerin and then with PEG, a 13- nanometer solution is obtained when the new mixture is mixed with water. Some glycerin and PEG that are not added to the complete mixture are also seen in the measurement. It ensures liposomes to be sent to the target organ without causing damage to the tissues and have a slower effect by using it in this form
- lipoproteins In order to increase the effectiveness of ozone emulsifiers, it is possible to bind the lipoproteins, some of which are in lipid structure, to the surfactant so as to send them to the appropriate target organ.
- the lipoprotein-coupled structure is coated with glycerin and PEG.
- phospholipid, sphingolipid, ceramide, proteolipid, glycolipid, isoprenoids, phosphoglyceride, lipids and terpenes, mineral, protein, cancer target protein, DMSO, acetyl cysteine, hyaluronic acid, menthol, acids, alcohols, enzymes such as ogenase, elastase, trypsin, lipase, alkans can be bind individually or in combinations to ozone emulsifiers.
- niosome The smallest form of the solutions obtained is referred to as niosome in the literature. These are the smallest liposome structures made with surfactants only in the smaller form of liposomes.
- the structure containing ozone or non-ozone phospholipid is coated with glycerin and/or PEG. It is especially found in the sphingomyelin nerve cell.
- the aim of this structure it is used to make selective drugs for nerve cells when given to the body, Said structure adheres to nerve cells and functions to repair the nerve cell with ozone. In this way, it is possible to play a role in the repair of nerve cells, such as the use of ozone in wound healing.
- the structure containing ozone or non-ozone sphingolipid is coated with glycerin and/or PEG. In this way, nano liposome that selectively adheres to the target organ for again nerve cells are obtained.
- the structure containing ozone or non-ozone proteolipid is coated with glycerin and/or PEG. In this way, nano liposomes that selectively adhere to the target organ for nerve cells are obtained.
- a glycolipid containing structure with or without ozone is coated with glycerin and/or PEG.
- This structure functions as a nanoliposome, which selectively adheres to the target organ for nerve cells.
- Cerebrosides, Ceramide oligosaccharides, Sulfatides, Gangliosides can be used in combination for ozone carrier nanoliposomes suitable for use according to their target organs.
- the structure containing lipoproteins with or without ozone is coated with glycerin and/or PEG.
- the nanoliposome HDL cholesterol target organ is the liver, which is attached to the target organ by combining lipids such as cholesterol. Cholesterol circulating in the blood goes to the liver last. It is used in the treatment of liver diseases and in liver cancer in combination with ozonated emulsifier and HDL cholesterol.
- the structure containing isoprenoids is coated with glycerin and/or PEG.
- glycerin and/or PEG for example, a combination of vitamins such as fat-soluble vitamins, vitamin A can be given.
- the structure containing ozone or non-ozone ester phosphaglycerides is coated with glycerin and/or PEG.
- Phosphatidylethanolamine kephalin, cephalin
- Cephalins are esters of phosphatidic acid that function in the brain. Since it is abundant in the brain as a target organ, it plays an active role in the transmission of ozone. Lecithin is the main constituent in many tissues.
- Phosphotidylserine is found in blood coagulation; phosphatidylinositol is intracellular messenger; phosphatidyl glycerol is found in Cardiolipin in cardiac cells; Malignolipin is found in malignant cells. It is possible to perform target organ treatments with the combination of these lipid derivatives.
- the structure containing minerals is coated with glycerin and/or PEG.
- Nano liposomes formed by the combination of metal ozone formed in this group are obtained.
- the combination formed in this group is directed to the target organs again It facilitates the penetration of ozone into the cancer cell by opening the channels with the use of magnesium so as to open the calcium channels of the cell in cancer treatment.
- Elements such as zinc, copper, sulfur and silver also increase the antibacterial properties of the combination and are used in different target organs. For example, in agriculture, leaf health can be used as nanoliposome to increase plant health.
- the structure containing DMSO in addition to ozone and emulsifier, is coated with glycerin and/or PEG.
- DMSO is selective for cancer cells with its combined use. In this way, ozone is transported to the target organ.
- the structure containing ozone or non-ozone vegetable oils is coated with glycerin and/or PEG. In this way, nano liposomal and liposomal structures formed for the transport of ozone to the tissue are obtained.
- the structure containing terpenes with or without ozone is coated with glycerin and/or PEG. It is used to form liposomes and nano liposomes of active oils secreted from plants.
- glycerin and/or PEG glycerin and/or PEG.
- antioxidants such as vitamins, minerals, dextran, mannan, chitosan, PLL and PEI polymers, protein, amino acid, sugar, sweetener, alcohol, acid, menthol, hyaluronic acid, tranexamic acid, N acetyl cysteine, anticancer drugs can be added to the combinations.
- a solution can be obtained by adding menthol and sucralose and finally coating with hyaluronic acid.
- viruses including SARS Cov 2
- SARS Cov 2 can be transmitted by hand (skin).
- eye contamination there is also the possibility of eye contamination. Therefore, biocompatibility tests were performed for the eyes and skin, with the determination of the antibacterial effects of the solution within the scope of the invention.
- zinc is also used in the liposome with hyaluronic acid glycerin.
- coating is made of glycerin, mannitol, dextran and/or PEG and polymer.
- ozonated polysorbate in the injection formula.
- polysorbate coating and mannitol, glycerin, dextran, PEG, hyaluronic acid alone or combinations can be coated on it.
- ozonated sunflower oil, glycerin, menthol, hyaluronic acid and zinc can be added to ozonated polysorbate.
- Nasal spray and mouth spray contain all of the ingredients mentioned. However, wound spray and eye drops only contain ozonated polysorbate, glycerin, hyaluronic acid and zinc.
- It can be used as livestock disinfectant, skin protector, by way of intra-arterial, intra- articular, subcutaneous, intramuscular, intraperitoneal, bladder, intrauterine, rectal, ear canal, nasal passage, oral, also as eye drops.
- the products can be used in ampoules, vials, sprays, creams and solutions.
- Tomato and lettuce seedlings were immersed into grouped solutions 1 (%0,2); 2 (%0,2) and 3 (%10) just before planting in the greenhouse. 5 applications were made from planting to the beginning of harvest on tomato plants. On the other hand, 2 applications were made on leaf lettuce plants. Applications continued with an interval of 15 days in both plant groups. It was made as 100 ml. (for each variety, each application dose) in tomato, in the process from fruit setting to harvest, 200 ml. (for each variety, for each application dose) foliar spraying was applied for each application. On the other hand, in leaf lettuce, 100 ml. (for each application dose) was applied as a foliar spray in each application.
- Leaf length, root length, number of marketable leaves, number of non-marketable leaves, root length, root fresh weight, root dry weight, leaf fresh weight, leaf dry weight, leaf proportional water content, color determination, chlorophyll determination of the samples taken after harvest in leaf lettuce were measured.
- Leaf Lettuce Results 3.2.1 .
- Leaf and Root Lengths When all application groups were compared, the application group that gave the best results in terms of leaf and root length was number 1 and was statistically different from the other groups. Applications numbered 2 and 3 were included in the same statistical group. The control group, on the other hand, gave the lowest application result.
- application groups 1 and 3 gave the best results and entered the same statistical group.
- the application no. 2 and the control group were included in different application groups from the application groups no. 1 and 3, and the lowest result was obtained from the control group. Thus, it was observed that application groups 1 and 3 were more resistant to stress conditions.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Environmental Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Plant Pathology (AREA)
- Pest Control & Pesticides (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Agronomy & Crop Science (AREA)
- Dentistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dispersion Chemistry (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Biotechnology (AREA)
- Insects & Arthropods (AREA)
- Biochemistry (AREA)
- Botany (AREA)
- Biophysics (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to liposomal ozone nanosolutions with antiviral, antifungal and antibacterial effects; wound healing, tissue healing properties suitable for use in human, veterinary, food, agriculture and chemistry and cosmetics fields. The inventive liposomal ozone nanosolution can be used as nasal spray, mouth spray, ear drops, eye drops, hand and face disinfectant, vaginal, intravesical, rectal solutions, intraarticular, subcutaneous, intramuscular, intravenous injection solutions for human and veterinary hygiene purposes and can be used as a surface cleaner as well. The effectiveness of the inventive liposomal ozone nanosolutions has been proven on viruses such as influenza or corona virus, especially Sars-Cov-2 and bacteria, especially Staphylococcus aureus and Escherichia coli.
Description
LIPOSOMAL OZONE NANOSOLUTIONS
Field of the Invention
The present invention relates to liposomal ozone nanosolutions with antiviral, antifungal and antibacterial effects suitable for use in human, veterinary, food, agriculture and chemistry.
State of the Art
The use of nanoparticles has become widespread in the chemical industry in recent years. Efficiency in nano sizes is achieved with smaller particles, and activities on viruses and bacteria increase with the help of these technologies. Simultaneously, active drugs can be transported to organelles such as mitochondria within the cell and more effective treatments can be provided with less chemicals. At the same time, the use of nano-sized products in other sectors of the chemical industry provides advantages. For example, disinfectant products made with nanoparticles form a film in the application area and cover the environment and it is possible to provide a longer effect with a small amount of product. Another particle system made for this purpose is the formation of liposomes. Liposomes are made by breaking down lipids with ultrasonic fat breakdown devices or similar nanotechnological methods. Drugs and active substances can be transmitted in these liposomes and the transmission of active substances into cells becomes easier. Normally, it is not possible for the active substances to enter the cancer cells, however it is possible to introduce the active substance into the cancer cell in the liposome. Developments continue in the technical field regarding the use of liposomes and nanocarriers created with oils in the fields of medicine, food, agriculture, veterinary medicine, cosmetics and disinfection.
For example, patent EP1746976B1 provides liposome compositions containing substituted ammonium and/or polyanion and optionally a desired therapeutic or imaging entity. TR97/01683 national patent application relates to the development of liposomal drug delivery systems for the biodistribution of cyclosporine A or similar hydrophobic drugs in body fluids and/or tissues.
Methods of use of ozone in gas form have been widely used for many years such as medical field, disinfection, antibacterial activity, repellent effect, insecticide effects, cosmetic effects,
food preservative effects, agriculture, and veterinary fields. However, these methods make it difficult for ozone gas to become widespread, as it is unstable and has a half-life of 20 minutes. In recent years, the transportation of ozone with water has started to become widespread in methods such as disinfection of water. However, these methods were not enough to generalize the use of ozone. Studies are carried out in different fields on the use of oils as ozone carriers so as to solve these problems. However, problems such as stable ozone transport and release capacities of oils and the lack of effective particle size optimization according to the application area are encountered in current applications.
As a result, due to the abovementioned disadvantages and the insufficiency of the current solutions regarding the subject matter, a development is required to be made in the relevant technical field.
Brief Description of the Invention
The present invention relates to liposomal ozone nanosolutions which fulfill the abovementioned requirements, eliminate all disadvantages and bring some additional advantages.
Another aim of the invention is to produce antiviral, antibacterial, antifungal insecticide, acaricide effective, wound healing tissue healer, plant developer, plant protector, bee treatment, liposomal ozone nanosolutions suitable for use in human, veterinary, agriculture and chemistry fields, to contribute to public health on a global scale.
Another aim of the invention is to present liposomal ozone nanosolutions in formulations with proven stability, whose nanoparticle size distribution, effective ozone dose and ozone release profile can be determined for the field of use and type of application.
An aim of the invention is to present liposomal ozone nanosolutions with both anti-viral and anti-bacterial activity; non-toxic effect; no negative effect on the viability of healthy cells; that have both regenerative and proliferative effects on human respiratory system (tracheo bronchial) cells.
Another aim of the invention is to present liposomal ozone nanosolutions that offer stable antibacterial activity on bacteria such as Staphylococcus aureu or Escherichia coli and stable antiviral activity on viruses such as Sars-Cov-2.
Another aim of the invention is to present liposomal ozone and nanocarrier polymer nanosolutions that do not have irritant or hyperreactive effects on skin, mucosal tissues or ocular, vaginal, rectal areas.
Another aim of the invention is to present liposomal ozone nanosolutions that do not have cytotoxic effects in mucosal tissues.
Another aim of the invention is to present products suitable for use as nasal spray, mouth spray, ear drops, eye drops, vaginal solution, rectal solution, intraperitoneal solution, bladder solution, hand and face disinfectant, and surface cleaner for personal hygiene, to be used in the prevention and healing of viral, bacterial or fungal diseases.
Another aim of the invention is to present antiviral, antibacterial, antiparasitic, antifungal effective barrier solutions on skin and surfaces, suitable for use in human, veterinary, agriculture and chemistry fields containing liposomal ozone nanosolutions.
Another aim of the invention is to present nasal spray, mouth spray, ear drops, eye drops, vaginal solution, rectal solution, intraperitoneal solution, intravesical solution, intravenous and intraarticular / subcutaneous / intramuscular injection solutions with antiviral, antibacterial, antifungal effect, wound healing tissue healing effect for human, veterinary use containing liposomal ozone nanosolutions.
In order to fulfill the above-described aims, the invention mainly consists of nanomaterials obtained from ozonated emulsifier, and also contains nanoparticle liposomes obtained from ozonated oil providing synergetic effect.
The structural and characteristic features of the present invention will be understood clearly by the following detailed description and therefore the evaluation shall be made by taking the detailed description into consideration.
Description of the Figures
Figure 1 , the size distribution graph of the nanosolution obtained from ozonated oil is given according to the density. [ Density (Percent) x Size (d.nm)]
Figure 2, the size distribution graph according to the density of the nanosolution obtained from the ozonized emulsifier is given. [ Density (Percent) x Size (d.nm) ]
Figure 3 is a coating of ozonated surfactant (emulsifier polysorbates) glycerin and PEG 400. [Density (Percent) x Size (d.nm)]
Figure 4 is coating with ozonated surfactant and non-ozone surfactant. [Density (Percent) x Size (d.nm)]
Figure 5, fruit height and diameter measurements of tomatoes are given.
Figure 6 shows the graph of color determination in tomato.
Figure 7, SCKM values in tomato are given.
Figure 8 gives TEA values in tomato.
Figure 9 gives the yield per plant in tomato.
Figure 10, leaf and root lengths of leaf lettuce are given.
Figure 11 , root wet and dry weight of the leaf lettuce is given.
Figure 12, leaf wet and dry weight of the leaf lettuce is given.
Figure 13, the number of marketable and non-marketable leaves is given.
Figure 14, leaf proportional water content of leaf lettuce is given.
Figure 15, the total amount of chlorophyll in the leaf in the leaf lettuce is given.
Figure 16, leaf color of leaf lettuce is given.
Detailed Description of the Invention
In this detailed description, the preferred embodiments of the inventive nanosolutions are described only for clarifying the subject matter in a manner such that no limiting effect is created.
In the state of the art, obtaining nanoparticles in sizes that will allow the penetration of ozone into application areas such as cells and the release rates of ozone provided by these particles were limited in systems where ozone is carried only by oils. Although in theory these nanoparticles appear to cover all nano sizes down to micron sizes, in practice, it was not possible to obtain stable particles of nano size, such as below 50 nm, that would allow penetration into the cell. Studies have been carried out with the invention so as to provide stable systems containing the smallest nanoparticles that can carry ozone in order to increase the application efficiency of ozone. Surprisingly, these studies have shown that substances such as Polysorbates and PEG, which are included in the emulsifier group, can be ozonized and form stable nanoparticles in smaller sizes compared to carrier oils.
Size distribution analysis was carried out only in nanosolutions obtained from ozonated oil in the studies carried out within the scope of the invention and the graph of size distribution according to density is given in Figure 1 . Liposomal nanosolutions made with ozonized oil containing 10% ozone gas by weight, ranged between 30 nm and 6000 nm, and at most concentrated solutions of 200 and 1000 nanometers could be formed. Dimensional analysis results are shown in Chart 1 below.
Chart 1 . Size distribution analysis results according to density in nanosolution obtained from ozonated oil (Dispersant Rl 1 ,330 Sample Rl 1 , Viscosity 0,8872 cP, 25 C,)
In the studies, size distribution analysis was also carried out for the nanosolution obtained from only ozonated emulsifier, the graph of the size distribution according to the density is given in Figure 2. In this example, the Polysorbate 80 emulsifier was ozonized at 3% by weight. It has been observed that ozonated polysorbate 80 concentrate can form
nanoparticles up to 16 nm in size. It has been observed that nanoparticles up to 7 nm in size can be formed in the nanosolution obtained from ozonated polysorbate 80 with water. In the size distribution analysis, nanoparticles with a distribution between 7 nm and 50 nm were obtained, as seen in Figure 2. Since nanoparticles of this size can transmit ozone into the cell, for example, they will have an antiviral effect on viruses. At the same time, it will increase the energy generation potential of the cell by entering the mitochondria inside the cell and will activate the intracellular repair mechanism by inducing intracellular growth factors.
Chart 2. Size distribution analysis results according to density in nanosolution obtained from ozonated emulgator (Dispersant Rl 1 ,330 Sample Rl 1 , Viscosity 0,8872 cP, 25 C,)
In the studies carried out within the scope of the invention, it has been demonstrated that alternative formulations in which the nanoparticle size distribution and ozone emission velocity distribution can be determined, can be developed with a nanotechnological method suitable for the content, in terms of the application area of ozonated emulsifier and liposomal ozone nanosolutions obtained from ozonated oils. Nanoparticles obtained by ozonation of emulsifiers provide relatively smaller and faster ozone release to oils. Ozonated liposomal nanosolutions, which are formed by the breakdown of ozonated oils by nanotechnological methods, create many areas of use due to their stability and long-lasting effectiveness. In solutions made with ozonated oil, ozonated emulsifier, and water, the ozone ratio in the oil is determined and solutions are created with the same standards. For example, a solution with a high oil content is used for a long-acting solution, and ozone gas is kept in the oil at a rate of 1-5% by weight. In order to create shorter-acting products, solutions containing 6- 15% by weight ozone gas are created. In this way, the effectiveness of liposomal ozone nanosolutions obtained according to the content has been proven by scientific studies in the fields of human, veterinary, food and agriculture; its use in formulations for these areas is also within the scope of the invention.
Since the pure structures formed by ozone emulsifiers are much smaller particles than liposomes, they reveal more active effects. These structures have active antibacterial effects and at the same time, it is important that they are be coated so as to provide slower released effects. Slower release properties are created by coating the ozone emulsifier with glycerin and PEG. Figure 3 shows the emulsifier liposome.
The smallest liposome structure formed by coating emulsifiers with emulsifiers is called niosome. The smallest niosome structure is formed by coating the ozone emulsifier with non-ozone emulsifiers. In this way, it is possible to obtain niosomes with active and slow- release ozone. In Figure 4, ozonated polysorbate is again coated with polysorbate.
At the same time, these niosomes can be coated with polymers such as glycerin, peg, chitosan, mannitol, and dextran. One or more of these coatings can be used, especially in intravenous formulations and regional injections, so as to reduce the burning effect of ozone and to ensure that it reaches the target organ more easily.
The invention described above is basically liposomal ozone nanosolutions containing ozonated emulsifier.
The "emulsifier" mentioned in the invention is individuals or combinations selected from lecithin, lysophospholipid, polyethylene glycol (PEG), phosphatidylethanolamine (PEG-PE), pluronic, polysorbates (polysorbate 20, polysorbate 80, etc.), or a pharmaceutically acceptable emulsifier.
In preferred embodiments of the invention, the emulsifier mentioned is a polysorbate or PEG.
The "ozone gas" mentioned in the invention is an allotrope of oxygen (O3), a colorless gas with molecules consisting of 3 oxygen atoms and is found in the upper layers of the atmosphere in nature. Under normal conditions, the amount of ozone in the lower parts of the atmosphere is about 0.04 ppm.
A preferred embodiment of the invention also contains water. “Water” mentioned in the invention are individuals or combinations selected from distilled water, salt water (NaCI- H2O), sugar water, mineral water, deionized water, demineralized water, spring water, saline solution, physiological saline, and plant waters.
A preferred embodiment of the invention also includes ozonated oil obtained by passing ozone gas through carrier oil. The "carrier oil" mentioned in the invention is individuals or
combinations selected from soybean oil, centaury oil, sesame oil, palm oil, poppy oil, soy lecithin, cholesterol, b-sterol, triglyceride, olive oil, fish oil, sunflower oil, castor oil, saffron oil, coconut oil, triglyceride derivatives, tributyrin, tricaproin, tricaprylin with paraffin, ethyl oleate, methyl oleate.
A preferred application of the invention also contains at least functional oil. “Functional oil” mentioned in the invention is individuals or combinations selected from fixed and/or essential vegetable oils. The fixed oils mentioned here are vegetable fixed oils such as coconut oil, almond oil, jojoba oil, rosehip seed oil, avocado oil, sesame oil, apricot seed oil, coconut oil, olive oil, sunflower oil, soybean oil. The essential oils mentioned here are essential oils such as sage oil, anise oil, calendula oil, rosemary oil, pine turpentine, cypress oil, tea tree oil, evening primrose oil, bay leaf oil, basil oil, rose oil, borage oil, black pepper oil, clove oil, thyme oil, cumin oil, coriander oil, lavender oil, lemon oil, lemon balm oil, violet oil, myrtle oil, peppermint oil, eucalyptus oil, chamomile oil, orange oil, grapefruit oil, nettle oil, fennel oil, sandalwood oil, garlic oil, cypress oil, jasmine oil, ylang ylang oil, geranium oil, patchouli oil, ginger oil.
A preferred application of the invention also contains at least one organic acid. “Organic acid” mentioned in the invention are individuals or combinations selected from among formic acid, phosphoric acid, hydrochloric acid, acetic acid, propionic acid, butyric acid, valeric acid, caproic acid, oxalic acid, lactic acid, malic acid, citric acid, benzoic acid, carbonic acid, phenol, uric acid, taurine, aminomethylphosphonic acid.
A preferred application of the invention also contains at least an excipient. “Excipients” mentioned in the invention are individuals or combinations selected from among anesthetics, pharmaceuticals pharmaceutical active substances such as water and/or fat soluble vitamins, minerals, hyaluronic acid, thymol, menthol, glycerin, ethyl alcohol, cetyl alcohol, butyl alcohol, benzyl alcohol, amino acids, acetyl cysteine, glutathione, herbal extracts, lidocaine, xylocaine.
Preferred applications of the invention consist of nanoparticle liposomes containing ozonated emulsifier and/or ozonated carrier oil, glycerin, hyaluronic acid, menthol, distilled water, NaCI composition.
The embodiments of the invention include 10 stock ppm- 60 000 stock ppm ozone gas.
The embodiments of the invention contain stable active ozone gas at doses of 100 ppm, 200 ppm, 500 ppm, 1000 ppm, 1600ppm, 2000 ppm, 3000 ppm, depending on the application area.
Preferred embodiments of the invention include liposomal ozone nanoparticles in sizes below 1000 nm, preferably below 200 nm, more preferably below 50 nm.
According to an embodiment of the invention, the method of forming liposomal ozone nanosolutions includes the following steps:
- Selecting the appropriate emulsifier and/or carrier oil for the application purpose,
- weighing the emulsifier and/or carrier oil,
- ozonation of emulsifier and/or carrier oil by passing ozone gas or nanobubble ozonated water through it,
-weighting ozonated emulsifier and/or carrier oil again and determining the ozone content, -coating of ozonated emulsifier and/or ozonated/non-ozone oil with glycerin and/or PEG.
- reduction of ozonated emulsifier and/or carrier oil to nanosize, preferably with water, by shredding for at least 1 hour with a min. 12000-revolution mixer,
- preferably adding and mixing components selected from at least one excipient, at least one functional oil, at least one organic acid.
EXAMPLE 1
An example of the invention consists of ozonated emulsifier. The emulsifier chosen for the production of this exemplary composition is weighed. It is ozonized by passing ozone gas through the emulsifier, the amount of which is determined. Ozonation processes are carried out with ozone micro/nano-bubble generators. The ozonized emulsifier is weighed again, and the amount of ozone gas absorbed in it is measured by weight. Nanoparticle sizes containing ozone nano-bubble can be reduced to the range of 5-50 nm by nanotechnological methods. In Table 1 , the content information of an example of the invention obtained by this method is given. Accordingly, emulsifiers containing 10 - 50 000 stock ppm ozone gas are obtained. The preferred ozonated emulsifier herein is a polysorbate or PEG. These nanosolution concentrates preferably contain 10000 stock ppm of ozone gas.
EXAMPLE 2
Another example of the invention is ozonated nanosolution obtained with water from ozonated emulsifiers. A nanosolution is obtained by mixing the ozonated emulsifier, whose ozone amount is determined as above, with the required amount of water with blade mixers with at least 12000 rpm. Nanoparticle sizes containing ozone nano-bubble can be reduced to the range of 5-50 nm by nanotechnological methods. In alternative methods, first the water is ozonated and the emulsifier ozonated water is mixed. In Table 2, the content information of an example of the invention obtained by said methods is given. Accordingly, nanosolutions containing 100 - 35 000 stock ppm ozone gas are obtained. The preferred ozonated emulsifier herein is a polysorbate or PEG. These examples may preferably contain at least one excipient described above. These nanosolution concentrates preferably contain 500 stock ppm of ozone gas.
EXAMPLE 3
Another example of the invention is the nanosolution obtained with ozonated carrier oil and water from ozonated emulsifiers. In this example, first of all, the amount of emulsifier is determined, ozonized and weighed to determine the ozone content. On the other hand, the selected carrier oils are ozonated by determining their amounts and weighed to determine the ozone content. The obtained ozonated emulsifier, ozonated carrier oil is mixed with the required amount of water with blade mixers with at least 12000 revolutions to obtain a nanosolution. Ultrasonic cavitation can be used to reduce the size of liposomes containing ozone nano-bubbles to the desired range by nanotechnological methods. Liposomal nanoparticle sizes containing ozone nano-bubble can be reduced to the range of 5-50 nm by nanotechnological methods. In Table 3, the content information of an example of the
invention obtained by said methods is given. Accordingly, nanosolutions containing 100 - 45 000 stock ppm ozone gas are obtained. The preferred example of ozonated emulsifier herein is ozonated polysorbate or PEG, and ozonated carrier oil is sunflower oil or olive oil. Preferably, thymol, orange oil, clove oil, lemon oil can be added. These examples may preferably contain at least one excipient described above. These nanosolution concentrates preferably contain 1100 stock ppm of ozone gas.
EXAMPLE 4
Another example of the invention is ozonated liposomal nanosolutions obtained with ozonated carrier oil from ozonated emulsifiers, and at least one organic acid. In this example, first of all, the amount of emulsifier is determined, ozonized and weighed to determine the ozone content. On the other hand, the selected carrier oils are ozonated by determining their amounts and weighed to determine the ozone content. Nanosolution is obtained by mixing the ozonized emulsifier, ozonated carrier oil with the required amount of water and selected organic acid with blade mixers with at least 12000 rpm. Ultrasonic cavitation can be used so as to reduce particle sizes. In Table 4, the content information of an example of the invention obtained by said methods is given. Accordingly, nanosolutions containing 10 000-60 000 stock ppm ozone gas are obtained. If the preferred ozonated polysorbate or PEG herein is ozonated carrier oil, it is a vegetable oil preferably sunflower oil, olive oil, soybean oil, thymol, orange oil, clove oil, lavender oil, nettle oil, lemon oil, if it is organic acid; it is preferably 100% acetic acid. These examples may preferably contain at least one excipient described above. These nanosolution concentrates preferably contain 30000 stock ppm of ozone gas.
EXAMPLE 5
Another example of the invention is ozonated liposomal nanosolutions obtained in situ with ozonated carrier oil, at least one organic acid and at least one functional oil from ozonated emulsifiers. In exemplary applications of the invention, ozonated oil, ozonated emulsifier and organic acid and functional oils are presented as a composition without mixing thereof. They stand in separate layers. Nanoparticles are formed as a result of mixing them with mixer and water by throwing them into water boilers in agriculture. The aim here is to make carrying easier. For example, 1-6 kilos of stock composition can be thrown into 1 ton of water and spraying can be done on the field. In Table 5, the content information of an example of the invention obtained by said methods is given. Accordingly, nanosolutions containing 10 000-60 000 stock ppm ozone gas are obtained. If the preferred ozonated polysorbate or PEG herein is ozonated carrier oil, it is a vegetable oil preferably sunflower oil, olive oil, soybean oil, functional oil preferably oil, thymol, orange oil, clove oil, lavender oil, nettle oil, if it is organic acid, it is preferably acetic acid. These samples preferably contain at least one excipient described above. These nanosolutions preferably contain 30 000 stock ppm of ozone gas.
EXAMPLE 6
Another example of the invention is ozonated liposomal nanosolutions obtained from ozonated emulsifiers with ozonated carrier oil, at least one organic acid, at least one functional oil and alcohol. In this example, first of all, the amount of emulsifier is determined,
ozonized and weighed to determine the ozone content. On the other hand, the selected carrier oils are ozonated by determining their amounts and weighed to determine the ozone content. Nanosolution is obtained by mixing the ozonized emulsifier, ozonated carrier oil with the required amount of water, selected organic acid, functional oil, and alcohol with blade mixers with at least 12000 rpm. In Table 6, the content information of an example of the invention obtained by said methods is given. Accordingly, nanosolutions containing 10 000-60 000 stock ppm ozone gas are obtained. Preferred herein are ozonated emulsifier polysorbate or PEG, ozonated carrier oil preferably sunflower oil, olive oil and/or soybean oil; the preferred organic acid is 100% acetic acid, and the alcohol is 100% pure vegetable alcohol; the preferred functional oil is thyme oil, orange oil, clove oil, lavender oil, nettle oil and/or lemon oil. These examples may preferably contain at least one excipient described above. These nanosolution concentrates preferably contain 30000 stock ppm of ozone gas.
The antibacterial, antivirus, antifungal, antiparasitic wound healing and tissue healing properties of the liposomal ozone nanosolutions described above have been proven by the following scientific analyzes. The barrier solution of the invention for barrier formation and applications for intraarticular / subcutaneous / intramuscular injection are suitable for use in the fields of human, veterinary, food, agriculture and chemistry, examples of which are as follows: as a disinfectant, preservative or food supplement in the food industry; as a disinfectant, repellent, feed additive in the livestock sector; use in the health sector, especially in dermatology, ear-nose-throat, eye diseases, oral-dental diseases, digestive system, urology, gynecology,
orthopedics, circulatory system diseases, in therapeutic pharmaceutical compositions in gastroenterology, ozone therapy and mesotherapy,
In treatment areas equivalent to treatments with gas ozone, in the cosmetics industry, especially in the production of personal care products used for skin, mouth and hair care; in the production of detergents and disinfectants in the chemical industry and as an additive for petroleum products; as a bleach, disinfectant, antibacterial textile chemical in the textile industry; preservative and repellent in final products in the agricultural sector, insecticide, pesticide, fungicide, virucidal, bactericide, plant and soil disinfectant in cultivated products;
The antiviral activity mentioned within the scope of the invention may comprise the following viral classes such as Herpesviridae, Hepadnaviridae, HIV, Togaviridae, Arenaviridae, Flaviviridae, Orthomyxoviridae (Influenzavirus A, influenzavirus B, influenzavirus C, isavirus, thogotovirusj, Paramyxoviridae, Bunyaviridae, Rhabdoviridae, Filoviridae, Coronaviridae (Corona virus, in particular Sars-Cov-2), Bornaviridae, Arteriviridae and Retroviridae.
The antibacterial activity mentioned within the scope of the invention may comprises bacterial classes such as; Aeromonas hydrophila, Arcanobacterium pyogene, Bacillus thurgiensis, Bacillus anthracis, Bacillus cereus, Clostridium botulinum, Clostridium perfringens, Clostridium septicum, Clostridium sordellii, Clostridium tetani, Corynebacterium diphtheriae, Escherichia coli, Listeria monocytogenes, Pseudomonas aeruginosa, Staphylococcus aureus, Streptococcus pneumonia, Streptococcus pyogenes intermedius or Vibrio cholera. Other bacterial infections considered are eye, ear, nose, throat, vaginal, rectal infections.
The following products containing liposomal ozone nanosolutions of the invention in their formulations for use in the areas described above are within the scope of the invention:
- Nose, eye, ear, throat solution, vaginal, rectal solutions, drops or sprays formulated for human or veterinary use. 500-3000ppm
For subcutaneous, intraarticular, intramuscular, intravenous, intraarticular, intravesical, intraperitoneal mesotherapy applications, ready-made glass syringes due to ozone interaction, silicone caps, glass vial, silicone caps, ampoules, bottles
with vaginal rectal apparatus, injectable solutions delivered in ozone resistant serum bottles and plastic bags. 500-3000ppm
Hair solutions containing combined vitamins, minerals, and active ingredients such as minoxidil and finasteride for hair growth and new hair growth. 500-2000ppm Bee solutions for use in beekeeping treatments. (2000 ppm liposomal ozone nanosolution + thymol + sugar water mixture)
It is a fruit and vegetable solution used in dried fruits and vegetables, fresh fruits and vegetables and meats to increase the shelf life with its oil content, to be stored for a long time and to reduce the harm of pesticides or to reduce the use of pesticides to make them look shiny. Liposomal ozone nanosolution containing glycerin, ozonated sunflower and/or ozonated polysorbate, containing 1000-2000 ppm ozone as insecticide, antiparasitic and antibacterial.
- Suitable skin solution for dermatitis treatments in allergic diseases. Ozone emulsifier and oil mixture, or ozone emulsifier water mixture containing 500-10000 ppm ozone Serum solution for use in parenteral injections. Ozone emulsifier water mixture or ozone emulsifier, ozonated oil and water containing 1-6 mg/kg 200ppm-2000 ppm ozone.
Injectable solution containing active ingredients such as combined fat-soluble vitamins, hyaluronic acid, amino acids and minerals, anesthetic agents such as lidocaine, for subcutaneous, intramuscular, intraarticular mesotherapy. It contains 300-2000 ppm of ozone.
- Washing solution used during surgery in the abdomen and other cavities. It contains 300-2000ppm ppm of ozone.
Solution presented in spray form for wound treatment, combined with disinfectants containing vitamins, minerals or iodine, zinc, betadine, silver ions. Ozone emulsifier water or ozone emulsifier and ozone oil water containing 500-10000 ppm ozone. Solutions or creams presented in spray forms in combination with other skin rejuvenating and spot lightening products for skin rejuvenation. Ozone emulsifier water or ozone emulsifier and ozone oil water containing 500-40000 ppm ozone.
- Solution for presentation in urology as an injector for an antiseptic probe or as a lubricant in one-shot silicone. Ozone emulsifier water or ozone emulsifier ozonated oil water containing 100-2000 ppm ozone.
- Glass injection for antibacterial bladder in urology, solution to be presented in ozone resistant puar forms. It contains 300-2000 ppm ozone.
- Solution for vaginal antisepsis presented in the form of disposable packages, sachets or injectors. It contains 1000-4000 ppm ozone.
Injectable solution offered in injection form for oviducts for infertility purposes. It contains 300-2000 ppm of ozone.
Injectable solution offered in antiseptic spray, ampoule, injection and vial forms for intracavity and root canal treatment in dental health. It contains 300-2000 ppm of ozone.
It is a solution containing ozone emulsifier, ozone emulsifier and oil-water in capsule or gel forms that dissolve in the stomach, dissolve in the small intestine, melt in the large intestine for the health of the digestive system. It containsl 0-200 ppm ozone. It is one-liter or disposable rectal solution to be used in large intestine diseases. It contains 100-2000 ppm ozone.
- Suppositories solidified with solid paraffin or witepsol for use in large intestine diseases. It contains 2000-10000 ppm ozone.
It is a toothpaste for oral health, a spray, a mouthwash and preferably a lozenge containing sweetener.
- Solution for use as a feed additive in animal health. Injectable solution offered in syringe, vial, ampoule forms for intramuscular, intra-articular, intravenous, subcutaneous, intravaginal, intraperitoneal injection for the treatment of infection in order to protect animal health. It contains 300-3000ppm ozone.
- Liter or single use rectal solution to protect animal health. It contains 300-3000ppm ozone.
- Suppositories solidified with solid paraffin or witepsol to protect animal health. It contains 2000-10000 ppm ozone.
- Solution for use as a repellent, insecticide and disinfectant in environments such as chicken farms, barns and pens. It contains 500-10000 ppm ozone.
- Hygiene product presented in the form of spray or solution for wound and skin care, disinfection, hygiene in order to protect animal health. It contains 2000-10000 ppm ozone.
- Hygiene product presented in the form of spray or solution for wound and skin care, disinfection, hygiene for human health. It contains 2000-10000 ppm ozone.
Food solution used in the food industry by dipping or spraying for the preservation of meats, fruits and vegetables, pesticide removal and antibacterial effect. It contains 300-3000 ppm ozone.
- Food solution, which is used by dipping or spraying method to prevent spoilage of dried foods and legumes, to provide insecticide and repellent effect. It contains 500- 3000 ppm ozone.
- Food solution served as a food supplement, as a capsule, as a single-use beverage or in combination with other beverages and sweeteners. It contains 100-1000 ppm ozone.
- Disposable or multiple wet wipes. It contains 1000-10000 ppm ozone.
- Environment, surface, device cleaner or detergents. It contains 1000-10000 ppm ozone.
- A plant solution that provides antibacterial, antifungal, antiparasitic and repellent effects on plants and is presented in intensive doses or in spray form suitable for dilution.co It contains 500-2000 ppm ozone.
It contains antibacterial, antiviral, antifungal, antiparasitic fertilizer solution for use in soilless agriculture. It contains 500-5000 ppm ozone.
- Seed solution for use in germination so as to develop seeds, to provide antibacterial effect in seed aquaculture and to remove soil pathogens. It contains 500-5000 ppm ozone
- Plant solution that both provides brightness and increases plant health in ornamental plants. It contains 200-1000 ppm ozone.
Fuel additive solution mixed with petroleum products to increase vehicle performance in the chemical industry. It contains 1000-20000 ppm ozone.
- Solution created to grow plants in oxygen-free environments. It contains 500-3000 ppm ozone.
- Ozonated emulsifier preferably polysorbate and water, thymol, carvacrol and other chemotherapeutic agents and solutions in liposome combined with ozonated oil and nanocarriers and cancer drugs such as paclitaxel combined with intravenous or local injection in cancer treatment. It contains 500-5000 ppm ozone.
An exemplary application of the invention is the mesotherapy products, the contents of which are explained below:
Mesotherapy products for skin repair contain ozonated emulsifier nanoparticle liposomes obtained from ozonated oil, amino acid complex, mineral complex, panthotenic acid; in particular, they contain nanoparticle ozone liposomes, l-arginine, glycine, l-histidine, I- isoleucine, l-leucine, l-lysine, l-methionine, l-phenylalanine, l-proline, l-serine, l-threonine, I- tryptophan , l-tyrosine, l-valine, sodium acetate, sodium glycerophosphate, potassium chloride, magnesium chloride, calcium chloride, panthothenic acid, sodium chloride, distilled water.
Anti-aging mesotherapy products for skin contain ozonated emulsifier, nanoparticle liposomes from ozonated oil, vitamin complex, tranexamic acid, acetyl cysteine; in particular, they contain nanoparticle ozone liposomes, thiamine pyrophosphate, riboflavin, pyridoxine hydrochloride, niacinamide, d panthenol, ascorbic acid, glutathione, tranexamic acid, acetyl cysteine, sodium chloride, distilled water.
Mesotherapy products for hair care contain ozonated emulsifier, nanoparticle liposomes obtained from ozonated oil, vitamin complex, biotin, acetyl cysteine, pantothenic acid; in particular, they contain nanoparticle ozone liposomes, thiamine pyrophosphate, riboflavin, pyridoxine hydrochloride, niacinamide, d panthenol, ascorbic acid, biotin, glutathione, acetyl cysteine, magnesium sulfate, sodium chloride, distilled water
-BARRIER SOLUTIONS TEST ANALYSIS RESULTS-
Liposomal Ozone Nanosolutions Accelerated Aging ( Stability ) and Antibacterial Efficacy
Tests:
Accelerated aging (stability) tests in accordance with ASTM F1980 standard on the inventive liposomal ozone nanosolution samples, sterility tests according to the ISO 11737- 2 standard and antibacterial activity tests according to the test method adapted from the CLSI M07 A9 standard were carried out. It was determined according to the test method adapted from the CLSI M07 A9 standard that 1 .000 ppm and 1 .600 ppm applications of the nanosolution had antibacterial (bactericidal) activity against Staphylococcus aureus (ATCC 25923) bacteria after 2 hours and activity against Escherichia coli (ATCC 25922) bacteria after 1 hour. Accelerated Aging Time (AAT) was calculated as 37 days corresponding to 365 days (1 year) Real Time Aging (RT) with accelerated aging (stability) tests of 1.000 ppm and 1.600 ppm applications of nanosolution according to ASTM F1980 standard. Accelerated Aging Time After 37 days, the solutions were found to be stable. After accelerated aging (stability) tests, no bacterial growth was observed in the solutions in sterility tests of 1 .000 ppm and 1 .600 ppm applications of nanosolution according to ISO 11737-2 standard. After 365 days accelerated aging (stability) of 1 .000 ppm and 1 .600 ppm applications of nanosolution according to ASTM F1980 standard, according to the test method adapted from the CLSI M07 A9 standard, it was determined that it has antibacterial (bactericidal) activity against Staphylococcus aureus (ATCC 25923) bacteria after 2 hours and against Escherichia coli { ATCC 25922) bacteria after 1 hour.
The antibacterial activities of 1.000 ppm and 1.600 ppm applications of the nanosolution of the invention were determined according to the method adapted from the CLSI M07 A9 standard test method.
Staphylococcus aureus (ATCC 25923) and Escherichia coli (ATCC 25922) bacterial suspensions were adjusted to 1x105 density and applied to 1.000 ppm and 1.600 ppm solutions. At the end of 2-360 minutes, it was transferred to the culture medium and then it was evaluated whether there was any growth in the media. Test results are given in Chart 1 and 2.
It was determined according to the test method adapted from the CLSI M07 A9 standard that 1.000 ppm and 1.600 ppm applications of the nanosolution had antibacterial (bactericidal) activity against Staphylococcus aureus (ATCC 25923) bacteria after 2 hours and activity against Escherichia coli (ATCC 25922) bacteria after 1 hour.
Accelerated aging (stability) tests of 1 ,000 ppm and 1 ,600 ppm applications of the inventive liposomal ozone nanosolution were determined according to the ASTM F1980 standard. 1.000 ppm and 1 .600 ppm applications of nanosolution were exposed to accelerated aging
(stability) in a Nuve FN 120 brand oven set at 550 and the accelerated aging (stability) time was calculated with the Arrhenius Equation [Q10(TAA-TRT)/10]. Test results are given in Chart 3.
Chart 3. Accelerated aging (stability) time
Accelerated Aging Time (AAT) was calculated as 37 days corresponding to 365 days (1 year) Real Time Aging (RT) with accelerated aging (stability) tests of 1 .000 ppm and 1 .600 ppm applications of nanosolution according to ASTM F1980 standard. Accelerated Aging Time After 37 days, the solutions were found to be stable.
After Accelerated aging (stability) tests of the inventive liposomal ozone nanosolution, sterility tests of 1.000 ppm and 1.600 ppm applications of nanosolution were determined according to ISO 11737-2 standard. In 1.000 ppm and 1.600 ppm applications of nanosolution, it was observed whether aerobic mesophilic bacteria grow in Triptone soy broth medium at a temperature of 30±2O and for 14 days, whether anaerobic mesophilic bacteria grow in liquid Thioglycolate medium at 30±2Ό and for 14 days, whether bacteria grow in the negative control of Triptone soy broth and Liquid Thioglycolate media at 30±2Ό and for 14 days, whether Bacillus atropheus grow in the positive control of Triptone soy broth and Liquid Thioglycolate media at 30±2Ό for 14 days. Test results are given in Chart 4.
Chart 4. Sterility values of 1 .000 ppm and 1 .600 ppm applications of nanosolution after accelerated aging (stability) tests
After accelerated aging (stability) tests, no bacterial growth was observed in the solutions in sterility tests of 1 .000 ppm and 1 .600 ppm applications of nanosolution according to ISO 11737-2 standard.
After 365 days accelerated aging (stability) of 1 ,000 ppm and 1 ,600 ppm applications of the inventive liposomal ozone nanosolution according to ASTM F1980 standard, antibacterial
activities were determined according to the test method adapted from the CLSI M07 A9 standard. After 365 days accelerated aging (stability) according to ASTM F1980 standard, Staphylococcus aureus (ATCC 25923) and Escherichia coli (ATCC 25922) bacterial suspensions were adjusted to 1x105 density and applied to 1.000 ppm and 1.600 ppm solutions. At the end of 2-360 minutes, it was transferred to the culture medium and then it was evaluated whether there was any growth in the media. Test results are given in Chart 5 and 6.
After 365 days accelerated aging (stability) of 1.000 ppm and 1.600 ppm applications of nanosolution according to ASTM F1980 standard, according to the test method adapted from the CLSI M07 A9 standard, it was determined that it has antibacterial (bactericidal) activity against Staphylococcus aureus (ATCC 25923) bacteria after 2 hours and against Escherichia coli (ATCC 25922) bacteria after 1 hour.
The antibacterial activities of 2000 ppm and 3000 ppm applications of the nanosolution of the invention were determined according to the method adapted from the CLSI M07 A9 standard test method. Staphylococcus aureus (ATCC 6538) and Escherichia coli (ATCC 25922) bacterial suspensions were adjusted to 1x105 density and applied to 2000 ppm and
3000 ppm solutions. At the end of 2-360 minutes, it was transferred to the culture medium
and then it was evaluated whether there was any growth in the media. Test results are given in Chart 6-14.
Chart 6. Liposomal ozone nanosolution+ 1% HYALURONIC ACID E.COLI 25922 2000ppm
Chart 7. Liposomal ozone nanosolution + glycerin Throat Spray E.Coli 25922 3000ppm
Chart 2000ppm 1-year E.Coli 25922 2000ppm
Chart 9. Ozonated oil and ozonated emulsifier 2000ppm E.Coli 25922 2000ppm
Chart 10. Liposomal ozone nanosolution 2000ppm + 0.5% Thymol E.Coli 25922 2000ppm
Chart 11. Ozonated oil + ozonated emulsifier 2000 ppm S.auneus 6538 2000 ppm
After 365 days accelerated aging (stability) of 2000 ppm and 3000 ppm applications of nanosolution according to ASTM F1980 standard, according to the test method adapted from the CLSI M07 A9 standard, it has been determined that it has antibacterial (bactericidal) activity at an increasing rate against Staphylococcus aureus bacteria and Escherichia coli bacteria.
Skin Irritation Test of Liposomal Ozone Nanosolutions:
The inventive irritation test of liposomal ozone nanosolution was carried out considering TS EN ISO 10993-10:2010 standard, the experimental animal used in the test is considered according to TS EN ISO 10993-2:2006 standard, the material preparation is made according to TS EN ISO 10993-12:2013 standard guidelines. Three healthy young New Zealand albino rabbits with a body weight of 2-3 kg were used as experimental animals.
Test material given under the title of TS EN ISO 10993-10:2010 annex A A.2,2 Liquid test materials; Liquids were applied without dilution or by direct precipitation or, if not applicable, at a dose of 1600 ppm, which is the usage dose according to the guideline. Sodium lauryl sulphate (SLS) was used as a positive control and distilled water was used as a negative control. The sponge impregnated with the nanosolution of the invention was kept in direct contact with the sample application areas. SLS impregnated sponge was applied to the positive control area. The samples were covered with gauze, fixed with a bandage, and topically contacted with the back skin for 4 hours. The primary irritation index was determined by evaluating the application areas (1 ± 0.1) s, (24 ± 2) s, (48 ± 2) s, and (72 ± 2) hours after the 4th hour application, according to the skin reaction score given in Chart 1 . As stated in the standard, the 1 st hour was not included in the calculation.
The observations made according to the TS EN ISO 10993-10:2010 standard and their evaluations are given in Chart 3 and Chart 4.
Irritation Test result in TS EN ISO 10993-10:2010 Standards
In the evaluation made based on the observation values (Chart 3, 4) made at the 24th, 48th, and 72nd hours after the application in the irritation test of the inventive nanosolution, it was
determined that the samples did not cause significant erythema and edema in any of the subjects. It has been determined according to the test results carried out in line with the directive of the TS EN ISO 10993-10:2010 standard that the inventive nanosolution does not have any irritating effect.
In Vitro Cytotoxicity Test of Liposomal Ozone Nanosolutions:
Cytotoxicity refers to the rate of toxic effects on living cells. Cytotoxicity tests are tests that are evaluated by considering the cell proliferation rate and the toxic effect on the cell in the appropriate cell culture of the substance considered to be toxic. These test systems are carried out for morphological observation of cellular damage, determination of cellular damage by various measurement methods, determination of cellular growth, determination of any change in cellular metabolism. Cytotoxicity tests can be performed in vivo or in vitro. In in vitro tests, the substance whose cytotoxicity is investigated is administered to cells in increasing concentrations. The effects of this substance on cell morphology and cell survival rates are investigated.
MTT method [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide]: In this method, MTT is reduced to formazan, while the color formed is measured colorimetrically. The amount of formazan produced gives the number of viable cells. MTT is a substance that is actively absorbed into cells and reduced to colored, water-insoluble formazan by a mitochondria-dependent reaction. The MTT reduction property of the cells is taken as a measure of cell viability and the dye density obtained as a result of MTT analysis correlates with the number of viable cells.
The test system used in this research is based on the following standards;
TS EN ISO 10993-5:2009, Biological evaluation of medical devices - Part 5:Tests for in vitro cytotoxicity. TS EN ISO 10993-1 :2018, Biological evaluation of medical devices - Part 1 Evaluation and testing. TS EN ISO 10993-5:2009, Biological evaluation of medical devices - Part 12: Sample preparation and reference materials. USP 31 , 2008, Chapter 87 - Biological reactivity tests, in vitro .
Extraction of test material, negative and positive groups was carrid out with 1600 ppm liposomal ozone nanosolution at 37°C for 24 hours in accordance with TS EN ISO 10993- 12:2012 standards.
The BALB/c 3T3 (CCL-163) cell line from ATCC was used for the cytotoxicity test study. Cells were propagated in DMEM (dulbecco's modified eagle medium) (ATCC Cat No: 30- 2006) medium supplemented with 10% FBS (fetal bovine serum) and 2% glutamine and incubated at 370 in an oven with 5% C02. A mixture of 0.25% trypsin and 0.03% EDTA was used for trypsinase of cells as recommended by ATCC. Cells were suspended in culture medium and 100mI was transferred to 96-well plates with 104 cells in each well.
After 24 hours of cell culture conditions, the medium on the culture was removed and 100mI of test material was added from the positive and negative control extracts. All doses were administered with at least 5 repetitions. At the end of 48 hours of waiting in an oven with 5% C02 at 37Ό and 95% humidity, the culture medium was removed after the plates were examined.
Negative control (NC): Polyethylene tube
Positive Control (PK): Serial dilutions of DMSO (Dimethylsulfoxide) (10-30 v/v)
Test Material (TM) concentrations: 100 -30-10 -3-v/v
After examining the plates, the culture medium was removed from the wells. 50 mI of MTT solution was added to each test well. The plates were incubated for 2 hours at 37 TT Then, the MTT solution was removed from the wells and 100 mI of isopropanol was added to each well. Absorbance measurements were taken and evaluated with a microplate reader containing a 570 nm filter.
If the viability of the test material is less than 70%, it is considered cytotoxic.
Chart 1 . Results of quantitative measurement of cytotoxic effects by MTT Test.
The % vitality value was determined according to the formula below.
Vitality %= 100 x OD570TM /OD570NK
OD570TM =lt is the average value of the optical density value of the test material after the blank is removed.
OD570NK =lt is the average value of the optical density value of the negative control after removing the blank.
According to the test results carried out in line with the directive of the TS EN ISO 10993- 5:2009 standard, it was determined that the test material, the liposomal ozone nanosolution of the invention, did not have a cytotoxic effect.
Liposomal Ozone Nanosolutions In vivo Acute Ocular Irritation Test:
The experiment aims to test the material or product that has the potential to cause ocular irritation. The ocular irritation test is only performed for materials that will come into contact with the eye or eyelid and when safety information cannot be obtained by other means. The test material is carried out in accordance with the directions specified in TS EN ISO 10993- 10:2010 annex A. If the material to be tested is liquid, 0.1 ml undiluted (1600 ppm dose) is dripped into the lower conjunctival sac of one eye. If the test material is in the spray pump, it is removed from the pump and tested by dropping 0.1 ml. as in liquids. We used 3 healthy young adult albino rabbits of both sexes weighing 2 kg to 3 kg from a single strain. The animals were kept in the environmental conditions specified in TS EN ISO 10993-2:2006. Both eyes of each rabbit are visually inspected up to 24 h prior to the start of the experiment so as to determine if an ocular abnormality is present. When the eyes are examined, 2% sodium fluorescein BP (British Pharmacopoeia) can be used to visualize any corneal damage.
After the test sample was instilled into the conjunctival sac, the eyelids were held together for about 1 hour. For Observation of Animals and determination of the Irritation index, it is examined at approximately (1 ± 0.1) s, (24 ±2) s, (48 ±2) s, and (72 ±2) s. Since no lesion was observed, it was not necessary to advance the observations to longer periods. Observations were graded according to the grading scale of the ocular lesions given in Chart 1.
Chart 1. Grading system of ocular lesions
0,1 ml of the product of the nanosolution of the invention was instilled In the left eye of the rabbits, both eyes were examined and evaluated approximately (1 ± 0.1) hour after instillation. No indication of any conjunctival irritation caused by the application was observed. Since no signs of permanent or other corneal irritation were observed in the examination performed by instilling 2% sodium fluorescein, it was not necessary to extend the observation period. Evaluations were graded according to Table 1 . No positive reaction was observed in any animal. In animals, no ocular changes such as mild or conjunctival membrane peeling and ulceration, corneal perforation (perforation), blood or pus in the anterior chamber of the eye) or - Bloody or hairy (purulent) discharge, or - Severe corneal ulceration were found.
When the eyes treated with control eyes in the ocular irritation test of the liposomal ozone nanosolution of the invention are evaluated, it was determined that there was no difference, and that the nanosolution of the invention did not cause any changes reflecting any irritation in ocular structures (Conjunctival, cornea, iris). It has been determined according to the observations of the Ocular Irritation Test" conducted in line with the directive of the TS EN ISO 10993-10:2010 standard that the inventive liposomal ozone nanosolution has no ocular irritation effect.
Oral Mucosal Irritation Test of Liposomal Ozone Nanosolutions:
Oral mucosal irritation test was carried out considering the TS EN ISO 10993-10:2010 standard, the experimental animal used in the test is considered according to TS EN ISO 10993-2:2006 standard, the material preparation is made according to TS EN ISO 10993- 12:2012 standard guidelines. The test is performed for materials intended to come into contact with oral tissue and where safety data cannot be obtained by other means.
Animals were acclimated to the environment by taking care of them as specified in TS EN ISO 10993-2:2006. Healthy young adult Syrian hamsters of both sexes, unrelated to a
single strain, were used for testing. Product sample-impregnated gauze was placed in the inner cheek pouch of each animal under ketamine/Xylazine anesthesia. The exposure time was evaluated according to the rule of reflecting the actual expected use time of the material, and the sample was kept in the inner cheek pouch for 1 hour.
Test material given under the title of ISO 10993-10:2010 annex A A.2,2 Liquid test materials; Liquids were applied without dilution or by direct precipitation or, if not applicable, at a dose of 1600 ppm, which is the usage dose according to the guideline. Saline solution- impregnated absorbent gauze was used as negative control. As a positive control, HCI acid solution adjusted to pH 1 .5 was used in our laboratory based on the rule that liquids with pH 2 and below are considered irritating.
The left inner cheek pouch of each animal was evaluated for the experimental sample, and the contralateral (Right) inner cheek was considered as the negative control. No material was placed into the right side inner cheek pouch, it was only washed with physiological saline and dissected at the end of the experiment.
Gauze cloth impregnated with a usage dose of 1600 ppm of the nanosolution of the invention was placed in the left inner cheek pouch of Syrian hamsters under ketamine/Xylazine anesthesia, whose inner cheeks were emptied and washed with saline. After the exposure of the subject to the sample for 1 hour, the sample was removed and the inner cheek was rinsed with saline solution, taking care not to contaminate the other cheek. Experiment (left) and control (right) inner cheek pouches were evaluated macroscopically according to chart 1. The experiment was terminated after 1 hour of contact.
Chart 1- Rating system for Oral and Penile reactions
According to the standard directive, the exposure time should reflect the actual expected use time of the material, but should not be less than 5 minutes. The repeated observation rating (Table 1) performed at long-term chronic exposures is summed up and divided by the total repeat application 4. Since it is a device with subacute use, the application was performed 4 times with one hour intervals. Observations of the sample applied left inner cheek were compared with the right inner cheeks (negative control) washed with saline.
Chart 2 - Grading system for microscopic examination of oral, penile, rectal and vaginal tissue reaction
The observations made according to the TS EN ISO 10993-10:2010 standard and their evaluations are given in Chart-43. In the macroscopic examination, no irritation appearance (erythema or eschar) was observed in the sample-applied inner cheek mucosa, similar to the controls. Areas of mucosal erosion were noted in the positive controls. The mean irritation index was calculated as zero (0) for each animal except the positive control.
Chart 4: Microscopic irritation score
When the Hematoxylin-Eosin (HE) stained preparations prepared from the inner cheek samples taken for histopathological examination from the test product applied group are examined under the microscope, there was no erosion or ulceration in the mucosa, epithelium, leukocyte infiltration and vascular congestion.
After Hematoxylin-Eosin (HE) stained preparations prepared from inner cheek samples taken for histopathological examination were examined under a microscope, it was evaluated whether there was any erosion or ulceration in the epithelium in the mucosa, leukocyte infiltration and vascular congestion. No findings reflecting the irritating appearance of the oral mucosal structures of the application of the product samples of the nanosolution of the invention were found in the subjects in the light microscopic histopathological examination. It was determined that the nanosolution of the invention did not have an irritating effect on the oral mucosa according to the results of the macroscopic and histopathological evaluations of the oral mucosal irritation test applied for materials likely to come into contact with the oral tissue (TS EN ISO 10993-10).
Nasal mucosal irritation test was carried out considering the TS EN ISO 10993-10:2010 standard, the experimental animal used in the test is considered according to TS EN ISO 10993-2:2006 standard, the material preparation is made according to TS EN ISO 10993- 12:2012 standard guidelines. The test is performed for materials intended to come into contact with nasal tissue and where safety data cannot be obtained by other means.
Animals were acclimated to the environment by taking care of them as specified in TS EN ISO 10993-2:2006. Twelve healthy young adult BalbC mice of both sexes (6 experiments, 6 controls) unrelated to a single strain were used for testing. A single dose (1 ml) of 1600 ppm nanosolution of the invention was instilled into the nasal cavity of each animal for 4 days.
Test material given under the title of ISO 10993-10:2010 annex A A.2,2 Liquid test materials; Liquids were applied without dilution or by direct precipitation or, if not applicable, by diluting with a suitable liquid at a dose of 1600 ppm, which is the usage dose according to the guideline. The comparison was made with the Negative control group using only saline. Positive control 4-day irritant application was not applied because it is not ethical in terms of animal welfare.
The experimental group was formed by dripping a single dose (1 ml) of 1600 ppm nanosolution of the invention into the nasal cavity for 4 days. The control group was formed by dripping the same amount of saline nanosolution into the nasal cavity for 4 days.
After 4 days of application, the noses of the subjects who were euthanized under high-dose Ketamine/Xylazine anesthesia were dissected and taken into decalcification process to soften the bones after 10% formalin fixative.
The animals were observed clinically during the 4-day administration of the test sample. No signs of nasal redness, discharge or restlessness were observed in the experimental and control group subjects. The animals displayed normal feeding and social behavior. Microscopic evaluation in the nasal mucosal irritation test was performed by considering the parameters examined in the vaginal, rectal and penile irritation tests (Chart 2).
Chart 2 - Grading system for microscopic examination of oral, penile, rectal and vaginal tissue reaction
Chart 3 - Irritation Index
Macroscopic observations and microscopic evaluations made according to TS EN ISO 10993-10:2010 standard are given in Chart 1. In the macroscopic examination, no irritation appearance (erythema or eschar) was observed in the sample-applied nasal mucosa, similar to the controls. Areas of mucosal erosion were noted in positive controls. The mean irritation index was calculated as zero (0) for each animal except the positive control.
Chart 1 : Microscopic irritation score
After Hematoxylin-Eosin (HE) stained preparations prepared from nasal samples taken for histopathological examination were examined under a microscope, it was evaluated whether there was any erosion or ulceration in the epithelium in the mucosa, leukocyte infiltration and vascular congestion. No findings reflecting the irritating effect of the nasal mucosal structures of the application of the product samples of the nanosolution of the invention were found in the subjects in the light microscopic histopathological examination. It was determined that the nanosolution of the invention did not have an irritating effect on the nasal mucosa according to the results of the macroscopic and histopathological evaluations of the nasal mucosal irritation test applied for materials likely to come into contact with the nasal tissue (TS EN ISO 10993-10).
Sensitization Test of Liposomal Ozone Nanosolutions:
Sensitization test was carried out considering the TS EN ISO 10993-10:2010 standard by the Closed Patch-Buehler Test method, the experimental animal used in the test is considered according to TS EN ISO 10993-2:2006 standard, the material preparation is made according to Annex A standard guidelines.
At the beginning of the experiment, 10 unrelated healthy young adult albino guinea pigs of both sexes (5 males, 5 females) from a single strain weighing between 300 g and 500 g were used. After the animals were depilated 24 hours before the stimulation, the areas to be treated were shaved. The hair-free areas were thoroughly washed with warm water and dried with a towel before the animals were taken into the cages. After 2 hours of trimming the hairs, the test sites were graded according to the Magnusson and Kligman rating given in Chart 1 .
Test material given under the title of ISO 10993-10:2010 annex A A.2,2 Liquid test materials; Liquids were applied without dilution or by direct precipitation or, if not applicable, by diluting with a suitable liquid at a dose of 1600 ppm, which is the usage dose according to the guideline. Saline solution-impregnated absorbent gauze was used as negative control. As a positive control, 0.8% paraformaldehyde solution is used in our laboratory.
The gauze impregnated with the inventive nanosolution was applied in direct contact with the upper left and lower right regions of the shaved area. The samples were thus kept in contact with the shaved back skin of the animal for 6 hours. The samples applied to the shaved area were covered with gauze and protected with plaster from the outside. This application was carried out three times a week for three weeks.
After three weeks of induction, after two weeks of rest, the samples were applied to the opposite sides of the previously induced areas for the stimulation experiment and kept for 6 hours. Evaluation was made at 24 and 48 hours following the stimulation application. In the induction phase, observations were made according to Magnusson and Kligman grading at 24±2 and 48±2 hours following three applications per week for three weeks. Re grading was performed 24±2 and 48±2 hours after the removal of the stimulation patch after a two-week interval. Test and control animal observation records according to Magnusson and Kligman grading are given in Chart 2 below.
In the sensitization test of the inventive nanosolution product using the Closed Patch- Buehler Test method, it was determined that the samples did not cause any appearance of erythema and edema, which is an indication of sensitivity / sensitivity in any of the subjects in the applications and observations made for 5 weeks.
In line with the directive of the TS EN ISO 10993-10:2010 standard, it was determined that the inventive liposomal ozone nanosolution did not have a delayed sensitizing effect as a result of the evaluation of our test observations with the Closed Patch-Buehler Experiment method.
Antivirus Efficacy Test of Liposomal Ozone Nanosolutions:
In order to investigate the biological effect and possible toxic effect of the inventive liposomal ozone nanosolution, epithelial cell culture was first performed. Therefore, the epithelial tissue piece obtained from a biobank was taken into saline (0.09% NaCI) after thawing and separated into small pieces in sterile petri dishes. Pre-prepared medium containing 10% fetal bovine serum and 1% antibiotic was cultured. After reaching sufficient maturity and saturation in cell culture dishes, they were left to incubate for varying times with varying doses of the product.
Tracheo-bronchial epithelial cells supplied and generally targeted by human respiratory system viruses were subjected to cell culture process by means of the bioreactor system in its infrastructure to provide an organotypic culture medium. In this process, after incubation with pre-prepared medium (DMEM) containing 10% fetal bovine serum and 1% antibiotic, in a 3-dimensional, closed system bioreactor containing 37Ό and 5% CO 2 for 48 hours,
cell culture was continued for another 48 hours by washing with ready-made media. At the end of this period, cells were trypsinized with 0.25% trypsin-EDTA and passaged into other units of the bioreactor system that allow passage into the same medium. The culture was maintained by renewing the medium based on color and pH changes until the cells planted in these areas covered 80% of the surface area. When the cells reach the saturation level in their environment, the cells in a single chamber are exposed to trypsin-mediated treatment, then the 3-dimensional cell culture was separated from the surface and washed. In the remaining chambers, the active substance studies were continued with time and dose adjustments. As a result of the studies, its positive effect on cell proliferation was determined. This study was carried out using bioreactors and culture media that have the ability to imitate human nature.
After washing, cells were counted, and viability test was performed by flow cytometry. The resuspended cells were read in a 3-laser flow cytometer until there are 10000 cells and viability percentages of the cells obtained from the culture were determined by staining with the viability dye (7AAD). In addition, cultured cells at the level to be harvested were washed and taken into an eppendorf of 500 pL. 100 pL of 0.4% trypan blue solution was added to this cell suspension and incubated for 5 minutes at room temperature, then 10 pL was taken from thereof. Cell viability percentages were determined by placing this volume on the cell count slide and reading in a cell imaging and counting device.
As can be seen in the chart, the fact that neither proliferation nor viability is observed on healthy host cells is considered as a finding that the product will not cause a toxic effect.
The effect of the active substance on the corona virus SARS COV-2 virus lysate was measured fluorometrically in a dose and time dependent manner in terms of both its effect on the initial volume and its effect on cDNA conversion, presented in the chart below. In the statistical analyzes performed with Student's t-test, the determination of statistically significant activity at 1000 ppm in a 5-minute incubation period is also in line with previous bacterial activity studies, it has been revealed that the product subject to the study can have both viral and bacterial activity.
As a result of the studies detailed above, the inventive liposomal ozone nanosolution was concluded that it has both viral and bacterial activity found; does not cause toxic effects; does not have a negative effect on the viability of healthy cells; has both regenerative and proliferative effects on human respiratory system (tracheo-bronchial) cells.
-TEST ANALYSIS RESULTS OF INJECTION SOLUTIONS -
In vitro Genotoxicitv Bacterial Ames Test of Liposomal Ozone Nanosolutions: Genotoxicity tests were performed on the samples of liposomal ozone nanosolutions of the invention for Intra-articular/Subcutaneous/lntramuscular Injection and has been shown to have no mutagenic potential.
Genotoxicity (Bacterial Ames Test) (OECD 471) Information: Studies for the development of various test systems to elucidate the mutagenic effect and the detection of mutagens and to reduce the risk of hereditary diseases and cancers caused by mutagenesis for humans constitute one of the most important research areas of genetic toxicology. The Ames test, which was developed by Bruce Ames in 1972 and applied as a screening test to determine the mutagenic effects of chemical substances, is widely and reliably used as a short-time bacterial test system.
One of the short-time test systems used to determine the mutations caused by chemicals at the cell level is the Ames test. The Ames test is considered as one of the reliable methods to examine the toxic, mutagenic-carcinogenic effects of test substances, which are intended to be used as pharmaceutical raw materials.
Preparation of test substance and control substance:
A. For solid test material: According to OECD 471 guidelines, 0.5 g of test product was dissolved in 10 mL of DMSO, vortexed, and a 2-fold serial dilution was made. Final concentrations of the test were adjusted to be 5 mg/plate, 2.5 mg/plate, 1 .25 mg/plate, 0.625 mg/plate, and 0.3125 mg/plate.
B. For liquid test material: According to OECD 471 guidelines, 50 mI_ of test product was dissolved in 1 mL of DMSO, vortexed, and a 2-fold serial dilution was made. Final concentrations of the assay were adjusted to be 5 pL/plate, 2.5 pL/plate, 1.25 pL/plate, 0.625 pL/plate, and 0.3125 pL/plate.
Strains used in the study: All strains were purchased from MOLECULAR TOXICOLOGY, INC. Strain numbers are shown below: a. Salmonella typhimurium TA98 : # 71 -098L b. Salmonella typhimurium TA100 : # 71-100L
Positive Control: Different positive control products are used based on different bacterial strains. Description of bacterial strains and individual concentrations of mutagens are shown below:
Negative control: DMSO
For the metabolic activation system (S9 mix), Arachlor 1254- induced lyophilized rat liver S9 microsomal fraction was used. The mutagenic potential of the extracts was evaluated in the presence and absence of the S9 mixture. A 30% S9 mixture was used in the tests.
Bacteria were incubated 1 night before inoculation on ampicillin medium. Control solutions were prepared separately for each bacterium in 1 ml of the appropriate solvent (DMSO or sterile distilled water) specified in the Control Chart. Six concentrations were determined for the test material.
Prepared culture solutions were added to 384 wellplates. According to the test protocol, it was incubated for 48 hours in a 37-degree oven. At the end of the period, 64 wells per concentration were counted and evaluated according to positive [(yellow-revertant)] and negative [(purple-non-revertant)] wells the test was considered as positive (mutation effect) if two times more mutations were observed in the test strains with and without S9 than in the negative control group.
Genotoxicity (Bacterial Ames Test) Result
Chart 1. Demonstration of mutant colony numbers of bacterial strains in S9 and S9-free medium of test material
Comment: It was observed that the colonies of the “Intra
Articular/Subcutaneous/Intramuscular Injection Solution” test product, Salmonella typhimurium TA98,TA100, did not appear to be 2 times higher than the colonies of the negative control group. As a result, it was determined according to the results of the test procedures (OECD 471) that the test material was not mutagenic at all lower concentrations with 2 different bacterial strains.
Liposomal Ozone Nanosolutions Acute Systemic Toxicity Test ( TS EN ISO 10993-
11:2018):
Acute systemic toxicity test was performed on the samples of liposomal ozone nanosolutions for Intra-Articular/Subcutaneous/lntramuscular Injection of the invention and it was determined that there was no acute toxicity effect.
Acute systemic toxicity test was carried out considering the TS EN ISO 10993-11 :2018 standard, the experimental animal used in the test is considered according to S EN ISO 10993-2:2006 standard, the material preparation is made according to TS EN ISO 10993- 12:2012 standard guidelines.
The test material was carried out in accordance with the TS EN ISO 10993-12:2012 sample preparation guide. Intra-Articular/Subcutaneous/lntramuscular Injection nanosolution was injected intramuscularly at an amount of 2ml/kg body weight (TS EN ISO 10993-11 :2018- 4, Appendix B).
Liposomal ozone nanosolution was injected intramuscularly into the gluteal region of the subjects at an amount of 2 ml/kg body weight. As the control group, 6 (3 $/3 ) BalbC mice were injected with saline in the amount of 2ml/kg body weight and the control group was formed. The control group subjects were kept in the same environment with the experimental group and fed in the same way. Subjects were kept under clinical observation for three days (Chart 1).
Clinical Observation:
Body weight: The body weight of the subjects was in the range of 23-33 g, and there was no remarkable change in weights.
Chart 1 : Common clinical signs, observations.
Activation: No changes were observed in the motility and daily activations of the subjects. Increasing and decreasing drowsiness, fatigue, trembling, twitching behaviors were not observed.
Stress: In the behavior of the subjects, neurotic behaviors such as stress indication, constant touring, aggression or cornering were not observed. They behaved in normal activity in the cage.
Death: No deaths were observed in any group.
Pain: Passivation, crawling, intermittent mobility, and shouting behavior were not observed as pain indicators.
Respiration: No difference in respiratory behavior and no cyanosis, nasal discharge, tachypnea was observed.
Food and water consumption: Food and water consumption was monitored similarly to controls.
Sight: Conjunctival hyperemia, lacrimation, conjunctivitis, opacification, iris inflammation was not observed in the eyes.
Cardiac observation: Tachycardia, bradycardia was not observed.
Body temperature: 36.5°C was observed at a normal level.
Gastrointestinal observation: Excessive salivation, diarrhea, soft stools were not observed. No evidence of toxicity was found during the experiment, in acute applications of Intra- Articular/ Subcutaneous/ Intramuscular Injection liposomal ozone nanosolution, which was tested with clinical observations and measurements according to the protocol and evaluation criteria specified in the TS EN ISO 10993-11 :2018 document. As a result, it was determined that liposomal ozone nanosolution for Intra-Articular / Subcutaneous / Intramuscular Injection did not have any acute toxicity effect.
In Vitro Cytotoxicity Test of Liposomal Ozone Nanosolutions ( TS EN ISO 10993-5:2009):
In Vitro Cytotoxicity test was performed on the liposomal ozone nanosolution samples of the invention for Intra-Articular/Subcutaneous/lntramuscular Injection and it was revealed that it did not have cytotoxic potential.
Extraction of test material, negative and positive groups was carried out in accordance with ISO 10993-12 standards. The extract was prepared by keeping 0.2 grams/ml of test material in DMEM 10% FBS for 72±2 hours at 37±1 oC in a shaking incubator at 200 rpm (The specified standard is based on irregular shaped solid devices. This case is chosen as the worst-case scenario). It was filtered through a 0.22 pm sterile filter and defined as 100% extract. Percentages of other extracts were formed by dilution of DMEM 10% FBS. No color change was observed (In-lab test method).
L-929 mouse fibroblast cell line from ATCC for cytotoxicity test study (NCTC clone 929: CCL 1 , American Type Culture Collection [ATCC] was used. Cells were propagated in DMEM (dulbecco's modified eagle medium) (ATCC Cat No: 30-2006) medium supplemented with 10% FBS (fetal bovine serum) and 2% glutamine and incubated at 370 in an oven with 5% C02. A mixture of 0.25% trypsin and 0.03% EDTA was used for trypsinase of cells as recommended by ATCC. Cells were suspended in culture medium and 100mI was transferred to 96-well plates with 104 cells in each well.
After 24 hours of cell culture conditions, the medium on the culture was removed and 10OmI of test material was added from the positive and negative control extracts. All doses were administered with at least 5 repetitions. At the end of 48 hours of waiting in an oven with 5% C02 at 37Ό and 95% humidity, the culture medium was removed after the plates were examined.
Negative control (NC): Cell culture medium (DMEM + 10% FBS) was incubated under the same conditions as the extracts for 72 hours.
Positive Control (PC): Serial dilutions of DMSO (Dimethylsulfoxide) (10-30 v/v) were made with DMEM+ 10% FBS.
Test Material (TM) concentrations: It was diluted with DMEM+ 10% FBS as 100 -30-10 -3- v/v.
After microscopic examination of the plates, the culture medium was removed from the wells. 50 mI of MTT solution was added to one of its test wells. The plates were incubated for 2 hours at 37 O. Then, the MTT solution was re moved from the wells and 100 mI of isopropanol was added to each well. Absorbance measurements were made and evaluated with a microplate reader containing a 570 nm filter. Absorbances greater than 0.2 were accepted as the general validity criterion of the test. If the viability of the test material is less than 70%, it is considered cytotoxic.
It has been determined that the test material does not have a cytotoxic effect according to the test results carried out in line with the directive of TS EN ISO 10993-5 standard.
Irritation Test result of Liposomal Ozone Nanosolutions in TS EN ISO 10993-10:2010 Standards
Irritation test on liposomal ozone nanosolution samples of the invention for Intra- Articular/Subcutaneous/lntramuscular Injection was carried out considering TS EN ISO 10993-10:2010 standard, the experimental animal used in the test is considered according to TS EN ISO 10993-2:2006 standard, the material preparation is made according to TS EN ISO 10993-12:2013 standard guidelines.
Three healthy young New Zealand albino rabbits with a body weight of 2-3 kg were used as experimental animals.
Test material given under the title of TS EN ISO 10993-10:2010 annex A A.2,2 Liquid test materials; Liquids should be tested without dilution or by direct precipitation or, if not applicable, by diluting with physiological saline to 1/4 dose, which is the usage dose in accordance with the directive that it should be tested by diluting with a suitable liquid.
Sodium lauryl sulphate (SLS) was used as a positive control and distilled water was used as a negative control.
The sponge impregnated with liposomal ozone nanosolution was kept in direct contact with the sample application areas no 2 as shown in figure 2. SLS-impregnated sponge was applied to the positive control area (area no 3). The samples were covered with gauze, fixed with a bandage, and topically contacted with the back skin for 4 hours.
The primary irritation index was determined by evaluating the application areas (1 ± 0.1 ) s, (24 ± 2) s, (48 ± 2) s, and (72 ± 2) hours after the 4th hour application, according to the skin reaction score given in Chart 1 . As stated in the standard, the 1st hour was not included in the calculation.
The observations made according to the TS EN ISO 10993-10:2010 standard and their evaluations are given in Chart 1 and Chart 2.
It was determined that liposomal ozone nanosolution for I ntra- Articular/ Subcutaneous/ Intramuscular Injection did not have any irritating effect according to the test results carried out in line with the directive of the TS EN ISO 10993-10:2010 standard.
Subcutaneous Implantation 7- 14 Days Test of Liposomal Ozone Nanosolutions iTS EN ISO
10993-6:2016)
Subcutaneous Implantation test was performed on the inventive liposomal ozone nanosolution samples for Intra-Articular/Subcutaneous/lntramuscular Injection and it has been shown that it does not cause any inflammatory reaction.
The purpose of the test method is to determine the history and course of the tissue response, which includes the eventual integration or resorption/degradation of the material
after medical device/biomaterial implantation. Particularly, the degradation properties and texture response of the material are determined for degradable/absorbable materials.
Implants are tested by placing them in the back subcutaneous tissue of adult mice, rats, guinea pigs or rabbits.
Healthy Wistar rats weighing 200-300 g and 10 weeks old of both sexes were used in the test studies. The subjects were kept in a sheltering area with 60% humidity and a constant temperature of 22°C during the test. The subjects were given normal rat feed and tap water. Dust-free autoclaved wood shavings were used as substrate. At the end of the experiment, all animals were euthanized.
Liposomal ozone nanosolution samples could not be applied directly under the skin (implantation). Product implantation was performed under operating room conditions by placing rats anesthetized at a dose of Ketamine 85 mg/kg, Xylazine 15 mg/kg body weight, under the dorsal skin on either side of the spine. After the hairs were removed by shaving the operation area, it was cleaned by wiping with an antiseptic solution. The implantation period was determined as 2 weeks, and at the end of the process, the subjects were euthanized using deep anesthesia, and the implantation areas were opened, and macroscopic observation was made. Tissue samples dissected from the implantation area were taken for microscopic examination.
The treated animals did not show any abnormalities in their daily behavior and activation. No abnormality was observed in its movements and walk. Their eating habits and social behavior in the cage were normal.
At the end of the fourteen-day implantation period, it was observed that the I ntra-Articu lar/ Subcutaneous/ Intramuscular Injection nanosolution product was absorbed under the skin and disappeared in the hypodermis in the macroscopic examination in the implantation area. No lymph node formation and inflammatory structure were observed around the implantation focus. No lymphatic focus or extra lymphocyte infiltration and metaplasic changes were observed at the implantation site in hypodermal tissues in the histopathological examination.
According to the protocol and evaluation criteria specified in the TS EN ISO 10993-6: 2016 document, it was observed that the I ntra-Articu lar / Subcutaneous / Intramuscular Injection
Nanosolution was completely absorbed and lost, and did not cause any inflammatory or metaplasic changes in harmony with the subcutaneous tight connective tissue in the implantation area in the 14-day subcutaneous implantation application as a result of the implantation experiments of the I ntra- Articular / Subcutaneous / Intramuscular Injection nanosolution product tested with the observations and measurements.
Consequently, following 14 days of subcutaneous implantation of Intra- Articular/Subcutaneous/lntramuscular Injection Nanosolution, it was determined that it was completely absorbed without leaving any residue in the implantation area and integrated with the surrounding tissue and did not cause any inflammatory reaction.
Intramuscular Implantation Test ( TS EN ISO 10993-6:2016 ) of Liposomal Ozone Nanosolutions:
Intramuscular Implantation test of liposomal ozone nanosolution samples of the invention for Intra-Articular/Subcutaneous/lntramuscular Injection was performed and it has been shown that it does not cause any deformative or inflammatory effects in muscle tissue.
The aim of the test method is to determine the date and course of the tissue response, which includes the eventual integration or resorption/degradation of the material after implantation of the medical device/biomaterial. Particularly, the degradation properties and texture response of the material are determined for degradable/absorbable materials. Implants should be inserted into the Panniculus carnosa or gluteal region muscles of adult mice, rats, guinea pigs or rabbits. Implant specimens should be implanted aseptically and without any damage prior to or during implantation. A minimum of three animals and sufficient space are used to obtain a total of 10 test and 10 control specimens for each material and implantation period. When multiple tissue samples are taken from a single implant site, the histology sections should be at least 1 cm apart.
In the test studies, 6 (3 female/3 male) BALB/c mice weighing 17-20 g were used as subjects. The subjects were kept in a sheltering area with 60% humidity and a constant temperature of 22°C during the test. The subjects were given normal rat feed and tap water. Dust-free autoclaved wood shavings were used as substrate. At the end of the experiment, all animals were euthanized.
2 ml of Intra-Articular/Subcutaneous/lntramuscular Injection Solution was injected into the right and left gluteal muscles of the subjects. 14 days after the injection, the gluteal muscles
of the right and left legs were dissected and examined microscopically from the subjects who were anesthetized with Ketamine 85 mg/kg and Xylazine 15 mg/kg.
The treated animals did not show any abnormalities in their daily behavior and activation. No abnormality was observed in its movements and walk. Their eating habits and social behavior in the cage were normal.
At the end of the 14-day implantation period, after ether anesthesia, cervical dislocation was applied to the subjects, and injection sites were opened in the gluteal muscles of the hind extremities. Injection areas were examined macroscopically. No residues related to Intra- Articular/Subcutaneous/lntramuscular Injection Nanosolution were found. In addition, lymphatic focus formation due to inflammation in the muscle was not observed.
When the gluteal regions where liposomal ozone nanosolution was injected were examined; it was observed macroscopically that the muscle structures have a normal appearance. It was observed during the dissection of the muscle that there were no different tissue masses or lymphatic foci within the muscle. It was observed that the liposomal ozone nanosolution injected into the muscle tissue was completely absorbed by the tissue and did not leave any residue. It was observed that the injection of liposomal ozone nanosolution in the muscle tissue did not cause any negative structural changes in the tissue.
It was determined that lyosomal ozone nanosolution samples for Intra-Articular / Subcutaneous / Intramuscular Injection did not cause any deterioration or deformation in the muscle tissue, and lymphocyte infiltration in the muscle during microscopic examinations.
The intramuscular implantation test of the liposomal ozone nanosolution product was performed according to the protocol and evaluation criteria specified in the TS EN ISO 10993-6:2016 document. Intra-Articular / Subcutaneous / Intramuscular Injection product at the end of the 2-week gluteal experiment period, it was determined that the samples were completely absorbed and there was no residue left in observation and evaluations. It was determined macroscopically and microscopically that the injection was in harmony with the muscle tissue and did not cause deformation and inflammatory reaction in the muscle structure.
lAs a result, it was determined that intramuscular implantation applications of liposomal ozone nanosolution product for I ntra- Articular / Subcutaneous / Intramuscular Injection did not cause any deformative or inflammatory effect on muscle tissue.
Liposomal Ozone Nanosolution Biopsv+Histopatholoov/Hematoxylin Eosin Staining Test: In the liposomal ozone nanosolution samples of the invention for Intra- Articular/Subcutaneous/lntramuscular Injection, in an experimental study on rats, 280 skin biopsy materials from 56 female rats of Sprague downey breed, 2 months old, were euthanized at the end of the experiment, microscopic examinations of the tissues of the lungs, liver and kidneys were made so as to observe the "Healing Effects in Regional Subcutaneous Applications”.
Applying physiological salt water, 10 ppm, 50 ppm, 100 ppm, 500 ppm, 1000 ppm, 5000 ppm subcutaneously to the experimental groups consisting of 56 animals, from the back region of the animal in each group, a total of 280 skin biopsies were examined followed by the 1st, 2nd, 3rd, 4th and 30th days. Lesions were scored and group average scores were obtained.
In the skin biopsies examined; it was observed that in the ratio of skin to epidermis (%) average of the first 4 days; 28.6 at a dose of 10 ppm, 48.3 on the 30th day; while it was
29.4 at a dose of 50 ppm, it was 42.8 on the 30th day; while it was 28.6 at a dose of 100 ppm, it was 33 on the 30th day; while it was 30,1 at a dose of 500 ppm, it was 455,6 on the 30th day; while it was 26 at 1000 ppm dose, it was 31.7 on the 30th day; while it was 34.1 at 5000 ppm dose, it was 27.1 on the 30th day.
The number of vascularization (in pieces) average of the first 4 days was observed as follows; while it was 7 at a dose of 10 ppm, it was 8.57 on the 30th day; while it was 6.83 at a dose of 50 ppm, it was 6.83 on the 30th day; while it was 5.33 at a dose of 100 ppm, it was 3.83 on the 30th day; while it was 6.12 at a dose of 500 ppm, it was 6.25 on the 30th day; while it was 4.84 at a dose of 1000 ppm, it was 4.57 on the 30th day; while it was 5.12 at 5000 ppm dose, it was 6.87 on the 30th day.
Hair follicle (in number) average of the first 4 days was observed as follows; while it was
16.5 at a dose of 10 ppm, it was 31 .25 on the 30th day; while it was 12 at a dose of 50 ppm, it was 21.33 on the 30th day; while it was 25.17 at a dose of 100 ppm, it was 35.5 on the 30th day; while it was 24 at a dose of 500 ppm, it was 55.5 on the 30th day; while it was
13.43 at a dose of 1000 ppm, it was 32.28 on the 30th day; while it was 24.75 at 5000 ppm dose, it was 38.38 on the 30th day.
In general, no increase in neutrophil counts in the skin was observed in the whole day and groups. No pathological findings were found in the lung, liver, or kidney.
Microscopic examinations of the tissues of 72 skin biopsy materials belonging to 72 female rats of Sprague downey breed which were 2 months old, were performed in the experimental study on rats for “Investigation of the wound effects after injection into the Laparotomy Incision Line from clinical and histopathological aspects " with the liposomal ozone nanosolution samples of the invention for Intra-articular/Subcutaneous/lntramuscular Injection.
A total of 72 skin biopsies of 72 animals from the abdomen were examined in the experimental groups in the applications on the wound lips on the skin line where the incision was made; Physiological Salt Water (FTS), 1% Lidocaine, ozone-free nanosolution, 250 ppm ozone nanosolution, 500 ppm ozone nanosolution, 500 ppm ozone nanosolution +2% Lidocaine (50% blend), 1000 ppm Ozone nanosolution + 2% Lidocaine (50% blend) and 2000 ppm ozone nanosolution + 2% Lidocaine (50% blend). Lesions were scored and group average scores were obtained.
Microscopic Findings: * Scoring values out of 3 in examined skin biopsies are presented in the chart below.
In the Intra-Articular / Subcutaneous / Intramuscular Injection nanosolution samples of the invention, for observing "Systemic Effects from Regional Subcutaneous Applications" , as a result of euthanasia of 6 Albino laboratory rabbits, microscopic examinations of the tissues of the lungs, liver, heart muscle and kidneys and peripheral smear were performed in the study performed on rabbits and the results are presented below.
Macroscopic Findings: Animals were euthanized after 10 days of repeating 100 ml serum containing 200 ppm (6mg/kg) ozone nanosolution intravenously.
Microscopic Findings: No pathological findings were found in the peripheral blood smears of the same animals, in the membrane structures and morphologies of erythrocytes; as well as in the lung, liver, heart muscle and kidney tissues.
In the liposomal ozone nanosolution samples of the invention for Intra- articular/Subcutaneous/lntramuscular Injection, for “ Clinical and histopathological investigation of the curative effects of regional intra-knee injection; Comparison of knees with hyaluronic acid and nanoparticle vitamin injections ", in the experimental study on rats, microscopic examinations of bone and cartilage tissues of 64 female rats of Sprague downey breed, 2 months old, were made and the report is presented below.
Macroscopic Findings: After the defect previously performed with a 250 micrometer stopper eye scalpel to the medial condyle, disarticulation at the 6th week resulted in knee joint insertion, Serum Physiological, of Hyaluronic (HA), 500 ppm intra-articular, 1000 ppm intra- articular, 2000 ppm intra-articular, 1000 ppm +HA (1/2 ratio mixture) intra-articular, 2000 ppm +HA (1/2 ratio mixture) intra-articular, 4000 ppm +HA (1/2 mixture) namely a total of 64 tissues were examined from the joint region of 8 animals.
Microscopic Findings: Semi-quantitatively, the modified form of the scores of the studies of Pineda et al. (1992)* and Wakitani et al. (1994)** was used.
-TEST ANALYSIS RESULTS OF HERBAL SOLUTIONS -
Laboratory Test on the Effect of Liposomal Ozone Nanosolutions on the Biolopical Activities of Harmful Carpoplyphus lactis (L.) (Acari: Carpoplyphidae) in Dried Apricots:
Carpoglyphus lactis (L.) (Astigmata: Carpoglyphidae), an important mite pest of dried fruits, causes the product to deteriorate, release unpleasant odors and eventually lose its market value when they are fed with fruit sugars of the dried apricots. Previous studies have shown that ozone gas can be used for control purposes in dried fruits due to its poisonous property against mites. However, due to the rapid decomposition of ozone gas into 02 and 0-, its short persistence limits the use of this gas in mite control. The biological activities of the inventive liposomal ozone nanosolutions on this harmful mite were investigated in the study carried out within the scope of the invention. The lethality [lethal concentrations (LC), lethal time (LT)], repellent and egg laying inhibitor effects and persistence of the formulation on mites were evaluated in the study. This study showed that 0.27% concentration of the formulation killed 90% of female mites within 48 hours. According to the results of the probit analysis, lethal time (LT90) was determined as 121 , 81 .5 and 66 hours, respectively in case the liposomal ozone nanosolution of the invention is used against mites at rates of 0.1 , 0.2 and 0.4%. Persistence tests showed that there was no statistically significant change in the lethal effects of the formulation during the first 7 days. However, after 10 days, a decrease of 12-17% in its lethal effect was detected. According to Pearson's chi-square test for
evasive effect, strong escapes of C. lactis females were observed from apricots sprayed with concentrations above 0.1% of the formulation. In conclusion, it was determined with this study that the determined doses of the nanosolutions of the invention had toxic and repellent effects on C. lactis females. It has been demonstrated by this study that the formulation can be used in the control of C. lactis if the dried apricots are exposed to the doses determined here, with the persistence of the formulation for 10 days.
Laboratory Test on Toxic Effect of Liposomal Ozone Nanosolutions on Bacterial Crown Gall Nematode (Meloidogyne so.):
The use of the inventive liposomal nanosolutions in the field of Plant Protection was investigated with three different samples containing Ozone (1 ), Ozone+Acetic Acid (2), Ozone+Acetic Acid+Tymol (3) so as to investigate the possibilities of use in agriculture. Bacterial crown gall nematodes, which cause crop losses in agriculture and have limited means of struggle, have been discussed in the studies carried out, the effects of the nanosolutions of the invention on the bacterial crown gall nematode (Meloidogyne sp.) were tested and it was investigated whether there were opportunities to fight this pest. Nanosolutions were stored at +4 Ό until use. Bacte rial crown gall nematodes used as target pests were collected as female individuals from the galls on infected plant roots in Bursa Karacabey tomato fields. Since the period that moves freely in the soil and infects the plant is the second period, 2nd period larvae were obtained from collected female individuals and experiments were carried out on 2nd period larvae. However, the species identification of bacterial crown gall nematode Meloidogyne was not made, it was expressed over the genus (Meloidogyne sp.).
The solutions were diluted in sterile distilled water to obtain the following doses: Solution #1 : (2000ppm liposomal ozone nanosolution) 50%, 25% and 12.5%, 2 Solutions 2 and 3: 0.1%, 0.2%, 0.3% and 0.4%.
Each solution was placed in sterile glass petri dishes with a diameter of 6 cm at the above doses, approximately 20 ml, and immediately after that, approximately 100 (±10) 2nd period nematode larvae were added to each petri dish. Afterwards, the petri dishes were shaken in a vortex for 1 minute and homogenization was achieved. Then, the petri dishes were covered and left for incubation at room temperature until the end of the experiment. As a control group, nematodes were kept only in sterile distilled water for the specified times.
The efficiency (toxicity) of the nanosolution was determined by counting the dead nematodes at the end of each solution trial at 6, 12 and 24 hours. Each experiment was carried out in 3 replications.
Solution 1 , that is, nanosolution containing only Ozone” in its content, tends to increase in its toxic effect as the exposure time on the nematode increases. However, there is no difference in efficacy between 12 hours and 24 hours. The lowest effect was detected after 6 hours and at the lowest dose of 12.5%, 25%, it was determined after 12 and 24 hours that it was effective on almost all nematodes at 50% dose, that is, it had a toxic effect. These 3 results show that solution 1 has a promising effect in combating Meloidogyne sp.
Solution 2, that is, nanosolution containing "Ozone + Acetic Acid", tends to increase in its toxic effect as the exposure time on the nematode increases. However, there is no difference in efficacy between 12 hours and 24 hours. While the lowest effect was detected at the rate of 35% at the lowest dose of 0.1% after 6 hours, it was determined that it had a toxic effect on almost all nematodes at 0.3% and 0.4% doses after 12 and 24 hours. This result shows that solution 2 has a promising effect in combating Meloidogyne sp.
Solution 3, that is, nanosolution containing "Ozone + Acetic Acid + Thymol", tends to increase in its toxic effect as the exposure time on the nematode increases. However, there is no difference in efficacy between 12 hours and 24 hours. While the lowest effect was detected at the rate of 42% at the lowest dose of 0.1% after 6 hours, it was determined that it had a toxic effect on almost all nematodes at 0.3% and 0.4% doses after 12 and 24 hours. This result shows that solution 3 has a promising effect in combating Meloidogyne sp.
As a result, increasing synergetic toxic effect of nanosolutions with 3 different ingredients on bacterial crown gall Meloidogyne sp. nematode has been shown. It has been demonstrated that the liposomal ozone nanosolutions of the invention have a high potential to suppress harmful nematodes, especially in the fight against this nematode in greenhouses.
In this test, 10-week-old seedlings of eggplant (Pala variety) [Solanum melongena L.(Solanaceae)] plants, which is the plant species most damaged by the spider mite, were
used as test material. Seedlings were grown from seed in a sterile climate room with artificial lighting (16 hours light: 8 hours dark) at 27Ό±1 a nd 60±5% relative humidity.
Two-spotted spider mites (Tetranychus urticae Koch) (Acari: Tetranychidae) individuals used in the experiment were recruited from a sensitive population collected from Bursa 8 years ago and grown continuously without pesticides. Colonies of the pest were reproduced on the same eggplant seedlings under controlled conditions.
Liposomal ozone nanosolutions of the invention were used in these tests. Two different (I and II) concentrations of two different formulations (N and S) were used in the first experiment. In the second experiment, combined formulations in which different concentrations of acetic acid (S+AA), orange oil (S+P), thyme oil (S+K) or lavender oil (S+L) were mixed to the I concentration of the S-coded formulation were tested.
The same volume of liposomal ozone nanosolutions was sprayed on and under the leaves of eggplant seedlings using hand sprays. As a control group, only one group was sprayed with water. Afterwards, the plants were kept in laboratory conditions for 30 minutes to dry the water and solutions applied to the leaves. 5 adult female (according to the economic damage threshold determined for eggplant) were placed on each leaf one by one with the help of a brush. Each experiment was carried out in 3 replications. Plants were kept in a sterile climate room with artificial lighting (16 hours light: 8 hours dark) at 27Ό±1 and 60±5% relative humidity for 7 days. At the end of the third 4th and 7th days, the living biological stages of the spider mite (egg, larva, and nymph, adult) were counted one by one under the stereomicroscope and noted.
The numbers of viable spider mites seen in eggplants in the water-only control group and the number of viable individuals on the eggplant leaf in which different formulations were applied were included in the Abbott formula (Abbott 1925).
According to the results of the tests performed under laboratory conditions on the 3rd day, concentrations I and II of the N formulation showed toxic effects respectively as follows; 80% and 93% on the eggs; 100% and 47 % on larvae; 55% and 0% on nymphs and 46% and 53% on adults. The same concentrations of S formulation showed toxic effects respectively as follows; 30% and 93% on the eggs; 66% and 94 % on larvae; 0% and 0% on nymphs and 8% and 69% on adults.
According to the results of the tests performed under laboratory conditions on the 7th day, concentrations I and II of the N formulation showed toxic effects respectively as follows; 46% and 73% on the eggs; 23% and 60 % on larvae; 68% and 95% on nymphs and 14% and 71% on adults. The same concentrations of S formulation showed toxic effects respectively as follows; 5% and 0% on the eggs; 0% and 30 % on larvae; 76% and 19% on nymphs and 15% and 29% on adults.
According to the results of the tests performed under laboratory conditions on the 3rd day, formulations in which a single formulation is combined with thyme oil (S+K), lavender oil (S+L), orange oil (S+P) and acetic acid (S+AA) to a concentration of 1000 mg/L showed toxic effects respectively as follows; 97, 99, 99 and 100 % on the eggs; 95, 100, 100 and 100% on larvae; 0% on nymphs and 100, 100, 100 and 100% on adults.
According to the test results on eggplant plants under laboratory conditions, the inventive liposomal ozone nanosolutions, after three days, killed the eggs and larvae of the two- spotted spider mite at a rate of 30-93% and 47-100%, adults at rates of 8-69%. Results were not considered as nymphs did not occur in the first 3 days. Effects ranged from 19- 76% as nymph populations naturally increased on day 7 of the test. Accordingly, different formulations and concentrations of the invention showed varying degrees of toxic effect on all biological stages of the spider mite. According to the best results, lethality (toxic effect) was observed up to 93% of eggs, 100% of larvae, 76% of nymphs and 69% of adults. The addition of plant-based oils to the formulations greatly increased the toxic effect on the spider mite and showed a synergistic effect. Even the lowest concentration (concentration no. I) of the nanosolution of the invention which is combined with thyme, lavender, orange oil or acetic acid showed toxic effect 97-100% to eggs, 95-100% to larvae; showed 100% on adults within three days. Since these mixtures showed a rapid effect within 3 days, they caused a very high rate of death of spider mites without allowing nymphs to form. As a result, it showed a toxic (poisonous) effect to the Two-spotted spider mite depending on the formulations and concentrations of the invention. The potential of using the inventive liposomal ozone nanosolution formulations as a Plant Protection Product in Plant Production stages in Agriculture has been demonstrated with this study.
Field Tests on the Toxic Effect of Liposomal Ozone Nanosolutions on Red Spider:
4 decares of land in Qe§mealti village of anakkale Biga district where farmer Halil Bagcioglu planted tomato seedlings that came early in the 80-85 days harvest on May 1
was divided into 100 square meters plots, the above table has been reached in the form of dose and mixture trials of the drugs that have been made and applied.
As of May 4, the plots in the form of doses and mixtures in the table were examined for red spider, early leaf blight from the seedling period. The plots were sprayed at intervals of I Q- 12 days and controls were made at intervals of 10-11 days by adding Lambda-cyhalothrin against powdery mildew from flowering period and green worm after fruit setting period.
In the observations made on Friday, May 15, no red spider pest, early leaf blight, powdery mildew and green worm have been encountered as of the seedling period.
In the observation made on Tuesday, May 26, it has been observed that the red spider population in the plots is 2-3 per m2 where the drug is used in doses of 75-100 ml A (33% ozone emulsifier, 34% ozone oil, 33% acetic acid) and drug B (30% ozone emulsifier, 30% ozone oil, 30% acetic acid, 10% functional oil thymol), in the drug A and drug B plots, which were applied at a dose of 50 ml, 7-8 live red spiders were seen per m2, and this was also found to be in a low population. Early leaf blight, powdery mildew and green worm have not been encountered since the seedling period. When we examined the green parts, no green worm eggs and larvae were found.
In the observation made on Tuesday, May 5, it has been observed that the red spider population in the plots is 4-5 per m2 where the drug is used in doses of 75-100 ml A (33% ozone emulsifier, 34% ozone oil, 33% acetic acid) and drug B (30% ozone emulsifier, 30% ozone oil, 30% acetic acid, 10% functional oil thymol), in the drug A and drug B plots, which were applied at a dose of 50 ml, 8-9 live red spiders were seen per m2, and this was also found to be in a low population. It was observed that there was no effect of drug A and drug B when compared with other drugs used against early leaf blight and powdery mildew at all doses used alone in plots. When all the plots were observed, when we examined the green parts, it was observed that there was a green worm egg and larva-dominated contamination with an average of 1 per 100 plants. Spraying will be done when there is 5% contamination against the green worm.
In the observation made on Tuesday, June 16, it was observed that the red spider population was 4-5 live per m2 with the continuation of favorable weather conditions in the drug A and drug B plots used in 75-100 ml doses, It was determined that the red spiders in the drug A and drug B plots, which were applied at a dose of 50 ml, were 9-10 per m2.
According to the observations in the plots, when compared with the other drugs used against early leaf blight and powdery mildew at all doses of drugs A and B used alone, it was observed again that there was no effect. The green parts of the plants in the whole plot were examined and dead green worm larvae were found from place to place. In drug A and drug B plots of dead green worm larvae, death occurred with an average of 1 -2% at a dose of 50 m, it was observed that the rate of dead in the drug A and drug B plots applied at a dose of 75-100 ml was 3-4%. It was observed that the mixtures with lambda-cyhalothrin were better in terms of performance compared to drug A and drug B used alone. In the observation made on Friday, June 26, it was observed that the red spider population was 3-4 live per m2 with the continuation of favorable weather conditions in the drug A and drug B plots used in 75-100 ml doses, It was determined that the red spiders in the drug A and drug B plots, which were applied at a dose of 50 ml, were 7-8 per m2. As a result of the examination of the green parts, 2 live green worm eggs and larvae were found in 100 plants.
Content A: Ozonated oil + ozonated polysorbate 80 and Acetic acid B Contains ozonated oil + ozonated polysorbate 80 + acetic acid + thyme oil.
As a result of the general observations in the trial plots we made in the field of farmer Halil Bagcioglu in Qe§mealti village of anakkale Biga district, Drug A and drug B showed a performance of 35-40% in 50 ml alone and 70-75% in 75-100 ml in red spider. It was observed that the expected performance was even better in the experimental plots observed with the addition of Abamectin to Drug A and Drug B. In the trial plots, it was determined that drugs A and drug B had no effect against early leaf blight and powdery mildew, compared to the other drugs we observed, between the dates we observed. It was determined that the drug A and drug B used in the experimental plot showed 10-15% success in 50 ml and 30-35% in 75-100 ml against green worms. It was observed that the performance against green worm was better in the experimental plots observed with Lambda-cyhalothrin added to Drug A and Drug B. It was also observed that there was no problem in the drug mixtures in the table.
Investigation of the efficacy of Liposomal Ozone Nanosolutions against Nosema apis and
Nosema cerenaeinfections in adult honey bees:
Nosema apis and Nosema cerenae cause Nosemosis in adult honey bees (Apis mellifera) and these factors settle in the digestive system of adult bees. Nosemosis is one of the most common bee diseases and causes significant bee losses worldwide. This disease causes digestive system disorders, decreased average lifespan of bees, colony number, honey production, pollen collection and significant winter losses in the colony. Nosemosis can progress with bacterial, protozoan and viral diseases, which adversely affects bee colony health, bee products and production. Various active substances have been used in the treatment of nosemosis until today, the most widely used of them is Fumagillin (Commercial name: Fumidil-B). However, this active ingredient is banned today because it poses a residue problem in honey. For this reason, treatment trials with organic acids, natural plant extracts and similar substances have been made in recent years. In this study, the efficacy of essential oils such as Origanum minutiflorum (Timol) and Artemisia absinthium (Wormwood) extract and Liposomal Ozone Nanosolutions against Nosemosis were investigated. Day 0 counts were made before the combinations created in this study were applied, sugar syrup used to feed bees was given to control groups in field trials. In the experiments, the combinations were mixed with sherbet (used to feed the bees) and applied to the sherbet inside the hive or to the frames by spraying. 50 bee samples were taken from each hive from the apiary and the protocol number was given before starting the
experiments. After the samples were kept in the freezer for one day, the digestion method was applied for the control of positiveness and negativeness in terms of Nosema spores. In this method, 10 bee samples were taken from each hive and the abdomens of the bees were separated from their bodies with the help of a scalpel. 1 ml per abdomen, 10 ml in total distilled water was added. Abdomen were crushed in a suitable beaker, a drop of abdominal fluid was transferred to a Neubauer Toma slide and Nosema spores were investigated at 40x10 magnification. In order to determine the spore load of Nosema fungus by the digestion method mentioned above in the positive hives, 20 bee samples were taken and the Nosema agents were counted under the microscope. While the experimental groups were formed with a certain amount of hives for each combination, it was noted that the Nosema spore number averages between the experimental groups were close to equal. The combinations were administered orally by spraying into the hives or by placing them in the sherbet inside the hive. 20 bee samples were collected from each hive at certain day intervals and Nosema spore counts were made by digestion method. Ozone (Liposomal Ozone Nanosolution), Thymol and Artemisia absinthium extracts and their combinations were tested in 5 different concentrations and dosages. According to the efficiency rates of the three combinations found most effective in these five field trials; Ozone+Thymol (Spray): 2000 ppm 200 ml Ozone+100 ml 3% Thymol+700ml sugar syrup 89.47%, Timol+Artemisia (Oral): 250 ml 2% Thymol+200 ml 2% Artemisia absinthium+550 ml sugar syrup 85.95%, Ozone (Oral): 100 ml 1000 ppm Ozone+400 ml sugar syrup 75.08% were given respectively. This result supported the previous studies with Timol, and when the combination was enriched with nanoparticle ozone, the results were found to be more effective against Nosema. There were no deaths or side effects caused by the application.
It has been determined that the antioxidant effect of ozone in nanocarrier systems is higher than the oils with larger molecules, and it shows its antibacterial effect at lower doses in the biocompatibility tests performed within the scope of the invention, It was understood that ozonated emulsifiers showed toxic effects in cytotoxicity tests performed at these doses. Therefore, in a different embodiment of the invention, ozonated emulsifiers are coated with biocompatible materials. In this way, in addition to the solutions created by the transportation of ozone with oils or emulsifiers containing oil and diversified by the addition of substances such as oil, acid, vitamin and mineral, it is possible to obtain new nanocarrier structures that provide high stability.
Coating of ozonated emulsifier is important for reducing the aggressive behavior of active ozone, providing slow release, obtaining small particle size and complying with sterilization
methods. Ozone cannot be sterilized by heat and there is no sterilization method other than filtration. In this sense, it is necessary to realize coatings suitable for filtration and to choose suitable coating materials.
In the most basic application of the invention, at least one emulsifier and ozone are used. Polysorbates such as polysorbate 20, polysorbate 60, polysorbate 80, polysorbate 85 can be used individually or in combination as emulsifiers. In another embodiment of the invention, dosage can be made by adding water (with or without mixing) to the ozonated emulsifier mentioned.
In a preferred embodiment of the invention, the ozonated emulsifier is coated with at least one emulsifier and/or polymer. The ozonated emulsifier and the emulsifier coated on it can preferably be polysorbate 20, polysorbate 60, polysorbate 80, polysorbate 85 or a combination thereof. The ozonated emulsifier and the emulsifier coated on the ozonated emulsifier can be the same or different polysorbates. For example, the structure obtained with polysorbate 80, and ozone can be coated with polysorbate 20. This structure may contain water. It is possible to use different polymers as a polymer, depending on the purpose and area of application.
Different polysorbates can be used in the invention, but not limited to those mentioned herein. Polysorbate 80 contains unsaturated fatty acid in the tail. Ozonated polysorbate 80 is formed by ozonation of this fatty acid. Polysorbate 85 carries 3 unsaturated fatty acids in its tail. Therefore, more ozone can be loaded.
In another embodiment of the invention, polyethylene glycol (PEG) and glycerin can be used as biocompatible materials for the coating. Ozone emulsifiers can be coated with glycerin alone, with PEG alone, or with a combination of glycerin and PEG. Coating ozonated emulsifiers with glycerin and PEG slows down the rapid antioxidant effect. Coating the ozonated emulsifier with polymers in addition to PEG and/or glycerin contributes to increased stability. Ozonated structures in the form of nanocarriers have two-year stability and have been found to maintain their antibacterial activity. Coating ozonated emulsifiers with glycerin and/or PEG provides a stability-enhancing effect within the scope of the invention However, coating with mannitol and/or dextran is also possible. The ozone emulsifier, coated with glycerin and / or PEG, reaches the target organ / tissue without the ozone gasification and, after reaching, it is possible to get rid of said coating and use it in tissue. For example, in the case of use in cancer treatment, cancer target protein or other
cancer drugs are bind to the ozone emulsifier and this new formation is coated with glycerin and/or PEG. The coating dissolves rapidly and the target protein binds to the cancer cell in the target tissue. In this way, ozone is dissolved and the cancer cell is broken down. This applies to all other chemicals.
The dimensions of ozonated emulsifiers are approximately 20 nanometers. Small coated nanoliposomes are formed by simply coating this molecule with PEG. Slightly larger nanoliposomes are obtained by coating with glycerin. Particle sizes increase when other chemicals are added to these nanoliposomes. It is important in drug formation that the products remain below 200 nanometers in these measurements The amount of coating and the ratio of glycerin and/or PEG are also important in terms of intended use and size. If the coating is done only in small quantities with PEG, the particles grow minimally. If the ratio is increased or the amount of glycerin is increased, the particle size increases.
When ozonated polysorbate 80 is first coated with glycerin and then with PEG, a 13- nanometer solution is obtained when the new mixture is mixed with water. Some glycerin and PEG that are not added to the complete mixture are also seen in the measurement. It ensures liposomes to be sent to the target organ without causing damage to the tissues and have a slower effect by using it in this form
In order to increase the effectiveness of ozone emulsifiers, it is possible to bind the lipoproteins, some of which are in lipid structure, to the surfactant so as to send them to the appropriate target organ. The lipoprotein-coupled structure is coated with glycerin and PEG. Similarly, phospholipid, sphingolipid, ceramide, proteolipid, glycolipid, isoprenoids, phosphoglyceride, lipids and terpenes, mineral, protein, cancer target protein, DMSO, acetyl cysteine, hyaluronic acid, menthol, acids, alcohols, enzymes such as ogenase, elastase, trypsin, lipase, alkans can be bind individually or in combinations to ozone emulsifiers.
Alternatives that can be used in different applications of the invention and the technical effects provided by them are explained below. The smallest form of the solutions obtained is referred to as niosome in the literature. These are the smallest liposome structures made with surfactants only in the smaller form of liposomes.
Aafter obtaining the smallest structure, it is aimed in the invention to develop products with increased stability and reduced toxicity by using different components. Accordingly, in
another application of the invention, in addition to ozone and emulsifier, the structure containing ozone or non-ozone phospholipid is coated with glycerin and/or PEG. It is especially found in the sphingomyelin nerve cell. The aim of this structure; it is used to make selective drugs for nerve cells when given to the body, Said structure adheres to nerve cells and functions to repair the nerve cell with ozone. In this way, it is possible to play a role in the repair of nerve cells, such as the use of ozone in wound healing.
In another application of the invention, in addition to ozone and emulsifier, the structure containing ozone or non-ozone sphingolipid is coated with glycerin and/or PEG. In this way, nano liposome that selectively adheres to the target organ for again nerve cells are obtained.
In another application of the invention, in addition to ozone and emulsifier, the structure containing ozone or non-ozone proteolipid is coated with glycerin and/or PEG. In this way, nano liposomes that selectively adhere to the target organ for nerve cells are obtained.
In another application of the invention, in addition to ozone and emulsifier, a glycolipid containing structure with or without ozone is coated with glycerin and/or PEG. This structure functions as a nanoliposome, which selectively adheres to the target organ for nerve cells. Cerebrosides, Ceramide oligosaccharides, Sulfatides, Gangliosides can be used in combination for ozone carrier nanoliposomes suitable for use according to their target organs.
In another application of the invention, in addition to ozone and emulsifier, the structure containing lipoproteins with or without ozone is coated with glycerin and/or PEG. The nanoliposome HDL cholesterol target organ is the liver, which is attached to the target organ by combining lipids such as cholesterol. Cholesterol circulating in the blood goes to the liver last. It is used in the treatment of liver diseases and in liver cancer in combination with ozonated emulsifier and HDL cholesterol.
In another application of the invention, in addition to ozone and emulsifier, the structure containing isoprenoids is coated with glycerin and/or PEG. For example, a combination of vitamins such as fat-soluble vitamins, vitamin A can be given.
In another application of the invention, in addition to ozone and emulsifier, the structure containing ozone or non-ozone ester phosphaglycerides is coated with glycerin and/or
PEG. As an example, Phosphatidylethanolamine (kephalin, cephalin) can be given. Cephalins are esters of phosphatidic acid that function in the brain. Since it is abundant in the brain as a target organ, it plays an active role in the transmission of ozone. Lecithin is the main constituent in many tissues. Phosphotidylserine is found in blood coagulation; phosphatidylinositol is intracellular messenger; phosphatidyl glycerol is found in Cardiolipin in cardiac cells; Malignolipin is found in malignant cells. It is possible to perform target organ treatments with the combination of these lipid derivatives.
In another application of the invention, in addition to ozone and emulsifier, the structure containing minerals is coated with glycerin and/or PEG. Nano liposomes formed by the combination of metal ozone formed in this group are obtained. The combination formed in this group is directed to the target organs again It facilitates the penetration of ozone into the cancer cell by opening the channels with the use of magnesium so as to open the calcium channels of the cell in cancer treatment. Elements such as zinc, copper, sulfur and silver also increase the antibacterial properties of the combination and are used in different target organs. For example, in agriculture, leaf health can be used as nanoliposome to increase plant health.
In another application of the invention, in addition to ozone and emulsifier, the structure containing DMSO is coated with glycerin and/or PEG. DMSO is selective for cancer cells with its combined use. In this way, ozone is transported to the target organ.
In another application of the invention, in addition to ozone and emulsifier, the structure containing ozone or non-ozone vegetable oils is coated with glycerin and/or PEG. In this way, nano liposomal and liposomal structures formed for the transport of ozone to the tissue are obtained.
In another application of the invention, in addition to ozone and emulsifier, the structure containing terpenes with or without ozone is coated with glycerin and/or PEG. It is used to form liposomes and nano liposomes of active oils secreted from plants. The effect of terpenes and at the same time the use of ozone as nano liposomes is possible with their combined use
Forms in different applications mentioned above or combinations of these forms can be used in the invention One or more combinations of antioxidants such as vitamins, minerals, dextran, mannan, chitosan, PLL and PEI polymers, protein, amino acid, sugar, sweetener,
alcohol, acid, menthol, hyaluronic acid, tranexamic acid, N acetyl cysteine, anticancer drugs can be added to the combinations.
In a different application of the invention, after the ozone emulsifier and oils are coated with glycerin, a solution can be obtained by adding menthol and sucralose and finally coating with hyaluronic acid. Various viruses, including SARS Cov 2, can be transmitted by hand (skin). However, there is also the possibility of eye contamination. Therefore, biocompatibility tests were performed for the eyes and skin, with the determination of the antibacterial effects of the solution within the scope of the invention. In the solution suitable for use as a nasal spray, in addition to the ozone emulsifier, zinc is also used in the liposome with hyaluronic acid glycerin.
In a different application of the invention, ozonated or unozonated phospholipid, cholesterol, sphingolipid, ceramide, proteolipid, glycolipid, isoprenoids, phosphoglyceride, lipids and terpenes, minerals, protein, cancer target protein, silicon dioxide, organic silicon, DMSO, acetyl cysteine, vitamins, hyaluronic acid, menthol, acids, alcohols, enzymes such as collagenase, elastase, trypsin, lipase, alkanes, protein, amino acid, sugar, sweetener and/or tranemic acid are added to the ozone emulsifier so as to form the main structure. In order to coat said main structure, coating is made of glycerin, mannitol, dextran and/or PEG and polymer.
There are two preferred main applications of the invention. These are the injection formula and the spray formula. Cholesterol can be added to ozonated polysorbate in the injection formula. In this formulation, polysorbate coating and mannitol, glycerin, dextran, PEG, hyaluronic acid alone or combinations can be coated on it. In the spray formula, ozonated sunflower oil, glycerin, menthol, hyaluronic acid and zinc can be added to ozonated polysorbate. It is also possible to make different variations of this formulation. Nasal spray and mouth spray contain all of the ingredients mentioned. However, wound spray and eye drops only contain ozonated polysorbate, glycerin, hyaluronic acid and zinc.
The usage areas and usage forms of the invention are listed below:
• In the medical and veterinary fields, it can be used by way of intravenous, intra arterial, intra-articular, subcutaneous, intramuscular, intraperitoneal, intra-bladder, intrauterine, rectal, inhaler, ear canal, nasal passage, oral route, eye drops, in vitro fertilization and oocyte sperm development and can be used in culture enhancing treatments.
• It can be used in disinfectant, antibacterial paint, antibacterial fabric, wound dressing in the field of chemistry.
• It can be used to increase the performance of fuels.
• It can be used in agriculture for plant health-enhancing, plant-enhancing disinfectant, insecticide, repellant, seed improvement and irrigation.
• It can be used as livestock disinfectant, skin protector, by way of intra-arterial, intra- articular, subcutaneous, intramuscular, intraperitoneal, bladder, intrauterine, rectal, ear canal, nasal passage, oral, also as eye drops.
• It can be used in textile fabric bleach and antibacterial fabrics.
• It can be used as a gasoline additive.
• It can be used as food raw material, food preservative and food additive.
• It can be used as skin rejuvenation and hair developer in cosmetics.
• The products can be used in ampoules, vials, sprays, creams and solutions.
Trial results determining the effects of three different solutions (Farmoxyn 1 , 2 and 3) applications produced in the studies carried out within the scope of the invention on the yield and quality of lettuce and tomato plants are given below. The aim of the experiment is to determine the effects of three different solutions (Farmoxyn 1 , 2 and 3) on the yield and quality of plants while investigating the possibilities of using them in agriculture. In this experiment, it was investigated whether the solution applications named Farmoxyn 1 , 2 and 3, which were made during the cultivation of lettuce and tomato plants, which are widely grown in our region, were compared with the control plants and whether they were effective on the yield and quality criteria. This research was carried out in Bursa Uludag University Faculty of Agriculture, Department of Horticulture, Application and Research Greenhouse and End Flarvest Physiology Laboratory between February 2021 - June 2021 .
1 . Material
In this study, 2 different tomato varieties (Nazli F1 and Atakan F1 ) and lettuce ( Lactuca sativa) belonging to the tomato ( Lycopersicon esculentum L.) species were used as plant material.
2. Method
In the trial, three different solutions (Farmoxyn 1 , 2 and 3), made by Biopharma Pharmaceuticals Chemistry Health Industry Trade. Ltd., were used. These doses are grouped as follows; Farmoxyn 1 (1), 0.2%; Farmoxyn 2 (2) is grouped as 0.2% and
Farmoxyn 3 (3) 10%. The untreated seedlings were considered as the control group. Water treatments were applied to the control group plants at the same time as the other treatments.
2.1 Ozone Application
Tomato and lettuce seedlings were immersed into grouped solutions 1 (%0,2); 2 (%0,2) and 3 (%10) just before planting in the greenhouse. 5 applications were made from planting to the beginning of harvest on tomato plants. On the other hand, 2 applications were made on leaf lettuce plants. Applications continued with an interval of 15 days in both plant groups. It was made as 100 ml. (for each variety, each application dose) in tomato, in the process from fruit setting to harvest, 200 ml. (for each variety, for each application dose) foliar spraying was applied for each application. On the other hand, in leaf lettuce, 100 ml. (for each application dose) was applied as a foliar spray in each application.
2.2. Analysis and measurements made in tomatoes
Fruit length (cm), fruit diameter (cm), color determination, water soluble dry matter (SSCM), titratable acid (TEA) and yield per plant (kg) of the samples taken from the beginning of the harvest were analyzed and measured.
2.3. Analysis and measurements made in leaf lettuce
Leaf length, root length, number of marketable leaves, number of non-marketable leaves, root length, root fresh weight, root dry weight, leaf fresh weight, leaf dry weight, leaf proportional water content, color determination, chlorophyll determination of the samples taken after harvest in leaf lettuce were measured.
3.1. Tomato Results
3.1.1. Fruit Length and Diameter
The best result for Nazli cultivar was obtained from the application number 1 and it was statistically different from other groups.
When the data of Atakan cultivar were evaluated, the best results in terms of fruit size were obtained from application groups 1 and 2 and they were in the same group statistically. In terms of fruit diameter, all application groups gave better results than the control group and were statistically included in the same group.
3.1.2. Determination of Color in Fruit
When the brightness values of Nazli F1 and Atakan F1 varieties are examined, the application group is statistically different from the other groups and gives the best result is the application number 1. The intensity of red color in tomato fruit is one of the most important criteria for determining the quality. When a value is evaluated, better results were obtained for Nazli variety in applications 1 and 3 compared to other application groups and statistical difference was determined. Application number 1 gave the best results for Atakan variety. This application is followed by application groups 2 and 3 and both are in the same statistical group. The lowest a values for both Nazli and Atakan cultivars were obtained from the control group. When b values were examined, the lowest value for Nazli variety was obtained from the application number 1. This value represents the yellow color. While the control group has the highest value, applications 2 and 3 fall into the same statistical group, although the lowest numerical value for Atakan cultivar was obtained from the application group number 1 , no statistical difference was determined.
3.1.3. WSDM Amount
Statistically different and the best results in terms of WSDM (Water Soluble Dry Matter) were obtained from the application no. 1 in Nazli cultivar, Application groups 1 and 3 in Atakan cultivar gave the best results and entered the same statistical group.
3.1 .4. TEA Amount
When TEA (Titratable acid) values were evaluated on the basis of variety, it was determined that the best result was found in application number 3 and the lowest result in application number 1 . There was no statistical difference in Atakan variety.
3.1.5. Yield per Plant (Kg)
Average yield was found by dividing the number of fruits per plant. The best result of Nazli cultivar was obtained from application group 1 with an average of 7.84 kg and a statistical difference was determined. Control and application group 2 are in the same statistical group and it was determined that lower yield was obtained than the yield obtained from number 1 . In Atakan cultivar, although the number 1 application seems to be numerically superior with 6,68 kg, the application 2 is in the same statistical group with 6,48 kg. The control group and the application group no. 3 gave lower results than the application groups no. 1 and 2.
3.2. Leaf Lettuce Results 3.2.1 . Leaf and Root Lengths
When all application groups were compared, the application group that gave the best results in terms of leaf and root length was number 1 and was statistically different from the other groups. Applications numbered 2 and 3 were included in the same statistical group. The control group, on the other hand, gave the lowest application result.
3.2.2. Wet and Dry Weights
Considering all weight parameters, the application group number 1 was statistically different from all groups and the best results were obtained.
3.2.3. Number of Marketable and Non-marketable Leaves
The application that gave the best results in the study was 1 (33.55 units) and was statistically different from the other groups. Considering the number of non-marketable leaves, the lowest result was again obtained from the application no. 1 (3,04 units). As a result, there are more marketable and less non-marketable leaves in application number 1 compared to other application groups.
3.2.4. Leaf Proportional Water Content (%)
When LPWC (%) was examined, application groups 1 and 3 gave the best results and entered the same statistical group. The application no. 2 and the control group were included in different application groups from the application groups no. 1 and 3, and the lowest result was obtained from the control group. Thus, it was observed that application groups 1 and 3 were more resistant to stress conditions.
3.2.5. Leaf Total Chlorophyll (pmol/m2) Amount
When the results of the leaf chlorophyll amount were evaluated in the study, it was determined that the best application was number 1 , followed by 2, 3 and control group applications
3.2.6. Leaf Color
As a result of the applications, it was determined that the best application in terms of brightness was the number 1 application and it was found to be statistically different. In the study, it was determined that the best result numerically was the number 1 application with the value of -19.14, however, it was determined that it is in the same statistical group with application number 3. It was determined that the salads in these treatment groups were greener than the other treatment groups. Considering the b values, although the number 1
application gave the best result in terms of numerical value, all of them were in the same statistical group, except for the control group.
In the final case, three different solutions included in the experiment were applied to the plants in tomato and leaf lettuce, and the obtained plants were harvested, and their quality parameters were examined. After the measurements and analyses, it was determined that 0.2% concentration of Farmoxyn 1 formulation had a positive effect on both types of vegetables.
Claims
1. A liposomal ozone nanosolution containing ozonated emulsifier.
2. The nanosolution according to claim 1 , characterized in that nanosolution is individuals or combinations selected from lecithin, lysophospholipid, polyethylene glycol, phosphatidylethanolamine, pluronic, polysorbates or a pharmaceutically acceptable emulsifier.
3. The nanosolution according to claim 1 , characterized by comprising individuals or combinations selected from distilled water, salt water, sugar water, mineral water, deionized water, demineralized water, spring water, saline solution, physiological saline, and plant waters.
4. The nanosolution according to claim 1 , characterized by comprising individuals or combinations selected from soybean oil, centaury oil, sesame oil, palm oil, poppy oil, soy lecithin, cholesterol, b-sterol, triglyceride, olive oil, fish oil, sunflower oil, castor oil, saffron oil, coconut oil, triglyceride derivatives, tributyrin, tricaproin, tricaprylin with paraffin, ethyl oleate, methyl oleate.
5. The nanosolution according to claim 1 , characterized by comprising individuals or combinations selected from fixed and/or essential vegetable oils.
6. The nanosolution according to claim 1 , characterized by comprising individuals or combinations selected from among formic acid, phosphoric acid, hydrochloric acid, acetic acid, propionic acid, butyric acid, valeric acid, caproic acid, oxalic acid, lactic acid, malic acid, citric acid, benzoic acid, carbonic acid, phenol, uric acid, taurine, aminomethylphosphonic acid.
7. The nanosolution according to claim 1 , characterized by comprising individuals or combinations selected from among anesthetics, pharmaceuticals pharmaceutical active substances such as water and/or fat soluble vitamins, minerals, hyarulonic acid, thymol, menthol, glycerin, ethyl alcohol, cetyl alcohol, butyl alcohol, benzyl alcohol, amino acids, acetyl cysteine, glutathione, herbal extracts, lidocaine, xylocaine.
8. The nanosolution according to claim 1 , characterized by comprising 100 stock ppm- 60 000 stock ppm ozone gas.
9. The nanosolution according to claim 8, characterized by comprising stable active ozone gas at doses of 1 ppm, 200 ppm, 500 ppm, 1000 ppm, 1600ppm, 2000 ppm, 3000 ppm, depending on the application area.
10. The nanosolution according to claim 1 , characterized by comprising liposomal ozone nanoparticles in sizes below 1000 nm, preferably below 200 nm, more preferably below 50 nm.
11. Liposomal ozone nanosolution production method according to any of the preceding claims, characterized by comprising the following process steps:
• Selecting the appropriate emulsifier and/or carrier oil for the application purpose,
• weighing the emulsifier and/or carrier oil,
• ozonation of emulsifier and/or carrier oil by passing ozone gas or nanobuble ozonated water through it,
• weighting ozonated emulsifier and/or carrier oil again and determining the ozone content,
• reduction of ozonated emulsifier and/or carrier oil to nanosize,
• preferably adding components selected from at least one excipient, at least one functional oil, at least one organic acid into nanosolution and mixing thereof.
12. The use of the liposomal ozone nanosolution according to any of the preceding claims, in product formulations in the fields of human, veterinary, food, agriculture and chemistry.
13. The use according to claim 12, characterized in that said liposomal ozone nanosolution is used in antiviral, antifungal and antibacterial effective formulations for human and veterinary applications, for skin barrier formation or intraarticular/subcutaneous/intramuscular injection.
14. The use according to claim 13, characterized in that formulations against Carpoglyphus Lactis (L.) pests are used in dry foods.
15. The use according to claim 13, characterized in that bacterial crown gall nematode formulations are used in agriculture.
16. The use according to claim 13, characterized in that anti two-spotted spider mite formulations are used in agriculture
17. The use according to claim 13, characterized in that formulations against Nosema infections are used in beekeeping.
18. The nanosolution according to claim 1 , characterized by comprising at least one emulsifier, ozone and water.
19. The nanosolution according to claim 1 , characterized by comprising
• one or a plurality of ozone emulsifiers,
• at least one emulsifier and/or polymer-containing coating to cover said ozone emulsifier.
20. The nanosolution according to claim 19, characterized by comprising individuals or combinations selected from polysorbate 20, polysorbate 60, polysorbate 80, polysorbate 85 as emulsifier.
21. The nanosolution according to claim 18, characterized by comprising glycerin, mannitol, dextran and/or PEG coating.
22. The nanosolution according to claim 18, characterized by comprising:
• one or more ozone emulsifiers,
• ozonated or unozonated phospholipid, cholesterol, sphingolipid, ceramide, proteolipid, glycolipid, isoprenoids, phosphoglyceride, lipids and terpenes, minerals, protein, cancer target protein, silicon dioxide, organic silicon, DMSO, acetyl cysteine, vitamins, hyaluronic acid, menthol, acids, alcohols, enzymes such as collagenase, elastase, trypsin, lipase, alkanes, protein, amino acid, sugar, sweetener and/or tranemic acid so as to form the main structure by adding the same to the ozone emulsifier,
• coating of glycerin, mannitol, dextran and/or PEG and polymer to coat said main structure.
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP22763707.1A EP4203920A4 (en) | 2021-03-01 | 2022-03-01 | Liposomal ozone nanosolutions |
US18/004,973 US20230240989A1 (en) | 2021-03-01 | 2022-03-01 | Liposomal ozone nanosolutions |
CN202280005798.1A CN116033824A (en) | 2021-03-01 | 2022-03-01 | Liposome ozone nano solution |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
TR2021/004032 | 2021-03-01 | ||
TR202104032 | 2021-03-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022186802A1 true WO2022186802A1 (en) | 2022-09-09 |
Family
ID=83155169
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/TR2022/050177 WO2022186802A1 (en) | 2021-03-01 | 2022-03-01 | Liposomal ozone nanosolutions |
Country Status (2)
Country | Link |
---|---|
EP (1) | EP4203920A4 (en) |
WO (1) | WO2022186802A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115969994A (en) * | 2022-10-08 | 2023-04-18 | 四川大学华西医院 | Core-shell structure nano ozone delivery controllable release system for targeting tumor, preparation method and application |
US11992483B2 (en) | 2021-03-31 | 2024-05-28 | Cali Biosciences Us, Llc | Emulsions for local anesthetics |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20160042209A (en) * | 2014-10-07 | 2016-04-19 | 세연에스앤알 주식회사 | Method of manufacturing ozonized composition of oil, and ozonized composition of oil manufactured by using the same |
WO2018020456A1 (en) * | 2016-07-27 | 2018-02-01 | Fb Vision S.R.L. | Oil and device for cleaning the ocular and periocular area |
CN107802640A (en) * | 2017-11-01 | 2018-03-16 | 湖南源绿科技有限公司 | A kind of preparation method of nanoemulsions ozone oil |
WO2019240713A2 (en) * | 2018-03-29 | 2019-12-19 | Sabanci Ahmet Uemit | Solutions comprising ozonized oil |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102015001289A1 (en) * | 2015-01-29 | 2016-08-04 | Wolfgang Winkelmann | Pharmaceutical compositions and pesticides containing oxygenated vegetable oils or fatty acids |
-
2022
- 2022-03-01 WO PCT/TR2022/050177 patent/WO2022186802A1/en unknown
- 2022-03-01 EP EP22763707.1A patent/EP4203920A4/en active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20160042209A (en) * | 2014-10-07 | 2016-04-19 | 세연에스앤알 주식회사 | Method of manufacturing ozonized composition of oil, and ozonized composition of oil manufactured by using the same |
WO2018020456A1 (en) * | 2016-07-27 | 2018-02-01 | Fb Vision S.R.L. | Oil and device for cleaning the ocular and periocular area |
CN107802640A (en) * | 2017-11-01 | 2018-03-16 | 湖南源绿科技有限公司 | A kind of preparation method of nanoemulsions ozone oil |
WO2019240713A2 (en) * | 2018-03-29 | 2019-12-19 | Sabanci Ahmet Uemit | Solutions comprising ozonized oil |
Non-Patent Citations (3)
Title |
---|
AYDIN R. SEDA TIGLI, FÜSUN KAZANCI: "Synthesis and characterization of ozonated oil nanoemulsions", JOURNAL OF THE AMERICAN OIL CHEMISTS' SOCIETY, vol. 95, no. 11, 5 October 2018 (2018-10-05), pages 1385 - 1398, XP055968517, DOI: 10.1002/aocs.12150 * |
PRAVIN K SHENDE, DRASHTI DESAI, R S GAUD: "Role of solid-gas interface of nanobubbles for therapeutic applications", CRITICAL REVIEWS IN THERAPEUTIC DRUG CARRIER SYSTEMS, BEGELL HOUSE PUBLISHING INC., US, vol. 35, no. 5, 30 November 2017 (2017-11-30), US , pages 469 - 494, XP009539779, ISSN: 0743-4863, DOI: 10.1615/CritRevTherDrugCarrierSyst.2018020229 * |
See also references of EP4203920A4 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11992483B2 (en) | 2021-03-31 | 2024-05-28 | Cali Biosciences Us, Llc | Emulsions for local anesthetics |
CN115969994A (en) * | 2022-10-08 | 2023-04-18 | 四川大学华西医院 | Core-shell structure nano ozone delivery controllable release system for targeting tumor, preparation method and application |
Also Published As
Publication number | Publication date |
---|---|
EP4203920A4 (en) | 2024-05-01 |
EP4203920A1 (en) | 2023-07-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101048064B (en) | Antiseptic compositions and methods of use | |
WO2022186802A1 (en) | Liposomal ozone nanosolutions | |
KR20070113281A (en) | Antimicrobial compositions and methods | |
TW201538181A (en) | A semi-fluid composition for lubricating, moisture retaining, disinfecting and sterilizing | |
JP2003515615A (en) | Antimicrobial composition for treatment | |
US20080286235A1 (en) | Antimicrobials and related methods | |
US20210007360A1 (en) | Solutions comprising ozonized oil | |
US11622556B2 (en) | Re-oiled and hyper-oiled lecithin carrier vehicles | |
WO2017092177A1 (en) | Natural broad-spectrum preservative composition comprising grapefruit seed extract and use thereof | |
CN105031609A (en) | Disinfectant with antimicrobial peptides Cbf-14, and preparation and application of disinfectant | |
US20080075794A1 (en) | Natural antimicrobial and method of manufacturing the same | |
WO2008038108A2 (en) | Antipediculosis composition having a lice-suffocating activity | |
KR20140042008A (en) | A mosquito repellent composition containing citronella oil | |
CN100431617C (en) | New use of orange essence in sterilizing | |
WO2005025587A1 (en) | Composition comprising ginkgolides and bilobalide | |
US20230240989A1 (en) | Liposomal ozone nanosolutions | |
KR102163976B1 (en) | trifoliate orange extracted by Tincture How to make odor reducing animal shampoo using this | |
Drury | Tea Tree Oil: A medicine kit in a bottle | |
US20230301884A1 (en) | Antiseptic compositions | |
CN1194662C (en) | Nim cosmetics series based on active component of nim for daily use and its preparing process | |
CN104815096A (en) | Nano composite skin disinfection emulsion and preparation method of same | |
ES2915273T3 (en) | Bee attractant and bee tranquilizer composition and methods of use thereof in agricultural, horticultural and beekeeping environments | |
WO2000062613A1 (en) | Pest removing composition | |
EP3638219B1 (en) | Composition comprising terpinene-4-ol for the treatment of demodicosis | |
CN112807259A (en) | Safe and nontoxic mosquito repelling composition and preparation method and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22763707 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2022763707 Country of ref document: EP Effective date: 20230329 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |